Document:

EX-10.12

 EXHIBIT 10.12 

EXECUTION COPY 

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of
information that the registrant treats as private or confidential. Double asterisks denote omissions. 
 NON-EXCLUSIVE LICENSE AGREEMENT 
 by and between 

ACUITAS THERAPEUTICS, INC. 

and 

VERVE THERAPEUTICS, INC. 

dated 
 October 14,
2020 
  

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	ARTICLE 1 DEFINITIONS	  	 	1	 
		
	ARTICLE 2 LICENSE GRANTS; TECHNOLOGY TRANSFER	  	 	10	 
			
	 2.1
	  	Licenses by Acuitas	  	 	10	 
			
	 2.2
	  	Sublicensing Rights	  	 	10	 
			
	 2.3
	  	Technology Transfer	  	 	11	 
			
	 2.4
	  	Updates to Appendix	  	 	13	 
		
	ARTICLE 3 LICENSE LIMITATIONS	  	 	13	 
		
	ARTICLE 4 PAYMENTS AND ROYALTIES	  	 	13	 
			
	 4.1
	  	License Maintenance Fees.	  	 	13	 
			
	 4.2
	  	Milestone Payments	  	 	13	 
			
	 4.3
	  	Royalties	  	 	14	 
			
	 4.4
	  	Payment Terms	  	 	15	 
		
	ARTICLE 5 OWNERSHIP AND INVENTORSHIP OF IP	  	 	17	 
		
	ARTICLE 6 PATENT PROSECUTION AND MAINTENANCE	  	 	17	 
			
	 6.1
	  	Generally	  	 	17	 
			
	 6.2
	  	Election Not to Prosecute or Maintain or Pay Patent Costs	  	 	17	 
			
	 6.3
	  	Regulatory Exclusivity Periods	  	 	18	 
			
	 6.4
	  	Patent Listings	  	 	18	 
			
	 6.5
	  	Cooperation	  	 	18	 
		
	ARTICLE 7 PATENT ENFORCEMENT AND DEFENSE	  	 	19	 
			
	 7.1
	  	Notice	  	 	19	 
			
	 7.2
	  	Enforcement and Defense	  	 	19	 
		
	ARTICLE 8 CONFIDENTIALITY	  	 	22	 
			
	 8.1
	  	Confidential Information	  	 	22	 
			
	 8.2
	  	Restrictions	  	 	22	 
			
	 8.3
	  	Exceptions	  	 	22	 
			
	 8.4
	  	Permitted Disclosures	  	 	22	 
			
	 8.5
	  	Return of Confidential Information.	  	 	23	 

  
 -i- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
	 8.6
	  	Publications	  	 	23	 
			
	 8.7
	  	Terms of this License Agreement; Publicity	  	 	23	 
		
	 ARTICLE 9 WARRANTIES; LIMITATIONS OF LIABILITY; INDEMNIFICATION
	  	 	24	 
			
	 9.1
	  	Representations and Warranties	  	 	24	 
			
	 9.2
	  	Additional Representations of Acuitas	  	 	24	 
			
	 9.3
	  	Disclaimers	  	 	26	 
			
	 9.4
	  	No Consequential Damages	  	 	26	 
			
	 9.5
	  	Performance by Others	  	 	26	 
			
	 9.6
	  	Indemnification	  	 	26	 
			
	 9.7
	  	Insurance	  	 	28	 
		
	 ARTICLE 10 TERM AND TERMINATION
	  	 	29	 
			
	 10.1
	  	Term	  	 	29	 
			
	 10.2
	  	Termination by Acuitas	  	 	29	 
			
	 10.3
	  	Termination by Verve	  	 	30	 
			
	 10.4
	  	Termination Upon Bankruptcy	  	 	31	 
			
	 10.5
	  	Effects of Termination	  	 	31	 
			
	 10.6
	  	Survival	  	 	32	 
		
	 ARTICLE 11 GENERAL PROVISIONS 
	  	 	32	 
			
	 11.1
	  	Dispute Resolution	  	 	33	 
			
	 11.2
	  	Cumulative Remedies and Irreparable Harm	  	 	33	 
			
	 11.3
	  	Relationship of Parties	  	 	33	 
			
	 11.4
	  	Compliance with Law	  	 	33	 
			
	 11.5
	  	Governing Law	  	 	33	 
			
	 11.6
	  	Counterparts; Facsimiles	  	 	33	 
			
	 11.7
	  	Headings	  	 	33	 
			
	 11.8
	  	Waiver of Rule of Construction	  	 	33	 
			
	 11.9
	  	Interpretation	  	 	34	 
			
	 11.10
	  	Binding Effect	  	 	34	 

  
 -ii- 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	  	 	  	Page	 
	 11.11
	  	Assignment	  	 	34	 
			
	 11.12
	  	Notices	  	 	34	 
			
	 11.13
	  	Amendment and Waiver	  	 	35	 
			
	 11.14
	  	Severability	  	 	35	 
			
	 11.15
	  	Entire Agreement	  	 	36	 
			
	 11.16
	  	Force Majeure	  	 	36	 

  
 -iii- 

 List of Appendices 

 

			
		
	Appendix 1.35	  	Jointly Owned Patents
		
	Appendix 1.44	  	Licensed Product including Human Genome Target(s), Genome Editing Protein Target(s) and Guide RNA(s)
		
	Appendix 1.44	  	Patents within the Licensed Technology as of the License Agreement Effective Date
		
	Appendix 9.2	  	Exceptions to Acuitas’ Representations and Warranties in Section 9.2

  

 Non-Exclusive License Agreement 

This Non-Exclusive License Agreement (“License Agreement”), dated as of
October 14, 2020 (the “License Agreement Effective Date”), is made by and between Acuitas Therapeutics, Inc., a British Columbia corporation (“Acuitas”), and Verve Therapeutics, Inc., a Delaware corporation
(“Verve”). Each of Acuitas and Verve may be referred to herein as a “Party” or together as the “Parties.” 

WHEREAS, Acuitas has proprietary LNP Technology (as defined below); 

WHEREAS, Verve has expertise and intellectual property relating to gene editing therapeutics, including mRNA Constructs (as defined
below) and Genome Editing Constructs (as defined below); 
 WHEREAS, Acuitas and Verve are parties to that certain Amended and
Restated Development and Option Agreement (dated October 6, 2020) (the “Development and Option Agreement”), pursuant to which Verve has options to take licenses under the Licensed Technology (as defined below) with respect to
Verve’s Genome Editing Constructs; and 
 WHEREAS, pursuant to the terms of the Development and Option Agreement, Verve has
exercised an option with respect to the Licensed Products and the Licensed Genome Targets (as defined below) and the Parties are now entering into a licensing arrangement whereby Verve will have a license under the Licensed Technology to develop and
commercialize Licensed Products (as defined below) based on such Licensed Genome Targets. 
 NOW, THEREFORE, in consideration of the
mutual covenants contained herein, and for other good and valuable consideration, the amount and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 

Definitions 
 The following terms
and their correlatives will have the following meanings: 
 1.1. “Acuitas Indemnitees” has the meaning set forth in
Section 9.6(a). 
 1.2. “Acuitas Patents” has the meaning set forth in Section 7.2(a)(i). 

1.3. “Acuitas Background Technology” has the meaning set forth in the Development and Option Agreement. 

1.4. “Acuitas LNP Technology” has the meaning set forth in the Development and Option Agreement. 

1.5. “Acuitas Sole Technology” has the meaning set forth in the Development and Option Agreement. 

  
 1 

 1.6. “Affiliate” of a person or entity means any other person or
entity which (directly or indirectly) is controlled by, controls or is under common control with such person or entity. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms
“controlled by” and “under common control with”) as used with respect to an entity will mean (a) in the case of a corporate entity, direct or indirect ownership of voting securities entitled to cast at least fifty
percent (50%) of the votes in the election of directors, or (b) in the case of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with
the power to direct the management and policies of such entity, provided that if local Law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum ownership percentage that may, under such local Law,
be owned by foreign interests. 
 1.7. “Calendar Quarter” means the respective periods of three (3) consecutive
calendar months ending on March 31, June 30, September 30 and December 31. 
 1.8. “cGMP” means
current Good Manufacturing Practices as specified in Parts 210 and 211 of Title 21 of the U.S. C.F.R., ICH Guideline Q7A, or equivalent Laws of an applicable Regulatory Authority at the time of manufacture. 

1.9. “CMO” has the meaning set forth in Section 2.3(a). 

1.10. “Combination Product” means a product that includes at least one additional active ingredient other than a
Licensed Product sold in conjunction with or used in combination with a Licensed Product (whether packaged together or packaged separately but sold together for a single price). Drug delivery vehicles and excipients shall not be deemed to be
“active ingredients,” except in the case where such delivery vehicle or excipient is recognized as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7) or equivalent Laws in other jurisdictions, provided however, should lipid
nanoparticles comprised in a Licensed Product be characterized as “active ingredients” at any time during the Term, such lipid nanoparticles will not be considered an “active ingredient” for the purposes of this definition. 

1.11. “Confidential Information” has the meaning set forth in Section 8.1. 

1.12. “Control” or “Controlled” means, with respect to a particular Technology, Acuitas owns or has a
license to use and practice such Technology and has the right to grant a license or sublicense to such Technology without violating the terms of any agreement with any Third-Party and without owing any milestone, royalty or other monetary
obligations to a Third-Party under the terms of any agreement with such Third-Party. 
 1.13. “Covered” and
“Covering” means, with reference to a Licensed Product, that without the licenses granted to Verve hereunder, the manufacture, development or commercialization of such Licensed Product would infringe a Valid Claim of an LNP
Technology Patent. 
 1.14. “Development and Option Agreement” has the meaning set forth in the Preamble. 

1.15. “Diligent Efforts” means, with respect to the efforts to be expended by each Party, active and sustained efforts
to conduct the applicable activity, or to attempt to achieve the applicable requirement or goal, in a prompt and expeditious manner, as is reasonably practicable under the circumstances and the terms of this Agreement. 

  
 2 

 1.16. “Disclosing Party” has the meaning set forth in
Section 8.1. 
 1.17. “Escrow Agent” means the Third-Party escrow agent designated by Acuitas and reasonably
acceptable to Verve, which escrow agent shall initially be [**]. 
 1.18. “Executive Officers” has the meaning set
forth in Section 11.1(b). 
 1.19. “Field of Use” means Genome Editing for all human therapeutic or prophylactic
uses of Licensed Products. 
 1.20. “First Commercial Sale” means the first sale for use or consumption for which
revenue has been recognized of any Licensed Product in a country after all required Marketing Authorization Approvals for commercial sale of such Licensed Product have been obtained in such country. 

1.21. “FTE” means the work of a full-time person for one year, or more than one person working the equivalent of a
full-time person for one year, where “full-time” is determined by the standard practices in the biopharmaceutical industry in the geographic area in which such personnel are working, but means [**] hours per year, in the performance of the
agreed activities for the Technology Transfer, including scientific management oversight as reasonably required. 
 1.22. “FTE
Costs” mean the actual FTEs employed by Acuitas in the conduct of the agreed activities for the Technology Transfer multiplied by an annual rate per FTE equal to [**] Dollars (US$[**]), which may be prorated on a daily or hourly basis as
necessary. Such FTE Costs represent reimbursement for all costs of FTEs in providing such activities (including salaries and benefits, lab supplies, reagents, equipment and overhead, as well as other G&A costs). 

1.23. “GAAP” means generally accepted accounting principles in the United States. 

1.24. “Genome Edit(ing)” means to correct, modify, insert, delete, inactivate or repair the expression of a Human
Genome Target for human therapeutic, diagnostic or prophylactic applications. 
 1.25. “Genome Editing Construct”
means a construct consisting of [**] mRNA Constructs that each encode a [**] to Genome Edit up to [**] Human Genome Targets. For the avoidance of doubt, each Genome Editing Construct (i) may, but shall not be required to, contain Guide RNAs
(whether or not formulated with Acuitas LNP Technology) in any combination or combinations and (ii) will be defined by the specific combination of [**] and each different combination of the foregoing will be a different Genome Editing Construct
(provided that each Genome Editing Construct may contain [**]). 
 1.26. “Genome Editing Protein Target” means a
Protein Target that is intended to Genome Edit the Human Genome Target. 

  
 3 

 1.27. “GMP” means current good manufacture practices as defined
under regulations promulgated by the U.S. Food and Drug Administration. 
 1.28. “Guide RNA” means a synthetic, short
ribonucleic acid sequence composed of a scaffold sequence that binds to the Genome Editing Protein Target and a sequence complementary to the site on the Human Genome Target at which the Genome Editing Protein Target is intended to Genome Edit. 

1.29. “Human Genome Target” means (a) a naturally occurring human gene, including all coding, non-coding and regulatory regions thereof, as identified by the applicable transcript identifier (i.e., NCBI Refseq transcript ID), gene identifier (i.e., NCBI Refseq Gene ID), gene name and synonyms and nucleotide
sequence coordinates, gene transcript and nucleotide sequence; (b) any naturally occurring non-coding region of the human genome including, but not limited to, transcriptional regulatory elements, non-protein coding RNA and intergenic regions; and with respect to a gene covered by (a) or (b) above, any variants of such gene, including the wild type and naturally occurring mutant and allelic
variants, provided, however, that any such variant (i) encodes a protein [**] to the protein product of the original (reference) gene and has a coding region with greater than [**] percent ([**]%) sequence identity to the coding
region of the original (reference) gene. For clarity, a nucleotide sequence may be considered to encode a protein regardless of whether such sequence contains a start codon. 

1.30. “Indemnification Claim Notice” has the meaning set forth in Section 9.6(c). 

1.31. “Indemnified Party” has the meaning set forth in Section 9.6(c). 

1.32. “Indemnifying Party” has the meaning set forth in Section 9.6(c). 

1.33. “Insolvency Legislation” has the meaning set forth in Section 10.4. 

1.34. “Joint IP” means the Joint IP as such term is defined in the Development and Option Agreement, including the
Jointly Owned Patents. 
 1.35. “Jointly Owned Patents” means the Patents listed in Appendix 1.35 hereto, as
amended from time to time. 
 1.36. “Know-How” means all Materials and all
confidential and proprietary commercial, technical, scientific and other know-how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills,
techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical, preclinical, clinical, safety, manufacturing and quality control data and know-how, including study designs and protocols), in all cases, provided such information is confidential and
proprietary, and regardless of whether patentable, in written, electronic or any other form now known or hereafter developed. 
 1.37.
“Know-How Royalties” has the meaning set forth in Section 4.4(a). 

  
 4 

 1.38. “Late Stage Development” means, with respect to a product,
that first dosing under Phase 2 Studies has been initiated. 
 1.39. “Law” or “Laws” means all laws,
statutes, rules, regulations, orders, judgments or ordinances having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. 

1.40. “License Agreement” has the meaning set forth in the Preamble. 

1.41. “License Agreement Effective Date” has the meaning set forth in the Preamble. 

1.42. “Licensed Genome Editing Construct” means a Genome Editing Construct consisting of one or more mRNA Constructs
that each encode a Genome Editing Protein Target to Genome Edit either a single specific Licensed Genome Target or [**] Licensed Genome Targets. For the avoidance of doubt, each Licensed Genome Editing Construct may, but shall not be required to,
contain up to [**] Guide RNAs (whether or not formulated with Acuitas LNP Technology) in any combination or combinations. 
 1.43.
“Licensed Genome Target” means the maximum of [**] Human Genome Targets set forth in Appendix 1.44. 
 1.44.
“Licensed Product” means any product that (a) consists of up to [**] Licensed Genome Editing Constructs including up to [**] specified Guide RNAs intended to Genome Edit up to [**] Licensed Genome Targets as specifically
described in Appendix 1.44 and (b) is derived from, incorporates, or utilizes, any LNP Technology that is Controlled by Acuitas or its Affiliates as of the License Agreement Effective Date or at any time during the Term. For clarity, each
Licensed Product will consist of a specific combination of Licensed Genome Editing Constructs ([**]) that target [**] Licensed Genome Target or [**] Licensed Genome Targets. 

1.45. “Licensed Product Royalty Term” has the meaning set forth in Section 4.3(d). 

1.46. “Licensed Technology” means LNP Technology Controlled by Acuitas or its Affiliates, as of the License Agreement
Effective Date or generated or obtained during the Term (including the Acuitas Background Technology, Acuitas Sole Technology and Acuitas’ interest in any Joint IP) necessary or useful for the research, development, manufacture, use or sale of
a Licensed Product. The Patents comprised in the Licensed Technology as of the License Agreement Effective Date are listed - without limiting the generality of the definition above - in Appendix 1.44 attached hereto. 

1.47. “License Maintenance Fees” means the fees set forth in Section 4.1. 

1.48. “LNP” means lipid nanoparticles. 

1.49. “LNP Technology” means any Technology that claims, embodies or incorporates delivery systems (and components
thereof) based on or incorporating LNPs. 

  
 5 

 1.50. “LNP Technology Patent(s)” means Patents comprised in the
Licensed Technology, including any future Patent which will become part of the Licensed Technology during the Term and further including Acuitas’ rights in the Jointly Owned Patents, unless otherwise set forth herein. 

1.51. “Losses” has the meaning set forth in Section 9.6(a). 

1.52. “Major Market Country” means each of [**]. 

1.53. “Marketing Authorization Approval” means, with respect to a country or extra-national territory, any and all
approvals (including a Biologics License Application approved by the FDA), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a product in such country or some or all
of such extra-national territory, including any pricing or reimbursement approvals. 
 1.54. “Materials” has the
meaning set forth in the Development and Option Agreement. 
 1.55. “Milestone Event” has the meaning set forth in
Section 4.3. 
 1.56. “Milestone Payment” has the meaning set forth in Section 4.3. 

1.57. “Minimum Royalty” has the meaning set forth in Section 4.4(c). 

1.58. “mRNA Construct” means any mRNA that encodes a Genome Editing Protein Target and any associated non-coding sequences, including any cap sequence, 5’ UTR, 3’UTR, and any polyadenylation sequences. The term “mRNA Construct” also includes the chemistry of natural and non-natural nucleic acids, and other chemical modifications associated with such mRNA and associated non-coding sequences. 

1.59. “Net Sales” means, with respect to any Licensed Product, the amount received by Verve and its Affiliates and/or
Sublicensees for bona fide sales of such Licensed Product to a Third-Party (other than Affiliates and Sublicensees but including distributors for resale), less: 

(a) discounts (including mandated, trade, cash, quantity, prompt pay and patient program discounts), retroactive price reductions, commissions,
charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments, their agencies, pharmacy benefit managers, and purchasers and reimbursers or to trade customers; 

(b) credits or allowances actually granted upon claims, damaged or defective goods, refunds, rejections or returns of, and for uncollectable
amounts on, such Licensed Product, including such Licensed Product returned in connection with recalls or withdrawals; 
 (c) freight,
postage, shipping, handling and insurance charges for delivery of such Licensed Product; 
 (d) taxes or duties levied on, absorbed or
otherwise imposed on the sale of such Licensed Product, including value-added taxes, or other governmental charges otherwise imposed upon the billed amount, as adjusted for rebates and refunds; 

  
 6 

 (e) any invoiced amounts from a prior period which are not collected and are written off by
Verve, its Affiliates or its or their Sublicensees, including bad debts; 
 (f) wholesaler and distributor administration fees and other
reasonable fees paid to selling agents, group purchasing organizations, Third-Party payors, other contractees and managed care entities, in each case with respect to such Licensed Product; and 

(g) other customary deductions taken in the ordinary course of business in accordance with GAAP. 

Net Sales shall not include any payments among Verve, its Affiliates and Sublicensees. Net Sales shall be determined in accordance with GAAP,
consistently applied. 
 Net Sales for any Combination Product shall be calculated on a country-by-country basis by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B), where A is the weighted average price paid for the Licensed Product contained in such Combination
Product sold separately in finished form in such country, and B is the weighted average invoice price paid for the other active ingredients contained in such Combination Product sold separately in finished form in such country, if such Licensed
Product and such other active ingredients are each sold separately in such country. 
 Net Sales of the Licensed Product for any Combination
Product if the Licensed Product or other active ingredients in such Combination Product are not sold separately in such country, shall be calculated by multiplying the Net Sales of the Combination Product by a fraction, the numerator of which shall
be the fair market value of the Licensed Product as if sold separately (in accordance with GAAP), and the denominator of which shall be the aggregate fair market value of all the other active ingredients of such Combination Product, including the
Licensed Product, as if sold separately. The fair market value of each component of a Combination Product will be a determined by a Third-Party expert selected by Verve and reasonably acceptable to Acuitas. 

1.60. “Option Exercise Fee” has the meaning set forth in the Development and Option Agreement. 

1.61. “Party” and “Parties” has the meaning set forth in the Preamble. 

1.62. “Patent(s)” means an (a) issued patent, a patent application, and a future patent issued from any such
patent application, (b) a future patent issued from a patent application filed in any country worldwide which claims priority from a patent or patent application included in (a), (c) any additions, divisions, continuations, continuations-in-part, invention certificates, substitutions, reissues, reexaminations, extensions, registrations, utility models, supplementary protection certificates and
renewals based on any patent or patent application under (a) or (b), but not including any rights that give rise to regulatory exclusivity periods (other than supplementary protection certificates, which will be treated as “Patents”
hereunder), and (d) any counterpart of any patent or patent application under (a), (b) or (c) filed in any country worldwide. 

1.63. “Patent Costs” means the reasonable, documented,
out-of-pocket costs and expenses paid to outside legal counsel, and filing and maintenance expenses, actually and reasonably incurred by a Party in prosecuting and
maintaining Patents. 

  
 7 

 1.64. “Patent Royalties” has the meaning set forth in
Section 4.4(a). 
 1.65. “Phase 1 Study” means a human clinical trial of a Licensed Product in any country, the
primary purpose of which is the determination of safety and which may include the determination of metabolism and pharmacologic actions of the Licensed Product in humans, the side effects associated with increasing doses, and, if possible, to gain
early evidence on effectiveness, as more fully defined in 21 C.F.R. §312.21(a) or its successor regulation, or the equivalent in any foreign country. 

1.66. “Phase 2 Study” means a human clinical trial of a Licensed Product in any country, the primary purpose of which
is to evaluate the effectiveness of the Licensed Product for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the Licensed
Product, as more fully defined in 21 C.F.R. §312.21(b) or its successor regulation, or the equivalent in any foreign country. 

1.67. “Phase 3 Study” means a human clinical trial of a Licensed Product in any country, the primary purpose of which
is to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the Licensed Product and to provide an adequate basis for physician labeling, as more fully defined in 21
C.F.R. §312.21(c) or its successor regulation, or the equivalent in any foreign country. 
 1.68. “Protein
Target” means either (a) any naturally occurring protein encoded by a specific gene locus, as identified by the applicable transcript identifier (i.e., NCBI Refseq transcript ID), gene identifier (i.e., NCBI Refseq Gene
ID), gene name and synonyms and DNA sequence coordinates, together with all variants of such protein, including the wild type, naturally occurring variants, engineered variants wherein modifications to the native amino acid sequence have been
introduced (for example, mutated versions, derivatives or fragments), and species homologs and orthologs thereof, provided however that any such naturally occurring variant, engineered variant, or species homolog or ortholog possesses a
substantially similar mechanism of action and biological activity to the naturally occurring human protein (for example immunogenicity in case of antigens); or (b) any protein that is not covered by subclause (a) above (together with any
variants, mutated versions, derivatives or fragments of such protein, provided that any such variant, mutated version, derivative or fragment possesses substantially similar mechanism of action and biological activity as such protein) and has
greater than [**] percent ([**]%) sequence identity to the reference amino acid sequence in subclause (b). For clarity, in the case of a Genome Editing Protein Target, substantially similar mechanism of action and biological activity
means that any variants, mutated versions, derivatives or fragments of such protein Genome Edit the same Human Genome Target at the same site. 

1.69. “Receiving Party” has the meaning set forth in Section 8.1. 

1.70. “Regulatory Authority” means any national (e.g., the United States Food and Drug Administration
(“FDA”)), supra-national (e.g., the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental authority, in any jurisdiction in the world, involved in the granting
of Marketing Authorization Approval. 

  
 8 

 1.71. “Regulatory Exclusivity” means with respect to any country or
other jurisdiction in the Territory, an additional market protection, other than Patent protection, granted by a Regulatory Authority in such country or other jurisdiction which confers an exclusive commercialization period during which Verve or its
Affiliates or Sublicensees have the exclusive right to market and sell a Licensed Product in such country or other jurisdiction through a regulatory exclusivity right (e.g., new chemical entity exclusivity, new use or indication exclusivity, new
formulation exclusivity, orphan drug exclusivity, pediatric exclusivity, or any applicable data exclusivity). 
 1.72.
“Royalties” has the meaning set forth in Section 4.4(a). 
 1.73. “Royalty Term” has the
meaning set forth in Section 4.3(d). 
 1.74. “Solely Owned Technology” has the meaning set forth in Article 5.

 1.75. “Sublicensee” means any Third-Party that is granted a sublicense as permitted by Section 2.3, either
directly by Verve or its Affiliates or indirectly by any other Sublicensee hereunder. 
 1.76. “Targets” means,
collectively, a Genome Editing Protein Target, a Guide RNA, and a Human Genome Target, as the case may be, each, as identified in the appropriate nomination form and Appendix 1.44. 

1.77. “Technology” means collectively Patents and Know-How. 

1.78. “Technology Transfer” has the meaning set forth in Section 2.3(a). 

1.79. “Technology Transfer Plan” has the meaning set forth in Section 2.3(a). 

1.80. “Term” has the meaning set forth in Section 10.1. 

1.81. “Territory” means worldwide. 

1.82. “Third-Party” means any person or entity other than Verve, Acuitas and their respective Affiliates. 

1.83. “Third-Party Claims” has the meaning set forth in Section 9.6(a). 

1.84. “Third-Party Royalty Payments” has the meaning set forth in Section 4.4(b). 

1.85. “Transferred Technology” has the meaning set forth in Section 2.3(a). 

1.86. “Valid Claim” means a claim of (a) an issued patent included in the Licensed Technology (other than the
Jointly Owned Patents) which has not expired or been abandoned and which has not been disclaimed, canceled, revoked or held invalid or unenforceable by a court or administrative agency of competent jurisdiction from which no further appeal is
possible and that is not admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a pending patent application included in the Licensed Technology (other than the Jointly Owned

  
 9 

 
Patents) which claim is being actively prosecuted and which has not been (i) canceled, (ii) withdrawn from consideration, (iii) finally determined to be unallowable by the applicable
governmental authority (and from which no appeal is or can be taken), (iv) abandoned, or (v) pending for more than [**] from the date of filing of such patent application. 

1.87. “Verve Indemnitees” has the meaning set forth in Section 9.6(b). 

1.88. “Workplan Leaders” has the meaning set forth in the Development and Option Agreement. 

ARTICLE 2 
 License
Grants; Technology Transfer 
 2.1 Licenses by Acuitas. 

(a) License. Subject to the terms and conditions of this License Agreement, Acuitas hereby grants to Verve a
non-exclusive license, with the right to sublicense only as permitted by Section 2.2(b), under the Licensed Technology, to research, develop, have developed, make, have made, keep, use and have used, sell, offer for sale, have sold, import
and have imported, export and have exported and otherwise commercialize and exploit Licensed Products in the Field of Use in the Territory. 

(b) Diligence. Verve will use Diligent Efforts to develop and commercialize Licensed Products pursuant to this Agreement. 

2.2 Sublicensing Rights. 

(a) Transfer. The licenses granted in Section 2.1 are transferable only upon a permitted
assignment of this License Agreement in accordance with Section 11.11. 
 (b) Verve Sublicenses. The
licenses granted in Section 2.1 may be sublicensed (with the right to sublicense through multiple tiers), in full or in part, by Verve, its Affiliates or Sublicensees to Verve’s Affiliates and Third Parties, provided, that for any
sublicense to Third Parties: 
 (i) Each sublicense will be in writing and on terms consistent with and subject to the terms
of this License Agreement; 
 (ii) Verve will provide Acuitas with a copy of any sublicense agreement with a Sublicensee
within [**] of execution thereof, which sublicense agreement may be redacted as necessary to protect commercially sensitive information and shall be treated as Verve Confidential Information hereunder; 

(iii) Verve will be responsible for any and all obligations of such Sublicensee as if such Sublicensee were Verve hereunder;
and 

  
 10 

 (iv) Any sublicense granted by Verve to any rights licensed to it hereunder
shall terminate immediately upon the termination of the license from Acuitas to Verve and its Affiliates with respect to such rights, provided that such sublicensed rights shall not terminate if, as of the effective date of such termination pursuant
to Sections 10.2, 10.3(a) or 10.4, a Sublicensee is not in material default of its obligations under its sublicense agreement, and within [**] of such termination, the Sublicensee agrees in writing to be bound directly to Acuitas under a
license agreement substantially similar to this License Agreement with respect to the rights sublicensed hereunder, substituting such Sublicensee for Verve. 

(c) Subcontractors. For clarity purposes, Verve is entitled to engage contract research organizations, contract manufacturing
organizations and other service providers for the development and manufacture of Licensed Products on behalf of Verve. To the extent such contract organizations and service providers require a license to perform such subcontracted activities under
applicable Laws, Verve is entitled to grant a limited research and/or manufacturing sublicense (as applicable) without an obligation to meet the conditions of Section 2.3(b)(ii) and (iv). 

2.3 Technology Transfer. 

(a) Technology Transfer. After the License Agreement Effective Date and promptly upon written request by
Verve (and in any event within [**] following designation of the applicable CMO (as defined below), provided such CMO is able to support this timeline), Acuitas will transfer the relevant formulation process, raw materials supply and analytical
characterization for the manufacture of Licensed Product (the “Transferred Technology”), to Verve or a GMP contract manufacturing organization (“CMO”)) designated by Verve and subject to Acuitas’ prior written
consent in accordance with the Development and Option Agreement (the “Technology Transfer”) pursuant to a mutually agreed plan (the “Technology Transfer Plan”). Acuitas will provide reasonable assistance to enable
such CMO to manufacture such Licensed Product. Initiation of such technology transfer will be determined by Verve and will be for the then current formulation of the Licensed Product. Specifically, in the event that Additional Development Studies
for a Licensed Product (as defined in the Development and Option Agreement) are undertaken, Verve will notify Acuitas once a formulation is selected for technology transfer. Acuitas will be reimbursed for such activities by Verve on an FTE basis and
Verve will also be responsible for all external costs incurred by Acuitas relating to transfer of the Licensed Product formulation to such CMO provided such costs have been approved by Verve in advance. For clarity, Acuitas’ Technology Transfer
obligations under this Section 2.3(a) shall be limited to LNP formulations previously tested by Verve in accordance with the Workplan (as defined in the Development and Option Agreement). Once a Licensed Product formulation is
transferred to such CMO, Verve will assume responsibilities for future manufacturing of Licensed Product. Acuitas will provide reasonably requested ongoing technical support if requested by Verve with such support reimbursed on a time, materials and
FTE basis. 

  
 11 

 (b) Activities. Acuitas shall in particular: 

(i) transfer to Verve or the CMO all documents relating to Licensed Technology necessary or useful for the manufacture of
Licensed Products, including documents relating to the Transferred Technology, and which are owned by Acuitas. In the event such documents are transferred to a CMO, Verve will also be copied; 

(ii) allow Verve to monitor the progress of the transfer and to confirm whether the transfer has been successfully completed;

 (iii) provide training to Verve or the CMO by fully qualified and experienced employees or contractors of Acuitas in
respect of the manufacture of Licensed Products. Unless otherwise agreed, the training will be provided at Verve or the CMO’s site. For purposes of the training, Acuitas shall make available at least [**] experienced and competent Acuitas FTEs,
the specific qualification of the Acuitas FTEs and the details of the training to be further described in the Technology Transfer Plan; and 

(iv) provide ongoing technical support in relation to the Transferred Technology to Verve or the CMO, as reasonably requested
by Verve from time to time. 
 (c) Diligence. Acuitas shall perform the Technology Transfer in a professional manner and in
accordance with the Technology Transfer Plan and use Diligent Efforts to meet the objectives and timelines set forth therein. Acuitas shall ensure that Verve or the CMO is trained and empowered to perform the manufacturing. It is understood that
successful Technology Transfer cannot be guaranteed and Acuitas will not be found not to have used Diligent Efforts based on the failure by Verve or the CMO to achieve any particular result, unless Acuitas contributed to or caused such failure. 

(d) Intellectual Property. Any intellectual property generated during the Technology Transfer shall be governed by the
intellectual property provisions of the Development and Option Agreement. 
 (e) Payment. Verve will reimburse Acuitas on a
Calendar Quarter-by-Calendar Quarter basis for (i) FTE Costs based on the number of hours worked by Acuitas’ FTEs, and (ii) any reasonable external costs approved by Verve in advance that are incurred by Acuitas, in each
case in the performance of the agreed technology transfer activities for the Technology Transfer. Acuitas will send a reasonably detailed invoice to Verve no later than [**] after the end of each Calendar Quarter, which invoice shall include a
summary of all activities by the name of each individual, number of hours devoted by each such individual, and the type/activity performed by each such individual during such Calendar Quarter, and all external costs incurred by Acuitas during such
Calendar Quarter. Verve agrees to pay undisputed amounts in each such invoice within [**] of Verve’s receipt thereof. 
 (f)
Right of Reference. Acuitas hereby grants Verve and its Sublicensees a “right of reference,” as that term is defined in 21 C.F.R. § 314.3(b), or a comparable right existing under the Laws of any other
jurisdiction, to any regulatory filings owned or otherwise controlled by Acuitas or its Affiliates relating to the Transferred Technology to the extent necessary or useful necessary to obtain Marketing Authorization Approval or otherwise make
regulatory filings for Licensed Products in the Field of Use in the Territory, and, upon request, shall promptly provide a signed statement to such effect in accordance with 21 C.F.R. §314.50(g)(3) or the Laws of any other jurisdiction. 

  
 12 

 2.4 Updates to Appendix 1.44. Acuitas shall notify Verve at least [**]
of Patents that are added to the Licensed Technology following the License Agreement Effective Date or any Patents that are no longer Licensed Technology because they have been abandoned or discontinued in accordance with the terms of
Section 6.2. Appendix 1.44 shall be automatically updated to include any such added or deleted Patents. 
 ARTICLE 3 

License Limitations 

No licenses or other rights are granted by Acuitas hereunder to use any trademark, trade name, trade dress or service mark owned or otherwise
Controlled by Acuitas or any of its Affiliates. All licenses and other rights are or shall be granted only as expressly provided in this License Agreement, and no other licenses or other rights are or shall be created or granted by either Party
hereunder by implication, estoppel or otherwise. 
 ARTICLE 4 

Payments and Royalties 

4.1 License Maintenance Fees. A license maintenance fee of Seven Hundred and Fifty Thousand Dollars (US$750,000)
will be payable on each anniversary of the License Agreement Effective Date until such time as the Milestone Payment for first dosing of the first patient in the first Phase 1 Study for a Licensed Product anywhere in the Territory is paid. In the
year in which first dosing of the first patient in the first Phase 1 Study for a Licensed Product anywhere in the Territory Initiation is achieved, Acuitas will credit the License Maintenance Fee for that year on a pro rata basis against the
Milestone Payment for such Milestone Event. For clarity, this pro rata credit will be for the remaining months in the year to which the License Maintenance Fee applies. 

4.2 Milestone Payments. Verve will make milestone payments (each, a “Milestone Payment”) to Acuitas upon
the first occurrence of each of the milestone events (each, a “Milestone Event”) by Verve or its Affiliates with respect to the Licensed Product as set forth below in TABLE 4.2. Verve will notify Acuitas of the
achievement of each Milestone Event within [**] of such achievement. Each Milestone Payment will be payable to Acuitas by Verve within [**] of the achievement of the specified Milestone Event and such payments when owed or paid will be non-refundable and non-creditable. If one or more of the Milestone Events set forth below are not achieved with respect to the Licensed Product for any reason, the payment for
such skipped Milestone Event will be due at the same time as the payment for the next achieved Milestone Event for the Licensed Product. For clarity, each Milestone Payment is payable a maximum of one (1) time only, and the maximum aggregate
Milestone Payments under this Agreement is Nineteen Million Two Hundred Fifty Thousand Dollars (US$19,250,000). 

  
 13 

 TABLE 4.2– Milestone Events 

 

			
	 Milestone Event
	  	 Milestone Payment

	 [**]
	  	[**] Dollars (US$[**])
	 [**]
	  	[**] Dollars (US$[**])
	 [**]
	  	[**] Dollars (US$[**])
	 [**]
	  	[**] Dollars (US$[**])
	 [**]
	  	[**] Dollars (US$[**])
	 First achievement of aggregate Net Sales of Licensed Products in a calendar year in the Territory
are equal to or greater than [**] Dollars (US$[**])
	  	[**] Dollars (US$[**])

 4.3 Royalties. 

(a) Royalties. Subject to the Royalty Term, Verve will pay to Acuitas a royalty equal to [**] percent ([**]%) of
Net Sales on annual Net Sales of all Licensed Products sold by Verve, its Affiliates, or Sublicensees in the Territory for which, but for the license granted to Verve hereunder, the manufacture or sale of such Licensed Product would infringe a Valid
Claim of an LNP Technology Patent in such country (“Patent Royalties”). If, at any time during the Royalty Term, the manufacture or sale of a Licensed Product in a particular country would not infringe a Valid Claim of an LNP
Technology Patent, then the Royalty rate used to calculate royalty payments on Net Sales of such Licensed Product in such country shall be the Minimum Royalty (“Know-How Royalties,” and together with the Patent Royalties, the
“Royalties”). 
 (b) Third-Party Royalty Payments. If Verve or its Affiliate or Sublicensee
considers it necessary or useful to obtain a license from any Third-Party under Technology relating to LNP Technology in order to develop, manufacture or commercialize a Licensed Product, the amount of Verve’s Royalty obligations under
Section 4.4(a) will be reduced by [**] percent ([**]%) of the amount of the royalty payments made to such Third-Party (“Third-Party Royalty Payments”), provided, however, that such reduction shall not result in less than
the Minimum Royalty. 
 (c) Minimum Royalty. In no event will the Royalty payable by Verve to Acuitas for any Licensed Product
and without regard to any Royalty reductions under subparagraph (a) and/or (b) above, be less than the Royalty payable using a royalty rate of [**] percent ([**]%) (the “Minimum Royalty”). 

  
 14 

 (d) Royalty Term. The Royalty term (“Royalty
Term”) shall be determined on a country-by-country and Licensed
Product-by-Licensed Product basis and shall commence on the First Commercial Sale of a Licensed Product in such country and shall expire on the last to occur of
(i) the expiration of the last to expire Valid Claim in the Licensed Technology that Covers the Licensed Product in such country, (ii) the expiration of any period of Regulatory Exclusivity, if any, for the Licensed Product in such
country, and (iii) ten (10) years from the First Commercial Sale of Licensed Product in such country (the “Licensed Product Royalty Term”). Thereafter, Verve’s license under Section 2.1 will become irrevocable, fully paid-up and royalty-free on a country-by-country and Licensed
Product-by-Licensed Product basis. 
 (e)
Blended Royalty. The Parties acknowledge and agree that the Licensed Technology licensed under this License Agreement may justify Royalty rates and/or Royalty Terms of differing amounts for the sale of Licensed Products in the
Territory, depending on the number of LNP Technology Patents and their respective expiry. The Parties have determined in light of such considerations and for reasons of mutual convenience that blended Royalty rates for the Licensed Technology
licensed hereunder will apply during a single Royalty Term for sales of a Licensed Product in the Territory. Consequently, the Parties have agreed to adopt the Royalty rates set forth in this Section 4.4 with respect to the sales of Licensed
Products in the Territory as blended Royalty rates. For the avoidance of doubt, Verve’s obligation to pay Royalties under this Section 4.4 is imposed only once at the applicable Royalty rate set forth in this Section 4.3 with respect
to the same unit of Licensed Product, notwithstanding that such Licensed Product may be Covered by more than one Valid Claim of an LNP Technology Patent. 

4.4 Payment Terms. 

(a) Manner of Payment; Invoices. All amounts specified in this License Agreement are in U.S. dollars and all
payments to be made by Verve hereunder will be made in U.S. dollars by wire transfer to such bank account as Acuitas may designate. All invoices to be delivered to Verve hereunder shall be delivered in accordance with Section 11.12 or in such
other manner specified by Verve from time to time. 
 (b) Records and Audits. Verve shall keep, and shall cause
each of its Affiliates and Sublicensees, as applicable, to keep adequate books and records of accounting for the purpose of calculating all Royalties payable to Acuitas hereunder. For the [**] next following the end of the calendar year to which
each shall pertain, such books and records of accounting of Verve (including those of Verve’s Affiliates) shall be kept at each of their principal places of business and shall be open for inspection at reasonable times and upon reasonable
notice by an independent certified accountant selected by Acuitas, and which is reasonably acceptable to Verve, for the sole purpose of inspecting the Royalties due to Acuitas under this License Agreement. In no event shall such inspections be
conducted hereunder more frequently than [**] or more than [**] for the same time period. Such accountant must have executed and delivered to Verve and its Affiliates a confidentiality agreement as reasonably requested by Verve, which shall include
provisions limiting such accountant’s disclosure to Acuitas to only the results and basis for such results of such inspection. The results of such inspection, if any, shall be binding on both Parties absent manifest error. Any underpayments
shall be paid by Verve within [**] of notification of the results of such inspection. Any overpayments shall be fully creditable against amounts payable in 

  
 15 

 
subsequent payment periods, or, upon the request of Verve, paid by Acuitas to Verve within [**] of notification of the results of such inspection. Acuitas shall pay for such inspections, except
that in the event there is any upward adjustment in aggregate Royalties payable for any calendar year shown by such inspection of more than [**] percent ([**]%) of the amount paid, in which case Verve shall reimburse Acuitas for any reasonable out-of-pocket costs of such accountant. 
 (c)
Reports and Royalty Payments. For as long as Royalties are due under Section 4.4, Verve shall furnish to Acuitas a written report for each Calendar Quarter, showing the amount of Net Sales of Licensed Products and
Royalties due for such Calendar Quarter. Reports shall be provided within [**] of the end of the Calendar Quarter for Net Sales generated by Verve and its Affiliates, and within [**] of the end of the Calendar Quarter for Net Sales generated by
Sublicensees. Royalty payments for each Calendar Quarter shall be due at the same time as the last such written report for the Calendar Quarter. The report shall include, at a minimum, the following information for the applicable Calendar Quarter,
each listed by Licensed Product and by country of sale: (i) the number of units of Licensed Products sold by Verve and its Affiliates and Sublicensees on which Royalties are owed to Acuitas hereunder; (ii) the gross amount received for
such sales; (iii) Net Sales; (iv) the amounts of any credits or reductions permitted by Section 4.4; and (v) the computations for any Acuitas currency conversions pursuant to subsection (d) below. Verve will require each
Sublicensee to share with Verve the information listed in the foregoing clauses as it relates to Net Sales made by such Sublicensee, and to the extent practicable, will include such Sublicensee information in such report. All such reports shall be
treated as Confidential Information of Verve. 
 (d) Currency Exchange. With respect to Net Sales invoiced in
U.S. dollars, the Net Sales and the amounts due to Acuitas hereunder will be expressed in U.S. dollars. With respect to Net Sales invoiced in a currency other than U.S. dollars, payments will be calculated based on standard methodologies employed by
Verve or its Affiliates or Sublicensees for consolidation purposes for the Calendar Quarter for which remittance is made for Royalties. 

(e) Taxes. Verve may withhold from payments due to Acuitas amounts for payment of any withholding tax that is required by Law to
be paid to any taxing authority with respect to such payments. Verve will provide Acuitas all relevant documents and correspondence and will also provide to Acuitas any other cooperation or assistance on a reasonable basis as may be necessary to
enable Acuitas to claim exemption from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Verve will give proper evidence from time to time as to the payment of any such tax. The Parties will
cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Verve making payments from a single source in the U.S., where possible. Apart
from any such permitted withholding and those deductions expressly included in the definition of Net Sales, the amounts payable by Verve to Acuitas hereunder will not be reduced on account of any taxes, charges, duties or other levies. 

(f) Blocked Payments. In the event that, by reason of applicable Law in any country, it becomes impossible or illegal for Verve
or its Affiliates or Sublicensees to transfer, or have transferred on its behalf, payments owed to Acuitas hereunder, Verve will promptly notify Acuitas of the conditions preventing such transfer and such payments will be deposited in local

  
 16 

 
currency in the relevant country to the credit of Acuitas in a recognized banking institution designated by Acuitas or, if none is designated by Acuitas within a period of [**], in a recognized
banking institution selected by Verve or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to Acuitas. 

(g) Interest Due. If any payment due to Acuitas under this License Agreement is overdue (and is not subject to a
good faith dispute), then Verve will pay interest thereon (before and after any judgment) at an annual rate of the lesser of [**] percent ([**]%) above the prime rate as reported in The Wall Street Journal, Eastern Edition, and the maximum rate
permitted by applicable Law, such interest to run from the date upon which payment of such sum became due until payment thereof in full together with such interest. 

(h) Mutual Convenience of the Parties. The Royalty and other payment obligations set forth hereunder have been agreed to by the
Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying Royalties and other amounts to Acuitas. 

ARTICLE 5 
 Ownership
and Inventorship of IP 
 As between the Parties, and except as set forth in Section 2.3(d), each Party will own and retain all
right, title and interest in and to any and all Know-How and Patents arising therefrom that are discovered, created, conceived, developed or reduced to practice solely by or on behalf of such Party under or in
connection with this License Agreement (“Solely Owned Technology”). For clarity, in the event that Verve elects to undertake Additional Development Studies for a Licensed Product, ownership of Technology arising under such studies
will be determined in accordance with the provisions of the Development and Option Agreement as applied to studies conducted under the Workplan. Subject to the licenses hereunder and the other terms and conditions of this License Agreement or any
other agreement between the Parties, each Party will be solely responsible for the prosecution and maintenance, and the enforcement and defense, of any Patents within its Solely Owned Technology. 

ARTICLE 6 
 Patent
Prosecution and Maintenance 
 6.1 Generally. As between the Parties and subject to Section 6.2 below,
Acuitas will have the sole right, at its sole cost, to prosecute and maintain LNP Technology Patents. The Parties will enter into a joint patent prosecution and maintenance agreement with respect to the Jointly Owned Patents, as further provided in
the Development and Option Agreement. 
 6.2 Election Not to Prosecute or Maintain or Pay Patent Costs. If
Acuitas elects not (i) to file, prosecute or maintain any LNP Technology Patents for which it is responsible under Section 6.1 in any particular country before the applicable filing deadline or continue such activities once filed in a
particular country, or (ii) to pay the Patent Costs associated with prosecution or maintenance of any such LNP Technology Patents, then in each such case Acuitas 

  
 17 

 
will so notify Verve, promptly in writing and in good time to enable Acuitas to meet any deadlines by which an action must be taken to preserve such LNP Technology Patent in such country, if
Verve so requests. Upon receipt of each such notice by Acuitas, Verve will have the right, but not the obligation, to notify Acuitas in writing on a timely basis that Acuitas should continue the prosecution and/or maintenance of such LNP Technology
Patent in the respective country, and thereafter, (a) Acuitas would prosecute and maintain such LNP Technology Patent in such country at the direction and expense of Verve and any other Acuitas Third-Party licensee of such LNP Technology Patent
so electing (on a pro rata basis), (b) Acuitas would make available to Verve all documentation and correspondence with respect to such LNP Technology Patent, and (c) Verve’s license to such LNP Technology Patent under Section 2.1
will automatically become irrevocable, perpetual, fully paid-up and royalty free but such LNP Technology Patent will thereafter no longer be part of the Licensed Technology in such country for all other
purposes of this License Agreement (e.g., such LNP Technology Patent will not be considered for purposes of determining whether a Valid Claim exists in a particular country). Verve is entitled to discontinue the payment of Patent Costs for any LNP
Technology Patents at any time, provided that it will so notify Acuitas in writing in time for such discontinuance. 
 6.3
Regulatory Exclusivity Periods. With respect to any Patent term extension, supplemental protection certificate or any other Patent listing or extension with respect to any LNP Technology Patent Covering a Licensed Product, the
Parties will discuss and seek to reach mutual agreement, subject to applicable Law, on which LNP Technology Patents will be subject to such action, and once such agreement is reached, Acuitas will cooperate with such action. Except where required
under applicable Law, without the written consent of Verve, Acuitas will not apply for, and is not authorized under this License Agreement to apply for, any Patent term extension, supplemental protection certificate or any other Patent listing or
extension required for any regulatory exclusivity periods for any Licensed Product. For the avoidance of doubt, Acuitas is not restricted from applying for any Patent term extension, supplemental protection certificate or any other Patent listing or
extension required for any regulatory exclusivity periods for any product but the Licensed Products. 
 6.4 Patent
Listings. Verve shall have the sole right, in its sole discretion, to make all filings with Regulatory Authorities in the Territory for the Licensed Products in the FDA’s Orange Book or Purple Book or in response to a biosimilar
application under Section 351(k) of the Public Health Service Act, and under any similar or equivalent Laws in other countries or jurisdictions. 

6.5 Cooperation. Each Party will reasonably cooperate with the other Party in those activities involving the LNP
Technology Patents set forth in Sections 6.1 to 6.4. Such cooperation includes promptly executing all documents, or requiring inventors, subcontractors, employees and consultants and agents of Verve and Acuitas and their respective Affiliates and
Sublicensees to execute all documents, as reasonable and appropriate so as to enable such activities in respect of any such LNP Technology Patents in any country. 

  
 18 

 ARTICLE 7 

Patent Enforcement and Defense 

7.1 Notice. To the extent not in breach of an obligation of confidentiality, each Party will promptly notify, in writing, the
other Party upon learning of any actual or suspected infringement of any LNP Technology Patents by a Third-Party, or of any claim of invalidity, unenforceability, or non-infringement of any LNP Technology
Patents, and will, along with such notice, supply the other Party with any evidence in its possession pertaining thereto. 
 7.2
Enforcement and Defense. 
 (a) Enforcement. 

(i) As between the Parties, Acuitas will have the first right, but not the obligation, at its sole cost to seek to abate any
infringement of the LNP Technology Patents other than the Jointly Owned Patents (the “Acuitas Patents”) by a Third-Party, or to file suit against any such Third-Party for such infringement. If Acuitas elects not to exercise its
first right to take action or to bring suit to prosecute such infringement or to continue such action or suit, it shall notify Verve in writing of such election within [**] after becoming aware of or receipt of the notice of the infringement or
within [**] after the election to stop any such action or suit, as applicable. If after the expiration of the [**] period (or, if earlier, the date upon which Acuitas provides written notice that it does not plan to bring such action), Acuitas has
neither obtained a discontinuance of infringement nor filed suit against any such Third-Party infringer of such Patent, or in the case of an election by Acuitas not to continue to prosecute an infringement of an Acuitas Patent, Verve shall have the
right, but not the obligation, to take action or bring suit against such Third-Party infringer of Acuitas Patents to the extent the Acuitas Patents are necessary or useful for the research, development, manufacturing and commercialization of the
Licensed Product but not necessary or useful for the research, development, manufacturing or commercialization of any other LNP comprising product covered by such Acuitas Patent that is licensed or optioned by Acuitas to a Third-Party or is under
Late Stage Development by Acuitas, provided that Verve shall bear all of the expense of such abatement action or suit. 

(ii) As between the Parties, Acuitas will have the right, but not the obligation, at its sole cost to seek to abate any
infringement of the Jointly Owned Patents by a Third-Party, or to file suit against any such Third-Party for such infringement, if such infringement is with respect to the LNP Technology. As between the Parties, Verve will have the right, but not
the obligation, at its sole cost to seek to abate any infringement of the Jointly Owned Patents by a Third-Party, or to file suit against any such Third-Party for such infringement, if such infringement is with respect to the Licensed Product. 

(iii) Except as expressly provided under Section 7.2(a)(ii), neither Party shall seek to abate any infringement of the
Jointly Owned Patents by a Third-Party, or file suit against any such Third-Party for such infringement, without the prior written consent of the other Party. For clarity, Verve shall have the sole right to enforce any Patents owned or controlled by
Verve other than the LNP Technology Patents. 

  
 19 

 (b) Defense. 

(i) As between the Parties, Acuitas will have the first right, but not the obligation, at its sole cost, to defend against a
declaratory judgment action or other action to the extent challenging the validity or enforceability of any Acuitas Patent. Verve will have the right but not the obligation, at its sole cost, to defend against any other declaratory judgment action
or other action challenging any Acuitas Patent that, on the date of first notice of such action, are not necessary or useful for the research, development, manufacturing and commercialization of any lipid nanoparticle comprising product that is
licensed or optioned by Acuitas to a Third-Party or is under Late Stage Development by Acuitas. If Acuitas does not take steps to defend within a commercially reasonable time, or elects not to continue any such defense (in which case it will
promptly provide notice thereof to Verve), then Verve shall have the right, but not the obligation, to defend any Acuitas Patents that cover a Licensed Product and no other product licensed or optioned by Acuitas to a Third-Party or commercialized
by Acuitas provided that Verve shall bear all the expenses of such suit. If a Third-Party files a declaratory judgment or other action challenging any Jointly Owned Patent, the Parties shall reasonably cooperate in good faith to determine each
Party’s responsibility with respect to the defense of such declaratory judgment or other action. 
 (ii) In the event
that any action, suit or proceeding is brought against either Party or an Affiliate of either Party, or a Sublicensee of Verve or its Affiliates, alleging the infringement of the Patents or Know-How of a
Third-Party by the research, development, manufacture, use, sale, import, export, commercialization or exploitation of a Licensed Product, such Party shall promptly notify the other Party within [**] of the earlier of (x) receipt of service of
process in such action, suit or proceeding, or (y) the date such Party becomes aware that such action, suit or proceeding has been instituted. Except as set forth in subsection (a) above of this License Agreement, Verve shall have the
right, but not the obligation, to defend such action, suit or proceeding in the Territory at its sole cost. For clarity, Verve shall have the sole right to defend any Patents owned or controlled by Verve other than the LNP Technology Patents. 

(c) Response to Infringement Claims. Notwithstanding the foregoing, any response to a Third-Party infringer’s counterclaim
of invalidity or unenforceability of any LNP Technology Patents shall be controlled by the Party who controls the relevant enforcement proceeding pursuant to Section 7.2(a) unless otherwise mutually agreed by the Parties. 

(d) Withdrawal, Cooperation and Participation. With respect to any infringement or defensive action identified above in
this Section 7.2 which may be controlled by either Verve or Acuitas: 
 (i) The
non-controlling Party will cooperate with the Party controlling any such action (as may be reasonably requested by the controlling Party), including by (A) providing access to relevant documents and other
evidence, (B) making its and its Affiliates and Sublicensees and all of their respective employees, subcontractors, consultants and agents available at reasonable business hours and for reasonable periods of time, but only to the extent
relevant to such action, and (C) if necessary, being joined as a party, subject for this clause (C) to the controlling Party agreeing to indemnify such 

  
 20 

 
non-controlling Party for its involvement as a named party in such action and paying those Losses incurred by such Party in connection with such joinder. The Party controlling any such action
will keep the other Party updated with respect to any such action, including providing copies of all documents received or filed in connection with any such action. 

(ii) Each Party will have the right to participate or otherwise be involved in any such action controlled by the other Party,
in each case at the participating (i.e., non-controlling) Party’s sole cost and expense. If a Party elects to so participate or be involved, the controlling Party will provide the participating Party and
its counsel with an opportunity to consult with the controlling Party and its counsel regarding the prosecution of such action (including reviewing the contents of any correspondence, legal papers or other documents related thereto), and the
controlling Party will take into account reasonable requests of the participating Party regarding such enforcement or defense. The foregoing shall not apply to any defensive actions described in Section 7.2(b)(ii) that do not involve claims
specifically relating to an LNP Technology Patent. 
 (e) Settlement. Neither Party will settle or consent to an
adverse judgment in any action described in this Section 7.2 and controlled by such Party, including any judgment which affects the scope, validity or enforcement of any LNP Technology Patents involved therewith, without the prior written
consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed); provided, that the foregoing shall not apply to the extent that such settlement or consent to an adverse judgment does not relate to an LNP Technology
Patent. 
 (f) Damages. Unless otherwise agreed by the Parties, all monies recovered upon the final judgment or
settlement of any action which may be controlled by either Verve or Acuitas and described in Section 7.2(a) or 7.2(b) in each case will be used first to reimburse the controlling Party, and thereafter the
non-controlling Party, for each of their out-of-pocket costs and expenses relating to the action, with the balance of any such
recovery to be divided as follows: 
 (i) To the extent such recovery reflects lost profits damages or a reasonable royalty
with respect to Licensed Products, Verve will retain such lost profits recovery, less the amount of Royalties payable to Acuitas by treating such lost profits recovery as “Net Sales” hereunder; and 

(ii) Any other recovery based on Licensed Products will be allocated [**] percent ([**]%) to the Party controlling the action
and [**] percent ([**]%) to the other Party; provided, that if such action is controlled by Verve and does not relate to an LNP Technology Patent or any other Patent claiming Joint IP, then any other recovery will be allocated [**] percent ([**]%)
to Verve. 

  
 21 

 ARTICLE 8 

Confidentiality 

8.1 Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party
(“Receiving Party”) and Receiving Party may acquire during the course and conduct of activities under this License Agreement, certain proprietary or confidential information of Disclosing Party in connection with this License
Agreement. The term “Confidential Information” means all information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, that is disclosed or made
available by or on behalf of the Disclosing Party to or on behalf of the Receiving Party in connection with this License Agreement. 
 8.2
Restrictions. During the Term and for [**] thereafter, or with respect to any trade secret included in the Confidential Information for so long as such trade secret is protected under applicable Laws (provided, that Receiving Party
has not publicly disclosed such trade secret in breach of its obligations under this Article 8), Receiving Party will keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party
holds its own confidential information, but in no event less than reasonable care. Receiving Party will not use Disclosing Party’s Confidential Information except for in connection with the performance of its obligations and exercise of its
rights under this License Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent to Receiving Party’s Affiliates, and each of their employees,
subcontractors, consultants and agents who have a need to know such Confidential Information in order to perform their obligations and exercise their rights under this License Agreement and who are under written obligation to comply with the
restrictions on use and disclosure that are no less restrictive than those set forth in this Section 8.2. Receiving Party assumes responsibility for such entities and persons maintaining Disclosing Party’s Confidential Information in
confidence and using same only for the purposes described herein. 
 8.3 Exceptions. Receiving Party’s obligation
of nondisclosure and the limitations upon the right to use the Disclosing Party’s Confidential Information will not apply to a specific portion of the Disclosing Party’s Confidential Information to the extent that Receiving Party can
demonstrate that such portion: (a) was known to Receiving Party or any of its Affiliates prior to the time of disclosure by the Disclosing Party without obligation of confidentiality; (b) is or becomes public knowledge through no fault or
omission of Receiving Party or any of its Affiliates; (c) is obtained on a non-confidential basis by Receiving Party or any of its Affiliates from a Third-Party who to Receiving Party’s knowledge is
lawfully in possession thereof and under no obligation of confidentiality to Disclosing Party; or (d) has been independently developed by or on behalf of Receiving Party or any of its Affiliates without the aid, application or use of Disclosing
Party’s Confidential Information. 
 8.4 Permitted Disclosures. Receiving Party may disclose Disclosing
Party’s Confidential Information to the extent (and only to the extent) such disclosure is permitted under Section 8.2 or is reasonably necessary in the following instances: 

(a) in order and to the extent required to comply with applicable Laws (including any securities Laws or regulations or the rules
of a securities exchange applicable to Receiving Party) or with a legal or administrative proceeding; 
 (b) in connection with
prosecuting or defending litigation; 

  
 22 

 (c) in connection with filing, prosecuting and enforcing LNP Technology
Patents in connection with Receiving Party’s rights and obligations pursuant to this License Agreement; 
 (d) to
acquirers or permitted assignees, investment bankers, investors and lenders, including potential acquirers, assignees, investment bankers, investors and lenders; and 

(e) in the case of Verve, to (i) subcontractors, (ii) licensees, Sublicensees, assignees and collaboration partners, or
(iii) potential licensees, Sublicensees, assignees or collaboration partners, but in case (iii) only such information that is reasonably necessary or useful for the potential licensee, Sublicensee, assignee or collaboration partner to
evaluate the Licensed Product and LNP/Licensed Product manufacturing processes; provided, that (1) where reasonably possible, Receiving Party will notify Disclosing Party of Receiving Party’s intent to make any disclosure pursuant to
subsections (a) and (b) sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and
(2) with respect to subsections (d) and (e), each of those entities are required to comply with the restrictions on use and disclosure in Section 8.2 (other than investment bankers, investors and lenders, which must be bound prior to
disclosure by commercially reasonable obligations of confidentiality). 
 8.5 Return of Confidential Information. Upon
expiry or earlier termination of this License Agreement, upon written request of a Party (such request, if made, to be made within [**] of such expiry or termination) the other Party will destroy or return (as shall be specified in such request) to
the requesting Party all copies of the Confidential Information of the requesting Party; provided, that a Party may retain: (a) one copy of such Confidential Information for record-keeping purposes, for the sole purpose of ensuring compliance
with this License Agreement; (b) any copies of such Confidential Information as is required to be retained under applicable Laws; (c) any copies of such Confidential Information as is necessary or useful for such Party to exercise a right
or fulfill an obligation under another License Agreement, if any, or as set forth in this License Agreement; and (d) any copies of any computer records and files containing Confidential Information that have been created by such Party’s
routine archiving/backup procedures, in each case provided that such copies are maintained in accordance with this Article 8. 
 8.6
Publications. Notwithstanding anything in this License Agreement to the contrary, Verve is permitted to publish the results of its development under this License Agreement, provided, however, that it will not disclose
Acuitas’ Confidential Information or Joint Confidential Information in any publication by Verve of the results of any Licensed Product development by Verve without Acuitas’ prior written consent, which will not be unreasonably withheld,
conditioned or delayed. Verve will comply with standard academic practice regarding authorship of scientific publications and recognition of the contributions of other parties in any scientific publications. 

8.7 Terms of this License Agreement; Publicity. The Parties agree that the existence and terms of the Parties’
relationship and this License Agreement will be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by Sections 8.2 or 8.4. Except as required by applicable Laws (including any securities Laws or the

  
 23 

 
regulations or rules of a securities exchange) or otherwise agreed by the Parties in writing, each Party agrees not to issue any press release or public statement disclosing information relating
to the existence of this License Agreement or the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party. 

ARTICLE 9 

Warranties; Limitations of Liability; Indemnification 

9.1 Representations and Warranties. Each Party represents and warrants to the other as of the License Agreement Effective
Date that: 
 (a) it is a corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction
in which it is incorporated, 
 (b) it has the legal right and power to enter into this License Agreement, to extend the rights
and licenses granted or to be granted to the other in this License Agreement, and to fully perform its obligations hereunder, 
 (c)
it has taken all necessary corporate action on its part required to authorize the execution and delivery of this License Agreement and the performance of its obligations hereunder, 

(d) this License Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and
binding obligation of such Party that is enforceable against it in accordance with its terms, 
 (e) the execution, delivery
and performance of this License Agreement by such Party does not violate any Law of any court, governmental body or administrative or other agency having jurisdiction over such Party, and 

(f) no government authorization, consent, approval, license, exemption of or filing or registration with any court or
governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is necessary for the transactions contemplated by this License Agreement or for the performance of its
obligations under this License Agreement. 
 9.2 Additional Representations of Acuitas. Except as set forth on
Appendix 9.2, Acuitas hereby represents and warrants to Verve as of the License Agreement Effective Date as follows 
 (a)
Impairment. Neither Acuitas nor any of its Affiliates has entered into any agreement or otherwise licensed, granted, assigned, transferred, conveyed or otherwise encumbered or disposed of any right, title or interest in or to any of its
assets, including any Technology, that would in any way conflict with or impair the scope of any rights or licenses granted to Verve hereunder. 

  
 24 

 (b) Patents and Know-How. Appendix
1.44 sets forth a complete and accurate list of all LNP Technology Patents. Acuitas Controls, and will Control during the Term, the Licensed Technology, and is entitled to grant the licenses specified herein. All Acuitas inventors of the
Licensed Technology have validly assigned their rights to the Licensed Technology to Acuitas. To Acuitas’ knowledge, the LNP Technology Patents have been diligently prosecuted and maintained in accordance with applicable Laws. None of the LNP
Technology Patents are or have been involved in any opposition, cancellation, interference, reissue or reexamination proceeding, and to Acuitas’ knowledge as of the License Agreement Effective Date, no Licensed Technology is the subject of any
judicial, administrative or arbitral order, award, decree, injunction, lawsuit, proceeding or stipulation. As of the License Agreement Effective Date, neither Acuitas nor any of its Affiliates has received any notice alleging that the LNP Technology
Patents are invalid or unenforceable or challenging Acuitas’ ownership of or right to use the Licensed Technology. 
 (c) Entire
LNP Technology. The Acuitas LNP Technology licensed to Verve under this License Agreement comprises all LNP Technology owned or Controlled by Acuitas. 

(d) Encumbrances. Acuitas and its Affiliates are not subject to any payment obligations to Third Parties as a result of the
execution or performance of this License Agreement. As of the License Agreement Effective Date, neither Acuitas nor any of its Affiliates has granted any liens or security interests on the Licensed Technology, and the Licensed Technology as licensed
hereby is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind. 

(e) Defaults. The execution, delivery and performance by Acuitas of this License Agreement and the consummation of the
transactions contemplated hereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any understanding, contract or agreement to which Acuitas is a party or by which it is bound, in each case as
would reasonably be expected to have a material adverse effect on the rights granted to Verve hereunder. 
 (f) Litigation.
There is no action, suit, proceeding or investigation pending or, to the knowledge of Acuitas, currently threatened in writing against or affecting Acuitas that questions the validity of this License Agreement, the right of Acuitas to enter into
this License Agreement or consummate the transactions contemplated hereby or that relates to the Licensed Technology. 
 (g)
Infringement. Neither Acuitas nor any of its Affiliates has received any notice of any claim, nor does Acuitas or its Affiliates have any knowledge of any reasonable basis for any claim, that any Patent,
Know-How or other intellectual property owned or controlled by a Third-Party would be infringed or misappropriated by the practice of any Licensed Technology in connection with the production, use, research,
development, manufacture or commercialization of any Licensed Product. 
 (h) Third-Party Infringement. To Acuitas’
knowledge, no Third-Party is infringing or has infringed any Patent within the Licensed Technology or is misappropriating or has misappropriated any Know-How within the Licensed Technology. 

  
 25 

 9.3 Disclaimers. Without limiting the respective rights and obligations
of the Parties expressly set forth herein, each Party specifically disclaims any guarantee that any Licensed Product will be successful, in whole or in part. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS LICENSE AGREEMENT, THE PARTIES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTY OF ANY KIND UNDER THIS LICENSE AGREEMENT, EITHER EXPRESS OR IMPLIED. 
 9.4 No
Consequential Damages. NOTWITHSTANDING ANYTHING IN THIS LICENSE AGREEMENT OR OTHERWISE, NEITHER PARTY WILL BE LIABLE TO THE OTHER OR ANY THIRD-PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS LICENSE AGREEMENT FOR ANY INDIRECT,
PUNITIVE, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES; PROVIDED THAT THIS SECTION 9.4 WILL NOT APPLY TO BREACHES OF A PARTY’S OBLIGATIONS UNDER ARTICLE EIGHT OR THE PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER SECTION 9.6. 

9.5 Performance by Others. The Parties recognize that each Party may perform some or all of its obligations under this
License Agreement through Affiliates and Third-Party agents provided, however, that each Party will remain responsible and liable for the performance by its Affiliates and Third-Party agents and will cause its Affiliates and Third-Party agents to
comply with the applicable provisions of this License Agreement in connection therewith. 
 9.6 Indemnification.

(a) Indemnification by Verve. Verve will indemnify Acuitas, its Affiliates and their respective directors,
officers, employees and agents, and their respective successors, heirs and assigns (collectively, “Acuitas Indemnitees”), and defend and hold each of them harmless, from and against any and all losses, damages, liabilities, costs
and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third-Party
Claims”) against the Acuitas Indemnitees to the extent arising from or occurring as a result of: (i) the breach by Verve of any provision of this License Agreement; (ii) any negligence or willful misconduct on the part of any
Verve Indemnitee in connection with this Agreement; or (iii) the development or commercialization by or on behalf of Verve or any of its Affiliates or Sublicensees of Licensed Products, except in each case (i)-(iii) to the extent Acuitas is
obligated to indemnify Verve in accordance with Section 9.6(b) of this License Agreement. 
 (b) Indemnification by
Acuitas. Acuitas will indemnify Verve, its Affiliates, its Sublicensees and their respective directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, “Verve Indemnitees”),
and defend and hold each of them harmless, from and against any and all Losses in connection with any and all Third-Party Claims against Verve Indemnitees to the extent arising from or occurring as a result of: (i) the breach by Acuitas of any
provision of this License Agreement; or (ii) any negligence or willful misconduct on the part of any Acuitas Indemnitee in connection with this Agreement; or any (iii) any allegation that the use of Licensed Technology in accordance with
the license and other rights granted to Verve hereunder infringes or misappropriates the Patents or other intellectual property rights of a Third Party, except in each case (i)-(iii) to the extent Verve is obligated to indemnify Acuitas in
accordance with Section 9.6(a) of this License Agreement. 

  
 26 

 (c) Notice of Claim. All indemnification claims provided for in
Sections 9.6(a) and 9.6(b) will be made solely by such Party to this License Agreement (the “Indemnified Party”). The Indemnified Party will promptly notify the Indemnifying Party (the “Indemnifying Party”) in
writing of any Losses or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under Section 9.6(a) and 9.6(b) (each such notice, an “Indemnification Claim Notice”), provided
that the failure to promptly provide such notice and details shall not relieve the Indemnifying Party of any of its indemnification obligations hereunder except to the extent that the Indemnifying Party’s defense of the relevant Third-Party
Claim is prejudiced by such failure. Each Indemnification Claim Notice must contain a description of the claim and the nature and estimated amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The
Indemnified Party will furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any Losses and Third-Party Claims. 

(d) Defense, Settlement, Cooperation and Expenses. 

(i) Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third-Party Claim by giving
written notice to the Indemnified Party within [**] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a Third-Party Claim, the Indemnifying Party may appoint as lead counsel in the defense
of the Third-Party Claim any legal counsel selected by the Indemnifying Party (the Indemnifying Party will consult with the Indemnified Party with respect to such counsel and a possible conflict of interest of such counsel retained by the
Indemnifying Party). In the event the Indemnifying Party assumes the defense of a Third-Party Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by the
Indemnified Party in connection with the Third-Party Claim. 
 (ii) Right to Participate in Defense. Without limiting
Section 9.6(d)(i), any Indemnified Party will be entitled to participate in, but not control, the defense of such Third-Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the
Indemnified Party’s own cost and expense unless (A) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 9.6(d)(i) (in which case the Indemnified Party will control the defense), (B)
the Indemnifying Party is not diligently defending the interests of both Parties, or (C) the interests of the Indemnified Party and the Indemnifying Party with respect to such Third-Party Claim are sufficiently adverse to prohibit the
representation by the same counsel of both Parties under applicable Law, ethical rules or equitable principles, in which case the Indemnifying Party will assume [**] percent ([**]%) of any such costs and expenses of counsel for the Indemnified
Party. 

  
 27 

 (iii) Settlement. With respect to any Third-Party Claims that relate
solely to the payment of money damages in connection with a Third-Party Claim and that will not (A) result in the Indemnified Party’s becoming subject to injunctive or other relief, (B) include any admission or concession of liability
or wrongdoing on the part of the Indemnified Party, or (C) otherwise adversely affect the business of the Indemnified Party in any manner, and as to which the Indemnifying Party will have acknowledged in writing the obligation to indemnify the
Indemnified Party hereunder, the Indemnifying Party will have the sole right to agree to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the Indemnifying Party, in its sole discretion, will
deem appropriate. With respect to all other Losses in connection with Third-Party Claims, where the Indemnifying Party has assumed the defense of the Third-Party Claim in accordance with Section 9.6(d)(i), the Indemnifying Party will have
authority to agree to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (such consent not to be unreasonably withheld, delayed or
conditioned). The Indemnifying Party will not be liable for any settlement or other disposition of a Loss by an Indemnified Party that is reached without the prior written consent of the Indemnifying Party. Regardless of whether the Indemnifying
Party chooses to defend or prosecute any Third-Party Claim, no Indemnified Party will admit any liability with respect to or settle, compromise or discharge, any Third-Party Claim without the prior written consent of the Indemnifying Party, such
consent not to be unreasonably withheld, delayed or conditioned. 
 (iv) Cooperation. Regardless of whether the
Indemnifying Party chooses to defend or prosecute any Third-Party Claim, the Indemnified Party will, and will cause each other Indemnified Party to, cooperate in the defense or prosecution thereof and will furnish such records, information and
testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith, at the Indemnifying Party’s expense. Such cooperation will include access
during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third-Party Claim, and making Indemnified Parties and other
employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith. 

(v) Costs and Expenses. Except as provided above in this Section 9.6(d), the costs and expenses, including
attorneys’ fees and expenses, incurred by the Indemnified Party in connection with any claim will be reimbursed on a Calendar Quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the
Indemnified Party’s right to indemnification and subject to prompt refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

9.7 Insurance. Each Party will maintain at its sole cost and expense, an adequate liability insurance or self-insurance
program (including product liability insurance) to protect against potential liabilities and risk arising out of activities to be performed under this License Agreement and upon such terms (including coverages, deductible limits and self-insured
retentions) as are customary in the respective industry of such Party for the activities to be 

  
 28 

 
conducted by such Party under this License Agreement. Subject to the preceding sentence, such liability insurance or self-insurance program will insure against all types of liability, including
personal injury, physical injury or property damage arising out of the manufacture, sale, use, distribution or marketing of Licensed Products. The coverage limits set forth herein will not create any limitation on a Party’s liability to the
other under this License Agreement. Upon the request of a Party, the other Party will provide evidence of the insurance coverage required by this Section 9.7. 

ARTICLE 10 
 Term and
Termination 
 10.1 Term. This License Agreement will commence as of the License Agreement Effective Date and,
unless sooner terminated in accordance with the terms hereof or by mutual written consent, will continue on a Licensed Product-by-Licensed Product and a country-by-country basis, until there are no more Royalty payments owed Acuitas in such country with respect to such Licensed Product (the longest such period of time
hereunder, the “Term”). Upon expiration of the Term with respect to the applicable Licensed Product in the applicable country, the license contained in Section 2.1 will become fully paid-up,
royalty-free, perpetual and irrevocable with respect to such Licensed Product in such country. 
 10.2 Termination by Acuitas.

 (a) Breach. Acuitas will have the right to terminate this License Agreement in full upon delivery of
written notice to Verve in the event of a material breach by Verve of its obligations under this License Agreement, provided that such breach has not been cured within [**] after written notice thereof is given by Acuitas to Verve specifying the
nature of the alleged breach. 
 (b) Disputed Breach. If Verve disputes in good faith the existence or materiality of a breach
specified in a notice provided in accordance with Section 10.2(a), and Verve provides Acuitas notice of such dispute within such [**] period, then Acuitas shall not have the right to terminate this License Agreement under Section 10.2(a)
unless and until it is finally determined, in accordance with Section 11.1, that Verve has materially breached this License Agreement and Verve has failed to cure such breach within [**] following such decision. It is understood and agreed that
during the pendency of such dispute, all of the terms and conditions of this License Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. During the pendency of any such dispute,
Verve shall pay to Acuitas all Milestone Payments and Royalty payments set forth herein that may become due during such period. 
 10.3
Termination by Verve. 
 (a) Breach. Verve will have the right to terminate this License Agreement in
full upon delivery of written notice to Acuitas in the event of a material breach by Acuitas of its obligations under this License Agreement, provided that such breach has not been cured within [**] after written notice thereof is given by Verve to
Acuitas specifying the nature of the alleged breach. 

  
 29 

 (b) Discretionary Termination. Verve will have the right to terminate this
License Agreement in full at its discretion for any reason by delivering written notice to Acuitas, such termination to be effective thirty (30) days following the date of such notice. 

(c) Alternative to Termination Under Section 10.3(a). 

(i) If Verve has the right to terminate this License Agreement under Section 10.3(a), then Verve may, in lieu of
exercising such termination right, elect by written notice to Acuitas before the end of such applicable cure period to have this License Agreement continue in full force and effect for the Term, provided that the following will apply: starting
immediately after the end of such applicable cure period, Verve may reduce by [**] percent ([**]%) the Milestone Payments and the Royalty rates subject to the Minimum Royalty. 

(ii) In the event Acuitas notifies Verve within [**] days of receipt of Verve’s notice of material breach that Acuitas
reasonably and in good faith disputes Verve’s right to terminate this License Agreement pursuant to Section 10.3(a), Verve shall instead deposit such [**] percent ([**]%) of Milestone Payments and Royalty payments into an escrow account
maintained by a mutually agreeable Third-Party pending the resolution of such dispute in accordance with Section 11.1. If Acuitas raises such dispute, the informal dispute resolution process in Section 11.1(a) shall not apply, and the
negotiation period for the Executive Officers in Section 11.1(a) shall be limited to [**]. 
 (iii) In the event that it
is established through the dispute resolution process that Verve did have the right to terminate this License Agreement under Section 10.3(a), then the escrowed funds shall be released to Verve and the [**] percent ([**]%) reduction shall
continue to apply going forward. In the event that it is established through the dispute resolution process that Verve did not have the right to terminate this License Agreement under Section 10.3(a), then the escrowed funds shall be released
to Verve and Verve will pay to Acuitas the full amount of the Milestone Payments and Royalties that would have been payable with interest payable by Verve in accordance with Section 4.4(g), and the Milestone Payments and the Royalty payments
going forward shall continue to be paid in accordance with Article 4 without any reduction under this Section 10.3(c). 
 10.4
Termination Upon Bankruptcy. If either Party makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over all or substantially all of its property, files a petition or
commences a proceeding under any bankruptcy or insolvency act in any state or country or has any such petition or application filed against it which is not discharged within [**] of the filing thereof, then the other Party may thereafter terminate
this License Agreement effective immediately upon written notice to such Party. All rights and licenses granted under or pursuant to this License Agreement by Acuitas are, and will otherwise be deemed to be, for purposes of Section 65.11(7) of
the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3 and Section 32(6) of the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36 (the
“Insolvency Legislation”), a grant of “right to use intellectual property” as 

  
 30 

 
used in the Insolvency Legislation. The Parties agree that Verve and its Affiliates and Sublicensees, as licensees of such rights under this License Agreement, will retain and may fully exercise
all of their rights and elections under the Insolvency Legislation subject to the payment of amounts provided for herein. Without limiting Verve’s rights under the Insolvency Legislation, if Acuitas becomes insolvent or makes an assignment for
the benefit of its creditors or there is filed by or against Acuitas any bankruptcy, receivership, reorganization or similar proceeding pursuant to or under the Insolvency Legislation or otherwise, Verve shall be entitled to a copy of any and all
such intellectual property and all embodiments of such intellectual property, and the same, if not in the possession of Acuitas, shall be promptly delivered to it (a) before this License Agreement is disclaimed, repudiated, rescinded or
terminated by or on behalf of Acuitas, within [**] after Verve’s written request, unless Acuitas, or its trustee or receiver, elects within [**] to continue to perform all of its obligations under this License Agreement, or (b) after any
disclaimer, repudiation, rescission or termination of this License Agreement by or on behalf of Acuitas, if not previously delivered as provided under clause (a) above. All rights of the Parties under this Section 10.4 and under the
Insolvency Legislation are in addition to and not in substitution of any and all other rights, powers, and remedies that each Party may have under this License Agreement, the Insolvency Legislation, and any other applicable Laws. 

10.5 Effects of Termination. Upon termination (but not expiration of the Term pursuant to Section 10.1) of
this License Agreement for any reason: 
 (a) Cessation of Rights. Except as otherwise expressly provided herein,
all rights and licenses granted by Acuitas to Verve in Section 2.1 will terminate. 
 (b) Sell Off.
Notwithstanding the termination of Verve’s licenses and other rights under this License Agreement, Verve shall retain the right to distribute, sell or otherwise dispose of its existing inventory of the Licensed Products, in each case that
is intended for distribution, sale or disposition in the Territory, for a period of not more than [**] following the date of the effective termination, as though this License Agreement had not been terminated, and such distribution, sale or other
disposition shall not constitute infringement of the Patents or other intellectual property or proprietary rights of Acuitas or its Affiliates. Verve’s right to distribute, sell or otherwise dispose of its existing inventory of the Licensed
Products pursuant to this Section 10.5(b) shall be subject to Verve’s continuing obligation to pay Royalties with respect to the Net Sales. 

10.6 Survival. In addition to the termination consequences set forth in Section 10.5, the following provisions will
survive termination or expiration of this License Agreement: Article 1 (to the extent applicable to any other surviving provisions), Article 3, Article 5, Article 8 and Article 11, and Sections 2.1(a) (in accordance with (i) the last sentence
of Section 4.4(d), to the extent applicable, (ii) Section 6.2, to the extent applicable, or (iii) the last sentence of Section 10.1 but only upon expiration of the Term), 2.3(b)(iv) (only upon the circumstances set forth
therein), 4.4(b), 9.3, 9.4, 9.5, 9.6, the last sentence of Section 10.1 (only upon expiration of the Term), 10.4, 10.5 and this Section 10.6. Termination or expiration of this License Agreement will not relieve the Parties of any liability
or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this
License Agreement nor prejudice either Party’s right to obtain performance of any obligation. All other rights and obligations will terminate upon termination or expiration of this License Agreement. 

  
 31 

 ARTICLE 11 

General Provisions 

11.1 Dispute Resolution. 

(a) Disputes. Disputes arising under or in connection with this License Agreement will be resolved pursuant to this
Section 11.1; provided, however, that in the event a dispute cannot be resolved without an adjudication of the rights or obligations of a Third-Party (other than any Verve Indemnitees or Acuitas Indemnitees identified in Section 9.6), the
dispute procedures set forth Sections 11.1(b) and 11.1(c) will be inapplicable as to such dispute. 
 (b)
Dispute Escalation. In the event of a dispute between the Parties, the Parties will first attempt in good faith to resolve such dispute by negotiation and consultation between themselves or the Workplan Leaders. In the event
that such dispute is not resolved on an informal basis within [**], any Party may, by written notice to the other, have such dispute referred to each Party’s Chief Executive Officer or his or her designee (who will be a senior executive
“Executive Officers”), who will attempt in good faith to resolve such dispute by negotiation and consultation for a [**] period following receipt of such written notice. 

(c) Dispute Resolution. In the event the Executive Officers of the Parties are not able to resolve such dispute as
set forth above, the Executive Officers will together elect whether to submit the dispute to mediation, litigation or arbitration. In the absence of such an agreement, either Party may elect to initiate litigation. 

(d) Injunctive Relief. Notwithstanding the dispute resolution procedures set forth in this Section 11.1, in the event of an
actual or threatened breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific performance or other injunctive relief) in any court or other forum, without first submitting to any dispute resolution
procedures hereunder. 
 (e) Tolling. The Parties agree that all applicable statutes of limitation and time-based defenses
(such as estoppel and laches) will be tolled while the dispute resolution procedures set forth in this Section 11.1 are pending, and the Parties will cooperate in taking all actions reasonably necessary to achieve such a result. 

(f) Prevailing Party. The prevailing Party in any suit related to this License Agreement will be entitled to recover from the
losing Party all out-of-pocket fees, costs and expenses (including those of attorneys, professionals and accountants and all those arising from appeals and
investigations) incurred by the prevailing Party in connection with such arbitration or suit. 

  
 32 

 11.2 Cumulative Remedies and Irreparable Harm. All rights and remedies
of the Parties hereunder will be cumulative and in addition to all other rights and remedies provided hereunder or available by agreement, at Law or otherwise. Each Party acknowledges and agrees that breach of any of the terms or conditions of this
License Agreement may cause irreparable harm and damage to the other and that such damage may not be ascertainable in money damages and that as a result thereof the non-breaching Party may be entitled to seek
from a court equitable or injunctive relief restraining any breach or future violation of the terms contained herein by the breaching Party without the necessity of proving actual damages or posting bond. Such right to equitable relief is in
addition to whatever remedies either Party may be entitled to as a matter of Law or equity, including money damages. 
 11.3
Relationship of Parties. Nothing in this License Agreement is intended or will be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the Parties. No Party will incur any debts or
make any commitments for the other, except to the extent, if at all, specifically provided therein. There are no express or implied Third-Party beneficiaries hereunder (except for Verve Indemnitees and Acuitas Indemnitees for purposes of
Section 9.6). For clarity, Verve does not grant to Acuitas any rights or licenses under this License Agreement to any Verve Technology or intellectual property rights. 

11.4 Compliance with Law. Each Party will perform or cause to be performed any and all of its obligations or the
exercise of any and all of its rights hereunder in good scientific manner and in compliance with all applicable Law. 
 11.5
Governing Law. This License Agreement will be governed by and construed in accordance with the Laws of the State of New York, United States, without respect to its conflict of Laws rules, provided that any dispute relating to the
scope, validity, enforceability or infringement of any Patents or Know-How will be governed by, and construed and enforced in accordance with, the substantive Laws of the jurisdiction in which such Patents or Know-How apply. 
 11.6 Counterparts; Facsimiles. This License Agreement may be
executed in one or more counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. Facsimile or PDF execution and delivery of this License Agreement by either Party will
constitute a legal, valid and binding execution and delivery of this License Agreement by such Party. 
 11.7 Headings.
All headings in this License Agreement are for convenience only and will not affect the meaning of any provision hereof. 
 11.8
Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this License Agreement. Accordingly, the rule of construction that any ambiguity
in this License Agreement will be construed against the drafting Party will not apply. 

  
 33 

 11.9 Interpretation. Whenever any provision of this License Agreement
uses the term “including” (or “includes”), such term will be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,”
“hereunder,” “hereof” and other equivalent words refer to this License Agreement as an entirety and not solely to the particular portion of this License Agreement in which any such word is used. All definitions set forth herein
will be deemed applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Appendices in this License Agreement are to Sections and Appendices of this License
Agreement. References to any Sections include Sections and subsections that are part of the related Section. 
 11.10 Binding
Effect. This License Agreement will inure to the benefit of and be binding upon the Parties, their Affiliates, and their respective lawful successors and assigns. 

11.11 Assignment. This License Agreement may not be assigned by either Party, nor may either Party delegate its
obligations or otherwise transfer licenses or other rights created by this License Agreement, except as expressly permitted hereunder or otherwise without the prior written consent of the other Party, which consent will not be unreasonably withheld,
conditioned or delayed; provided that either Party may assign this License Agreement without such consent to an Affiliate or to its successor in connection with the sale of all or substantially all of its assets or business or that portion of its
business pertaining to the subject matter of this License Agreement (whether by merger, consolidation or otherwise). 
 11.12
Notices. All notices, requests, demands and other communications required or permitted to be given pursuant to this License Agreement will be in writing and will be deemed to have been duly given upon the date of receipt if
delivered by hand, email, recognized international overnight courier, or registered or certified mail, return receipt requested, postage prepaid to the following addresses: 

 

			
	if to Verve:	  	 Verve Therapeutics, Inc.
 500 Technology
Square
 Cambridge, MA 02139
 Attention: COO

Email: [**]

		
	With a copy to:	  	 Wilson Sonsini Goodrich & Rosati
 650
Page Mill Road
 Palo Alto, CA 94304
 Attention: Lowell
Segal
 Email: [**]

		
	If to Acuitas:	  	 Acuitas Therapeutics Inc.
 6190 Agronomy Road
Suite 405
 Vancouver, B.C.
 Canada V6T 1Z3

Attention: President and CEO
 Email:
[**]

  
 34 

			
	With a copy to:	  	 McCarthy Tetrault LLP
 Suite 2400 745 Thurlow
Street
 Vancouver, B.C.
 Canada V6E 0C5

Attention: Miranda Lam, Esq.
 Email: [**]

 Either Party may change its designated address by notice to the other Party in the manner provided in
this Section 11.12. 
 11.13 Amendment and Waiver. This License Agreement may be amended, supplemented, or
otherwise modified only by means of a written instrument signed by both Parties; provided that any unilateral undertaking or waiver made by one Party in favor of the other will be enforceable if undertaken in a writing signed by the Party to be
charged with the undertaking or waiver. Any waiver of any rights or failure to act in a specific instance will relate only to such instance and will not be construed as an agreement to waive any rights or fail to act in any other instance, whether
or not similar. 
 11.14 Severability. In the event that any provision of this License Agreement will, for any reason,
be held to be invalid or unenforceable in any respect, such invalidity or unenforceability will not affect any other provision hereof, and the Parties will negotiate in good faith to modify the License Agreement to preserve (to the extent possible)
their original intent. 
 11.15 Entire Agreement. This License Agreement is the sole agreement with respect to the
subject matter hereof and supersedes all other agreements and understandings between the Parties with respect to same. 
 11.16
Force Majeure. Neither Acuitas nor Verve will be liable for failure of or delay in performing obligations set forth in this License Agreement (other than any obligation to pay monies when due), and neither will be deemed in breach
of such obligations, if such failure or delay is due to natural disasters or any causes reasonably beyond the control of Acuitas or Verve; provided that the Party affected will promptly notify the other of the force majeure condition and will exert
reasonable efforts to eliminate, cure or overcome any such causes and to resume performance of its obligations as soon as possible. 

[Remainder of this Page Intentionally Left Blank] 

  
 35 

 WITNESS WHEREOF, the Parties have caused this
Non-Exclusive License Agreement to be executed by their respective duly authorized officers as of the License Agreement Effective Date. 

 

			
	 ACUITAS THERAPEUTICS, INC.

		
	By:	 	 /s/ T.D. Madden

		 	(Signature)
		
	Name:	 	Thomas Madden
		
	Title:	 	President & CEO
		
	Date:	 	October 15, 2020
	
	 VERVE THERAPEUTICS, INC.

		
	By:	 	 /s/ Andrew D. Ashe

		 	(Signature)
		
	Name:	 	Andrew D. Ashe
		
	Title:	 	President & COO
		
	Date:	 	10/15/2020

 Signature Page to Non-Exclusive License AgreementEX-10.13

 Exhibit 10.13 

Execution Version 

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of
information that the registrant treats as private or confidential. 
 Double asterisks denote omissions. 

CAS9 LICENSE AGREEMENT 

by and between 

THE PRESIDENT AND FELLOWS OF HARVARD
COLLEGE, 
 THE BROAD INSTITUTE, INC. 

and 

VERVE THERAPEUTICS, INC. 

March 14, 2019 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 1. DEFINITIONS
	  	 	2	 
		
	 2. LICENSE
	  	 	27	 
			
	 2.1
	 	License Grants	  	 	27	 
			
	 2.2
	 	Reservation of Rights	  	 	28	 
			
	 2.3
	 	Affiliates	  	 	29	 
			
	 2.4
	 	Right to Subcontract	  	 	30	 
			
	 2.5
	 	Sublicenses	  	 	30	 
			
	 2.6
	 	U.S. Manufacturing	  	 	32	 
			
	 2.7
	 	No Other Grant of Rights	  	 	32	 
			
	 2.8
	 	Additional Limitations on Exercise of License Rights	  	 	32	 
		
	 3. DEVELOPMENT AND COMMERCIALIZATION
	  	 	32	 
			
	 3.1
	 	Diligence; Development Milestones	  	 	32	 
			
	 3.2
	 	Inclusive Innovation Model	  	 	33	 
			
	 3.3
	 	Development Plan; Adjustments	  	 	35	 
			
	 3.4
	 	Reporting	  	 	35	 
			
	 3.5
	 	Failure to Meet Development Milestone; Opportunity to Cure	  	 	35	 
		
	 4. CONSIDERATION FOR GRANT OF LICENSE
	  	 	37	 
			
	 4.1
	 	Division of Consideration	  	 	37	 
			
	 4.2
	 	License Issue Fee	  	 	38	 
			
	 4.3
	 	License Maintenance Fees	  	 	38	 
			
	 4.4
	 	Issuance of Equity	  	 	38	 
			
	 4.5
	 	Milestone Payments	  	 	39	 
			
	 4.6
	 	Royalties	  	 	41	 
			
	 4.7
	 	Sublicense Income	  	 	45	 
			
	 4.8
	 	Sublicense Income Offset	  	 	45	 
			
	 4.9
	 	Complex Consideration	  	 	45	 
			
	 4.10
	 	Additional Consideration	  	 	46	 
			
	 4.11
	 	Share Issuance Limitation	  	 	49	 
			
	 4.12
	 	Non-Circumvention	  	 	49	 
		
	 5. REPORTS; PAYMENTS; RECORDS
	  	 	49	 
			
	 5.1
	 	Reports and Payments	  	 	49	 

  
 i 

							
	 5.2
	 	Payment Currency	  	 	50	 
			
	 5.3
	 	Records	  	 	50	 
			
	 5.4
	 	Late Payments	  	 	51	 
			
	 5.5
	 	Payment Method	  	 	51	 
			
	 5.6
	 	Withholding and Similar Taxes	  	 	52	 
		
	 6. PATENT PROSECUTION
	  	 	52	 
			
	 6.1
	 	Prosecution of Patent Rights	  	 	52	 
			
	 6.2
	 	Fees and Expenses	  	 	52	 
			
	 6.3
	 	Abandonment	  	 	53	 
			
	 6.4
	 	Large Entity Designation	  	 	54	 
			
	 6.5
	 	Marking	  	 	54	 
		
	 7. ENFORCEMENT OF PATENT RIGHTS
	  	 	54	 
			
	 7.1
	 	Notification	  	 	54	 
			
	 7.2
	 	Licensor Institutions’ Enforcement Right	  	 	54	 
			
	 7.3
	 	Suit by Owner Institutions	  	 	56	 
			
	 7.4
	 	Own Counsel	  	 	57	 
			
	 7.5
	 	Cooperation	  	 	57	 
			
	 7.6
	 	Patent Validity Challenge	  	 	57	 
		
	 8. WARRANTIES; LIMITATION OF LIABILITY
	  	 	57	 
			
	 8.1
	 	Compliance with Law	  	 	57	 
			
	 8.2
	 	Representations, Warranties and Covenants	  	 	57	 
			
	 8.3
	 	Disclaimer	  	 	59	 
			
	 8.4
	 	Limitation of Liability	  	 	59	 
		
	 9. INDEMNIFICATION AND INSURANCE
	  	 	59	 
			
	 9.1
	 	Indemnification	  	 	59	 
			
	 9.2
	 	Insurance	  	 	61	 
		
	 10. TERM AND TERMINATION
	  	 	62	 
			
	 10.1
	 	Term	  	 	62	 
			
	 10.2
	 	Termination	  	 	62	 
			
	 10.3
	 	Effect of Termination	  	 	64	 
			
	 10.4
	 	Survival	  	 	67	 
		
	 11. MISCELLANEOUS
	  	 	67	 
			
	 11.1
	 	Confidentiality	  	 	67	 
			
	 11.2
	 	Use of Name	  	 	69	 

  
 ii 

							
	 11.3
	 	Press Release	  	 	70	 
			
	 11.4
	 	No Security Interest	  	 	70	 
			
	 11.5
	 	Entire Agreement	  	 	70	 
			
	 11.6
	 	Notices	  	 	70	 
			
	 11.7
	 	Dispute Resolution	  	 	71	 
			
	 11.8
	 	Governing Law and Jurisdiction	  	 	71	 
			
	 11.9
	 	Binding Effect	  	 	71	 
			
	 11.10
	 	Headings	  	 	71	 
			
	 11.11
	 	Counterparts	  	 	71	 
			
	 11.12
	 	Amendment; Waiver	  	 	72	 
			
	 11.13
	 	No Agency or Partnership	  	 	72	 
			
	 11.14
	 	Assignment and Successors	  	 	72	 
			
	 11.15
	 	Force Majeure	  	 	72	 
			
	 11.16
	 	Interpretation	  	 	72	 
			
	 11.17
	 	Severability	  	 	73	 
			
	 11.18
	 	HHMI Third Party Beneficiary	  	 	73	 

 List of Exhibits: 
  

	
	 Exhibit 1.23 – Cas9 Patent Rights Categories

Exhibit 1.25 – Cas9-I Patent Rights

Exhibit 1.31 – Cas9-II Patent Rights

Exhibit 1.144 – Reviewed Patent Rights

	 Exhibit 1.166 – Targets

	 Exhibit 3.1 – Development Milestones

Exhibit 3.3 – Development Plan

	 Exhibit 4.4.1 – Stock Issuance Agreement

  
 iii 

 CAS9 LICENSE AGREEMENT 

This Cas9 License Agreement (this “Agreement”) is entered into as of this 14th day of March, 2019 (the “Effective
Date”), by and between, on the one hand, the President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business
at Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”) and The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at
415 Main Street, Cambridge, MA 02142 (“Broad,” together with Harvard, the “Licensor Institutions” and each individually, a “Licensor Institution”) and, on the other hand, Verve
Therapeutics, Inc., a Delaware corporation, with a principal office at 26 Landsdowne Street, Cambridge, MA 02139 (“Company”). Company and the Licensor Institutions are each referred to herein as a “Party” and
together, the “Parties.” 
 WHEREAS, the technology claimed in the Cas9-I
Patent Rights (as defined below) was discovered by researchers at the Licensor Institutions; 
 WHEREAS, the technology claimed in
the Cas9-II Patent Rights (as defined below) was discovered by researchers at one or more of the Cas9-II Institutions (as defined below); 

WHEREAS, one or more of such researchers at the Licensor Institutions is an employee of the Howard Hughes Medical Institute
(“HHMI”) and HHMI has assigned to Harvard its rights in those Cas9-I Patent Rights on which an HHMI employee is an inventor, subject to certain rights retained by HHMI as specifically
described below; 
 WHEREAS, Harvard is a sole owner of certain of the Cas9-I Patent Rights,
which are identified as “Harvard Controlled Patents” on the attached Exhibit 1.25 (the “Harvard Controlled Patents”); 

WHEREAS, the Massachusetts Institute of Technology (“MIT,” a not-for-profit Massachusetts Corporation with a principal place of business at 77 Massachusetts Avenue, Cambridge, Massachusetts 02139) and Broad are co-owners of
certain of the Cas9-I Patent Rights (the “MIT/Broad Co-Owned Cas9-I Patent Rights”) set forth on Exhibit 1.25;

 WHEREAS, Harvard, MIT and Broad are co-owners of certain of the Cas9-I Patent Rights (the “Harvard/MIT/Broad Co-Owned Cas9-I Patent Rights”), identified together with the MIT/Broad Co-Owned Cas9-I Patent Rights as “Broad Controlled Patents” on the attached Exhibit 1.25; 

WHEREAS, The Rockefeller University (“Rockefeller,” a
not-for-profit New York corporation with a principal place of business at 1230 York Avenue, New York, NY 10065) and Broad are
co-owners of certain of the Cas9-I Patent Rights set forth on Exhibit 1.25; 

WHEREAS, Broad, MIT, Harvard and/or the University of Iowa Research Foundation (“Iowa,” a not-for-profit corporation existing under the laws of the State of Iowa, having a place of business at 112 N. Capitol Street, 6 Gilmore Hall, Iowa City, IA 52242) are co-owners of certain of the Cas9-II Patent Rights set forth on Exhibit 1.31; 

  
 1 

 WHEREAS, (i) pursuant to that certain Operating Agreement by and among Broad,
MIT and Harvard, dated July 1, 2009, MIT and Harvard have authorized Broad to act as their sole and exclusive agent for the purposes of licensing, as applicable, the MIT/Broad Co-Owned Cas9-I Patent Rights and the Harvard/MIT/Broad Co-Owned Cas9-I Patent Rights, as well as their interest in the co-owned Cas9-II Patent Rights, and MIT and Harvard have authorized Broad to enter into this Agreement on their behalf with respect to such patent rights, (ii) pursuant
to that certain Joint Invention Administration Agreement by and between Broad, MIT and Iowa dated December 9, 2014, as amended August 19, 2016, MIT and Iowa have authorized Broad to act as their sole and exclusive agent for the purposes of
licensing their interest in the co-owned Cas9-II Patent Rights, and MIT and Iowa have authorized Broad to enter into this Agreement on their behalf with respect to such
patent rights and (iii) pursuant to that certain Inter-Institutional Agreement by and between Broad and Rockefeller dated February 13, 2017, Rockefeller has authorized Broad to act as its sole and exclusive agent for the purposes of
licensing its interest in the co-owned Cas9-I Patent Rights, and Rockefeller has authorized Broad to enter into this Agreement on its behalf with respect to such patent
rights; 
 WHEREAS, Company wishes to obtain a license under the Cas9-I Patent Rights; 

WHEREAS, Company wishes to obtain a co-exclusive license in the Field under the Cas9-II Institutions’ interest in the Cas9-II Group A Patent Rights and a non-exclusive license under the Cas9-II Institutions’ interest in the Cas9-II Group A Patent Rights and the Cas9-II Group B Patent Rights; 

WHEREAS, the Owner Institutions desire to have products based on the inventions described in the Patent Rights developed and
commercialized to benefit the public; and 
 WHEREAS, Company has represented to the Licensor Institutions, in order to induce the
Licensor Institutions to enter into this Agreement, that Company shall commit itself to the development and commercialization of such products so that public utilization shall result. 

NOW, THEREFORE, the Parties hereto, intending to be legally bound, hereby agree as follows: 

1. DEFINITIONS. 
 Whenever used in
this Agreement with an initial capital letter, the terms defined in this Article 1, whether used in the singular or the plural, shall have the meanings specified below. 

1.1. “Abandoned Patent Rights” has the meaning set forth in Section 6.3.1 

1.2. “Achieved Milestone” has the meaning set forth in Section 4.5.1. 

1.3. “Acquisition Value” means, with respect to a Company Sale, the sum of the Upfront Acquisition Value and the Trailing
Acquisition Value. For the purpose of determining Upfront Acquisition Value or Trailing Acquisition Value, the valuation of any securities or other non-cash assets paid as consideration with respect to a
Company Sale shall be determined by reference to the operative transaction agreement(s) for such Company Sale, provided that, if no such valuation is readily determinable from such operative transaction agreement(s), then: 

  
 2 

 (a) for securities primarily listed and quoted for trading on the New York Stock Exchange,
the NYSE Amex Equities (formerly the American Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or other securities exchange, the per share value shall be deemed to be the average of the closing
prices of such securities on such exchange or market, as applicable, over the [**] period ending [**] prior to the Company Sale Date; 
 (b)
for securities primarily listed and quoted for trading on the OTC Bulletin Board or equivalent, the per share value shall be deemed to be the average of the closing bid prices over the [**] period ending [**] prior to the Company Sale Date; 

(c) for all other securities or for assets other than securities or cash, the value shall be determined in good faith by mutual agreement of
the Licensor Institutions and Company (or Company’s acquirer or successor entity, as applicable). If the Parties are not able to agree in good faith on such value within [**] after payment of such securities or property, then such dispute will
be handled pursuant to Section 11.7 of the Agreement. 
 1.4. “Adverse Disclosure” has the meaning set forth in
Section 4.10.3.3. 
 1.5. “Affiliate” means, as to any Person, any other Person that controls, is
controlled by, or is under common control with, such Person. For purposes of this definition only, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” means the
possession, directly or indirectly, of the power to direct the management or policies of an organization or entity, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance, or otherwise.
Without limiting the foregoing, control shall be presumed to exist when a Person (a) owns or directly controls more than fifty percent (50%) of the voting securities or other ownership interest of another Person or (b) possesses, directly
or indirectly, the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the other Person. 
 1.6.
“Ag Product” means any product comprising a plant, plant tissue, plant cell, plant part or plant seed, including any organism in the microbiome used in association with such plant, plant tissue, plant cell, plant part or plant seed,
that is used for agricultural purposes. 
 1.7. “Agreement” has the meaning set forth in the Preamble. 

1.8. “Anti-Dilution Shares” has the meaning set forth in Section 4.4.2. 

1.9. “Anti-Dilution Threshold” means (a) [**] percent ([**]%) of Company’s outstanding capital stock on a Fully-Diluted
Basis or (b) following an Equity Event, if applicable, [**] percent ([**]%) of Company’s outstanding capital stock on a Fully-Diluted Basis. 

  
 3 

 1.10. “Applicable Law” means (a) with respect to a given
jurisdiction, all applicable laws, rules and regulations (including any rules, regulations, guidelines or other requirements of any regulatory authorities) that may be in effect from time to time in such jurisdiction, and (b) with respect to
any jurisdiction that does not have laws, rules or regulations that govern genetically modified organisms (including genetically modified crops), all applicable laws, rules and regulations (including any rules, regulations, guidelines or other
requirements of any regulatory authorities) of the United States federal government that may be in effect from time to time to the extent applicable to genetically modified organisms (including genetically modified crops). 

1.11. “Asset Sale” means the sale, lease, assignment, transfer, exclusive license or other disposition of all or
substantially all of the assets of Company to one or more entities that are not wholly owned subsidiaries of Company. 
 1.12.
“Average Market Capitalization” means the result of (i) the sum of the Market Capitalizations on each Trading Day during a specified period of time divided by (ii) the number of Trading Days during such specified period of
time. 
 1.13. “Bankruptcy Event” means, with respect to any Person, any of the following: 

(a) such Person shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself
or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, or shall
consent to any such relief or to the appointment of, or taking possession by, any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally
to pay its debts as they become due, or shall take any corporate action to authorize any of the foregoing; 
 (b) an involuntary case or
other proceeding shall be commenced against such Person seeking liquidation, reorganization or other relief with respect to it or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment
of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of [**]; or an order for relief
shall be entered against such Person under the federal bankruptcy laws as now or hereafter in effect; or 
 (c) a receiver or trustee shall
be appointed with respect to such Person or all or substantially all of the assets of such Person. 
 1.14. “Broad” has the
meaning set forth in the Preamble. 
 1.15. “Broad Confidential Information” has the meaning set forth in
Section 11.1.1. 
 1.16. “Broad Controlled Patents” has the meaning set forth in the Recitals. 

  
 4 

 1.17. “Calendar Quarter” means each of the periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 during the Term. 
 1.18.
“Calendar Year” means any twelve (12) month period commencing on January 1. 
 1.19. “Cardiovascular
Disease” means atherosclerotic cardiovascular diseases and aortic valve diseases and their prevention through lipid (cholesterol and/or triglyceride) reduction. For the avoidance of doubt, “Cardiovascular Disease” does not
include any inflammatory disease or condition or any form of cancer or symptoms of any of the foregoing, or side effects of such inflammatory disease or condition or cancer or the treatment thereof. 

1.20. “Cardiovascular Disease Field” means, solely with respect to products and processes directed to the Targets, intended
for the prevention or treatment of Cardiovascular Disease (i) using gene therapy, (ii) using editing (including modifying) of Genetic Material or (iii) using targeting of Genetic Material (including targeting of Genetic Material to
modify associated chromatin), either (a) ex vivo for subsequent administration to a human, in the case of the foregoing clause (ii) or (iii) of a product so edited or targeted, or (b) in vivo, by a product administered to a human, in
the case of the foregoing clause (ii) or (iii) of a product that so edits or targets; provided that, the Cardiovascular Disease Field does not include (I) the prevention or treatment of Cardiovascular Disease using a small or large
molecule that (A) was identified or discovered using technology Covered by the Patent Rights, (B) is Covered by (x) a Valid Claim of the Patent Rights Covering the identifying or discovering of small or large molecules, and/or
(y) a product-by-process or similar Valid Claim of the Patent Rights directed to a small or large molecule so identified or discovered, and (C) is not Covered
by any other Valid Claim of the Patent Rights; (II) (A) modifying animals or animal cells for the creation, making, having made, use, sale, offer for sale, having sold, exportation and importation of organs suitable for xenotransplantation into
humans or (B) research and development, and commercialization and other use or exploitation, of products or services in the field of Livestock Applications; (III) production or processing of small or large molecules, including for the
prevention or treatment of Cardiovascular Disease, that are made using technology Covered by the Patent Rights, unless such small or large molecules (xx) are used for (1) gene therapy, (2) editing (including modifying) of Genetic
Material or (3) targeting of Genetic Material (including targeting of Genetic Material to modify associated chromatin), in the case of (2) and (3) to the extent such editing or targeting is achieved through the use of CRISPR Technology or
TALE Technology (other than through the making of such small or large molecules) and in each case (1), (2) and (3) as set forth in clauses (a) and (b) above, and (yy) are not otherwise excluded from this definition of Cardiovascular
Disease Field; (IV) Ag Products; and (V) any products, including without limitation any Ag Product or any product in the field of Livestock Applications, that provide nutritional benefits, unless such products (aa) are regulated by a
Regulatory Authority as a drug or biologic pursuant to Section 505 of the United States Federal Food, Drug, and Cosmetic Act of 1938, as amended, Section 351 of the United States Public Health Service Act of 1944, as amended, or any
successor laws, or equivalent laws or regulations in jurisdictions outside the United States and (bb) are otherwise included in this definition of Cardiovascular Disease Field. In addition, with respect to the Delivery Patent Rights, the
Cardiovascular Disease Field only includes targeting of Genetic Material as set forth in clauses (a) and (b) above if such targeting is related to the use of CRISPR Technology, TALE Technology or zinc finger nuclease technology. 

  
 5 

 1.21. “Cas9 Enabled Product” means any product or process,
other than a Licensed Product, which is or incorporates, or which is made, identified, discovered, developed, optimized, characterized, selected, derived from or determined to have utility, in whole or in part, by the use or modification of,
(a) any Cas9-I Patent Rights or Cas9-II Group A Patent Rights or any technology or invention covered thereby, (b) any Cas9 Licensed Product, (c) any
progeny, modification or derivative of a Cas9 Licensed Product, or (d) any living or nonliving cell, organism, microorganism (including viruses) made or modified through use of a Cas9 Licensed Product or technology covered by the Cas9-I Patent Rights or Cas9-II Group A Patent Rights, or any progeny, clone, modification or derivative of such living or nonliving cell, organism, microorganism (including
viruses); provided, however, that the term “Cas9 Enabled Product” shall not include any large or small molecule that (i) was identified or discovered using a Cas9 Licensed Product or technology Covered by the Cas9-I Patent Rights or Cas9-II Group A Patent Rights and (ii) does not otherwise meet the definition of Cas9 Enabled Product (i.e., it is identified or discovered using
a Cas9 Licensed Product or technology covered by the Cas9-I Patent Rights or Cas9-II Group A Patent Rights but otherwise is not, or does not incorporate, or is not made,
developed, optimized, characterized, selected, derived from or determined to have utility, in whole or in part, by the use or modification of a Cas9 Licensed Product or technology covered by the Cas9-I Patent
Rights or Cas9-II Group A Patent Rights in a way that would cause it to be included in the definition of Cas9 Enabled Product). For clarity, the term “Cas9 Enabled Product” shall also not include any
product or process (other than a Licensed Product), for which the sole use of the Cas9-I Patent Rights or Cas9-II Group A Patent Rights or technology covered thereby in
connection with such product or process was to (x) serve as a control in the development of, or comparator in the pre-clinical development of, such product or process or (y) evaluate the efficacy of
such Cas9-I Patent Rights or Cas9-II Group A Patent Rights or technology covered thereby as applied to such product or process. 

1.22. “Cas9 Licensed Product” means, on a
country-by-country basis, any product or process the making, using, selling, offering for sale, exporting or importing of which product or process in the country in
question is Covered by at least one Valid Claim of the Cas9-I Patent Rights or Cas9-II Group A Patent Rights in that country. If, during the Royalty Term for a given
Cas9 Licensed Product, such Cas9 Licensed Product is no longer Covered by at least one Valid Claim of the Cas9-I Patent Rights or Cas9-II Group A Patent Rights in a
country, and is not Covered by at least one Valid Claim of any other Patent Right in such country, then such Cas9 Licensed Product shall be deemed a Cas9 Enabled Product in such country from that time forward for the purposes of calculating
Milestone Payments under Section 4.5 and Royalties under Section 4.6, unless and until such product or process is again Covered by at least one Valid Claim of the Cas9-I Patent Rights or Cas9-II Group A Patent Rights, at which time it shall again be deemed a Cas9 Licensed Product for such purposes. 

1.23. “Cas9 Patent Rights Categories” means the CRISPR Patent Rights, the TALE Patent Rights and the Delivery
Patent Rights. 

  
 6 

 1.24. “Cas9-I Institution” means
each of the Licensor Institutions, MIT and Rockefeller individually, and “Cas9-I Institutions” means the Licensor Institutions, MIT and Rockefeller, collectively. 

1.25. “Cas9-I Patent Rights” means the patents and patent applications
that are listed on the attached Exhibit 1.25 and any and all divisionals, continuations, continuations-in-part (only to the extent of claims that are entitled to
the priority date of and directed specifically to the subject matter claimed in the applications listed on the attached Exhibit 1.25), substitutes, counterparts and foreign equivalents thereof filed in any country, and any patents issuing thereon
(but in the case of patents issuing on continuations-in-part applications, only to the claims thereof that are entitled to the priority date of and directed specifically
to the subject matter claimed in the applications listed on the attached Exhibit 1.25) and any reissues, reexaminations or extensions thereof. The Cas9-I Patent Rights are the CRISPR Patent Rights, the TALE
Patent Rights and the Delivery Patent Rights. 
 1.26. “Cas9-II Group A Patent
Rights” means the patents and patent applications that are listed on the attached Exhibit 1.31 under the heading “Cas9-II Group A Patent Rights” and any and all divisionals,
continuations, continuations-in-part (only to the extent of claims that are entitled to the priority date of and directed specifically to the subject matter claimed in
the applications listed on the attached Exhibit 1.31 under the heading “Cas9-II Group A Patent Rights”), substitutes, counterparts and foreign equivalents thereof filed in any country, and any
patents issuing thereon (but in the case of patents issuing on continuations-in-part applications, only to the claims thereof that are entitled to the priority date of
and directed specifically to the subject matter claimed in the applications listed on the attached Exhibit 1.31 under the heading “Cas9-II Group A Patent Rights”) and any reissues, reexaminations or
extensions thereof; provided, however, that Cas9-II Group A Patent Rights shall exclude any and all foreign equivalents in [**] related to any patent or patent application denoted with a “+” symbol
on the attached Exhibit 1.31 under the heading “Cas9-II Group A Patent Rights.” 
 1.27.
“Cas9-II Group B Enabled Product” means any product or process, other than a Licensed Product or Cas9 Enabled Product, which is or incorporates, or which is made, identified,
discovered, developed, optimized, characterized, selected, derived from or determined to have utility, in whole or in part, by the use or modification of, (a) any Cas9-II Group B Patent Rights or any
technology or invention covered thereby, (b) any Cas9-II Group B Licensed Product, (c) any progeny, modification or derivative of a Cas9-II Group B Licensed
Product, or (d) any living or nonliving cell, organism, microorganism (including viruses) made or modified through use of a Cas9-II Group B Licensed Product or technology covered by the Cas9-II Group B Patent Rights, or any progeny, clone, modification or derivative of such living or nonliving cell, organism, microorganism (including viruses); provided, however, that the term “Cas9-II Group B Enabled Product” shall not include any large or small molecule that (i) was identified or discovered using a Cas9-II Group B Licensed Product
or technology Covered by the Cas9-II Group B Patent Rights and (ii) does not otherwise meet the definition of Cas9-II Group B Enabled Product (i.e., it is
identified or discovered using a Cas9-II Group B Licensed Product or technology covered by the Cas9-II Group B Patent Rights but otherwise is not, or does not
incorporate, or is not made, developed, optimized, characterized, selected, derived from or determined to have utility, in whole or in part, by the use or modification of a Cas9-II Group B

  
 7 

 
Licensed Product or technology covered by the Cas9-II Group B Patent Rights in a way that would cause it to be included in the definition of Cas9-II Group B Enabled Product). For clarity, the term “Cas9-II Group B Enabled Product” shall also not include any product or process (other than a Cas9-II Group B Licensed Product), for which the sole use of the Cas9-II Group B Patent Rights or technology covered thereby in connection with such product or process was to
(x) serve as a control in the development of, or comparator in the pre-clinical development of, such product or process or (y) evaluate the efficacy of such
Cas9-II Group B Patent Rights or technology covered thereby as applied to such product or process. 

1.28. “Cas9-II Group B Licensed Product” means, on a country-by-country basis, any product that (a) is not a Cas9 Licensed Product and (b) the making, using, selling, offering for sale, exporting or importing of which
product in the country in question is Covered by at least one Valid Claim of the Cas9-II Group B Patent Rights in that country. If, during the Royalty Term for a given
Cas9-II Group B Licensed Product, such Cas9-II Group B Licensed Product is no longer Covered by at least one such Valid Claim in a country, and is not Covered by at
least one Valid Claim of any other Patent right in such country, then such Cas9-II Group B Licensed Product shall be deemed a Cas9-II Group B Enabled Product in such
country from that time forward for the purposes of calculating Milestone Payments under Section 4.5 and Royalties under Section 4.6, unless and until such product is again Covered by at least one Valid Claim of the Cas9-II Patent Rights (other than the Cas9-II Group A Patent Rights), at which time such product shall again be deemed a Cas9-II Group
B Licensed Product for such purposes. 
 1.29. “Cas9-II Group B Patent
Rights” means the patents and patent applications that are listed on the attached Exhibit 1.31 under the heading “Cas9-II Group B Patent Rights” and any and all divisionals,
continuations, continuations-in-part (only to the extent of claims that are entitled to the priority date of and directed specifically to the subject matter claimed in
the applications listed on the attached Exhibit 1.31 under the heading “Cas9-II Group B Patent Rights”), substitutes, counterparts and foreign equivalents thereof filed in any country, and any
patents issuing thereon (but in the case of patents issuing on continuations-in-part applications, only to the claims thereof that are entitled to the priority date of
and directed specifically to the subject matter claimed in the applications listed on the attached Exhibit 1.31 under the heading “Cas9-II Group B Patent Rights”) and any reissues, reexaminations or
extensions thereof; provided, however, that Cas9-II Group B Patent Rights shall exclude any and all foreign equivalents in [**] related to any patent or patent application denoted with a “+” symbol
on the attached Exhibit 1.31 under the heading “Cas9-II Group B Patent Rights.” 
 1.30.
“Cas9-II Institution” means each of Broad, Harvard, MIT and Iowa individually, and “Cas9-II Institutions” means Broad, Harvard, MIT and
Iowa, collectively. 
 1.31. “Cas9-II Patent Rights” means the Cas9-II Group A Patent Rights and the Cas9-II Group B Patent Rights. 

1.32. “Challenging Party” means any Person that brings, assumes or participates in or that knowingly, willfully or recklessly
assists in bringing a Patent Challenge. 

  
 8 

 1.33. “Change of Control” means, with respect to Company,
(a) a merger or consolidation of Company with a Third Party which results in the voting securities of Company outstanding immediately prior thereto ceasing to represent at least fifty percent (50%) of the combined voting power of the surviving
entity immediately after such merger or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the owner of fifty percent (50%) or more of the combined voting power of
Company’s outstanding securities other than through issuances by Company of securities of Company in a bona fide financing transaction or series of related bona fide financing transactions, or (c) the sale or other transfer to a Third
Party of all or substantially all of Company’s assets or all or substantially all of Company’s business to which this Agreement relates. 

1.34. “Change of Control Multiplier” has the meaning set forth in Section 4.5.4. 

1.35. “Church IP” means the Patent Rights identified in Exhibit 1.25 as Church IP. 

1.36. “Claims” has the meaning set forth in Section 9.1.1. 

1.37. “Clinical Study” means any clinical study that meets the requirements of a Phase I Clinical Study, Phase II Clinical
Study or Phase III Clinical Study. 
 1.38. “Closing Price” means, with respect to a particular date,
the last reported sales price on (i) such date if such date is a Trading Day, or (ii) if such date is not a Trading Day, the most recent date prior to such date that is a Trading Day. 

1.39. “Common Stock” means the common stock, par value $0.001 per share, of Company. For the purpose of
Section 1.115, Section 4.10.1 and related definitions, “Common Stock” means the equity securities of any of Company or its Affiliates, or any successor thereto, that are Public Securities. 

1.40. “Company” has the meaning set forth in the Preamble. 

1.41. “Company Confidential Information” has the meaning set forth in Section 11.1.1. 

1.42. “Company Notification” has the meaning set forth in Section 3.2.1.  

1.43. “Company Patents” has the meaning set forth in Section 1.129. 

1.44. “Company Sale” means (i) an Asset Sale to one or more Person(s) in a single transaction or series of
related transactions, (ii) a Merger or (iii) an acquisition of at least [**] percent ([**]%) of Company’s shares by a Person or by a Group in a single transaction or a series of related transactions. Notwithstanding anything to the
contrary, (a) any Person that controls, is controlled by, or is under common control with, Company shall not be a “Person” for the purpose of this definition, (b) any Group that is solely comprised of Persons that control, are
controlled by, or are under common control with, Company shall not be a “Group” for the purpose of this definition, and (c) for the purpose of this definition only, “control” and, with correlative meanings, the terms
“controlled by” and “under common control with” means the (1) ownership or control of more than fifty percent (50%) of the voting securities or other ownership interest of another Person or (2) the possession, directly
or indirectly, of the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the other Person. 

  
 9 

 1.45. “Company Sale Date” means the date of closing of a Company Sale. 

1.46. “Company Sale Success Payment” means the amount equal to the sum of all Success Payments that
(i) correspond to Value Triggers that are lower than or equal to the Company Sale Value Trigger and (ii) are unpaid as of the day immediately prior to the Company Sale Date. By way of example, if Company has only paid the first two Success
Payments to the Licensor Institutions (excluding any share issuance pursuant to Section 4.4) as of the day immediately prior to the Company Sale Date, and the Company Sale Value Trigger is [**] dollars ($[**]), then the Company Sale Success
Payment shall be [**] dollars ($[**]). 
 1.47. “Company Sale Value Trigger” means the highest Value Trigger that is lower
than or equal to the Upfront Acquisition Value. By way of example, if the Upfront Acquisition Value is [**] dollars ($[**]), then the Company Sale Value Trigger is [**] dollars ($[**]). 

1.48. “Competing Program” has the meaning set forth in Section 4.6.2.3. 

1.49. “Competing Program Notice” has the meaning set forth in Section 4.6.2.3. 

1.50. “Confidential Information” has the meaning set forth in Section 11.1.1. 

1.51. “Covered” means, with respect to a given product, process, method or service, that a Valid Claim would
(absent a license thereunder or ownership thereof) be infringed by the making, using, selling, offering for sale, importation or other exploitation of such product, process, method or service. With respect to a claim of a pending patent application,
“infringed” refers to activity that would infringe or be covered by such Valid Claim if it were contained in an issued patent. Cognates of the word “Covered” shall have correlative meanings. 

1.52. “Cpf1 Agreement” means that certain Cpf1 License Agreement between Broad and Company dated as of the
Effective Date. 
 1.53. “CRISPR Patent Rights” means the (a) Cas9-I Patent
Rights identified on Exhibit 1.25 as CRISPR Patent Rights and (b) Cas9-II Patent Rights. 

1.54. “CRISPR Technology” means an enzymatically active or inactive Cas9 or Cpf1 endonuclease combined with a
nucleic acid moiety that preferentially binds to a specified DNA sequence and targets the endonuclease to the DNA sequence, where either the endonuclease or nucleic acid moiety can be engineered and/or linked to an effector moiety. 

1.55. “Deductions” means, with respect to a Company Sale, any amounts that are deducted from the gross proceeds,
and thereby reduce the amount paid to the holders of capital stock of Company, including, without limitation: (i) amounts paid to investment bankers, accountants or attorneys in connection with the transaction, (ii) severance or change of
control payments made to employees or directors of Company, (iii) payments made to a Third Party to pay off indebtedness, (iv) liquidation preference payments or (v) amounts placed into escrow or a similar holdback. 

  
 10 

 1.56. “Delivery Patent Rights” means the Cas9-I Patent Rights identified on Exhibit 1.25 as Delivery Patent Rights. 
 1.57.
“Developing Country” means any country identified as a Low-income or Lower-middle-income economy in the World Bank “Country and Lending Groups” classification. 

1.58. “Development Milestones” means, with respect to a given product, the diligence milestones for the
development and commercialization of such product. 
 1.59. “Development Plan” means the plan for the
development and commercialization of Licensed Products attached hereto as Exhibit 3.3, as such plan may be adjusted from time to time pursuant to Section 3.3. 

1.60. “Direct License” has the meaning set forth in Section 10.3.1.2. 

1.61. “Dispute” has the meaning set forth in Section 11.7. 

1.62. “Documentation and Approvals” has the meaning set forth in Section 10.3.4.2. 

1.63. “Editas” means Editas Medicine, Inc. 

1.64. “Editas Cas9-I Exclusive Field” means the “Field,” as
such term is defined in the Editas Cas9-I License Agreement. As of the Effective Date, the definition of “Field” in the Editas Cas9-I License Agreement is as
follows (with all capitalized terms in the following definition having the respective meanings ascribed to such terms in the Editas Cas9-I License Agreement): 

““Field” [as such term is defined in the Editas Cas9-I License Agreement] means the prevention or treatment of human disease (i) using gene therapy, (ii) using editing (including modifying) of Genetic Material or
(iii) using targeting of Genetic Material (including targeting of Genetic Material to modify associated chromatin), either (a) ex vivo for subsequent administration to a human, in the case of the foregoing
clause (ii) or (iii) of a product so edited or targeted, or (b) in vivo, by a product administered to a human, in the case of the foregoing clause (ii) or (iii) of a product that so edits or
targets; provided that, (I) the Field does not include the prevention or treatment of human disease using a small or large molecule that (A) was identified or discovered using technology Covered by
the Patent Rights, (B) is Covered by (x) a Valid Claim of the Patent Rights Covering the identifying or discovering of small or large molecules, and/or (y) a product-by-process or similar Valid Claim of the Patent Rights directed to a small or large molecule so identified or discovered, and (C) is not Covered by
any other Valid Claim of the Patent Rights; (II) the Field does not include (A) modifying animals or animal cells for the creation, making, having made, use, sale, offer for sale, having sold, 

  
 11 

 
exportation and importation of organs suitable for xenotransplantation into humans or (B) research and development, and commercialization and other use or exploitation, of
products or services in the field of Livestock Applications; (III) with respect to the Delivery Patent Rights, the Field only includes targeting of Genetic Material as set forth in clauses (a) and
(b) above if such targeting is related to the use of CRISPR, TALE or zinc finger nuclease technology; (IV) the Field does not include production or processing of small or large molecules, including for the prevention or treatment
of human disease, that are made using technology Covered by the Patent Rights, unless such small or large molecules (xx) are used for (1) gene therapy, (2) editing (including modifying) of
Genetic Material or (3) targeting of Genetic Material (including targeting of Genetic Material to modify associated chromatin), in the case of (2) and (3) to the extent such editing or targeting is achieved
through the use of CRISPR Technology or TALE Technology (other than through the making of such small or large molecules) and in each case (1), (2) and (3) as set forth in clauses (a) and (b) above, and (yy) are
not otherwise excluded from this definition of Field; (V) the Field does not include Ag Products; and (VI) the Field does not include any products, including without limitation any Ag Product or any
product in the field of Livestock Applications, that provide nutritional benefits, unless such products (aa) are regulated by a Regulatory Authority as a drug or biologic pursuant to Section 505 of the United States
Federal Food, Drug, and Cosmetic Act of 1938, as amended, Section 351 of the United States Public Health Service Act of 1944, as amended, or any successor laws, or equivalent laws or regulations in jurisdictions outside the United
States and (bb) are otherwise included in this definition of Field.” 
 The Licensor Institutions will promptly notify Company in writing of any
modifications or amendments to the definition of “Field” in the Editas Cas9-I License Agreement, including by providing written notice of any such modification or amendment which would reduce the
scope of Company’s rights under this Agreement within [**] following the effective date of such modification or amendment. Notwithstanding the foregoing, Licensor Institutions will use good faith efforts to provide prior notice to Company, to
the extent permitted by Editas. 
 1.65. “Editas Cas9-I License
Agreement” means the Amended and Restated Cas9-I License Agreement by and between, on the one hand, Harvard and Broad and, on the other hand, Editas dated December 16, 2016, as amended
from time to time. 
 1.66. “Editas Cas9-II Exclusive Field” means the
“Field,” as such term is defined in the Editas Cas9-II License Agreement. As of the Effective Date, the definition of “Field” in the Editas Cas9-II
License Agreement is as follows (with all capitalized terms in the following definition having the respective meanings ascribed to such terms in the Editas Cas9-II License Agreement): 

““Field” [as such term is defined in the Editas Cas9-II License Agreement] means the prevention or treatment of human disease (i) using gene therapy, (ii) using editing (including modifying) of Genetic Material or
(iii) using targeting of Genetic Material (including targeting of Genetic Material to modify associated chromatin), either (a) ex vivo for subsequent administration to a human, in the case of the foregoing
clause (ii) or (iii) of a product so edited or targeted, or (b) in vivo, by a product administered to a  

  
 12 

 
human, in the case of the foregoing clause (ii) or (iii) of a product that so edits or targets; provided that, (I) the Field does not
include the prevention or treatment of human disease using a small or large molecule that (A) was identified or discovered using technology Covered by the Patent Rights, (B) is Covered by
(x) a Valid Claim of the Patent Rights Covering the identifying or discovering of small or large molecules, and/or (y) a
product-by-process or similar Valid Claim of the Patent Rights directed to a small or large molecule so identified or discovered, and (C) is not
Covered by any other Valid Claim of the Patent Rights; (II) the Field does not include (A) modifying animals or animal cells for the creation, making, having made, use, sale, offer for sale, having sold,
exportation and importation of organs suitable for xenotransplantation into humans or (B) research and development, and commercialization and other use or exploitation, of products or services in the field of Livestock
Applications; (III) the Field does not include production or processing of small or large molecules, including for the prevention or treatment of human disease, that are made using technology Covered by the Patent Rights,
unless such small or large molecules (xx) are used for (1) gene therapy, (2) editing (including modifying) of Genetic Material or (3) targeting of Genetic Material
(including targeting of Genetic Material to modify associated chromatin), in the case of (2) and (3) to the extent such editing or targeting is achieved through the use of CRISPR Technology or TALE Technology (other than through
the making of such small or large molecules) and in each case (1), (2) and (3) as set forth in clauses (a) and (b) above, and (yy) are not otherwise excluded from this definition of Field;
(IV) the Field does not include Ag Products; and (V) the Field does not include any products, including without limitation any Ag Product or any product in the field of Livestock Applications, that provide
nutritional benefits, unless such products (aa) are regulated by a Regulatory Authority as a drug or biologic pursuant to Section 505 of the United States Federal Food, Drug, and Cosmetic Act of 1938, as amended,
Section 351 of the United States Public Health Service Act of 1944, as amended, or any successor laws, or equivalent laws or regulations in jurisdictions outside the United States and (bb) are otherwise included in this definition
of Field.” 
 The Licensor Institutions will promptly notify Company in writing of any modifications or amendments to the definition of
“Field” in the Editas Cas9-II License Agreement, including by providing written notice of any such modification or amendment which would reduce the scope of Company’s rights under this Agreement
within [**] following the effective date of such modification or amendment. Notwithstanding the foregoing, Licensor Institutions will use good faith efforts to provide prior notice to Company, to the extent permitted by Editas. 

1.67. “Editas Cas9-II License Agreement” means the Cas9-II License Agreement by and between Broad and Editas dated December 16, 2016, as amended from time to time. 

1.68. “Effective Date” has the meaning set forth in the Preamble. 

1.69. “Election Date” has the meaning set forth in Section 4.10.3. 

1.70. “Enabled Product” means any product or process that (a) is not a Licensed Product and (b) is a
Cas9 Enabled Product or Cas9-II Group B Enabled Product. 

  
 13 

 1.71. “Enrolled” means that a human research subject has met
the initial screening criteria for inclusion in a clinical study and has been deemed eligible to participate in such clinical study, all as provided in the applicable clinical study protocol(s) and statistical analysis plan(s). For clarity, human
research subjects that have been screened for inclusion in a clinical study and deemed ineligible based on the results of screening shall not be deemed to be “Enrolled” for the purposes of this Agreement. 

1.72. “Enterprise Value” means, with respect to an entity, the equity value of such entity as determined in a Valuation
Analysis. 
 1.73. “Environmental Impact” means any release, spill, emission, leaking, injection, outcross, deposit,
disposal, discharge, dispersal, leaching or migration of material (including any hazardous material, plant, plant part, plant cell, plant tissue or plant seed) into the atmosphere, soil, surface water, groundwater, sewer system or property. 

1.74. “Equity Event” means the first to occur of the following: 

(a) the first bona fide financing of Company, including the first equity financing involving the sale of Company’s preferred stock (the
“Next Financing Shares”) to investors (the “Next Financing”), which results in a Post-Money Valuation of at least $[**], where “Post-Money Valuation” means the product of (i) the highest price
per Next Financing Share paid by investors in the Next Financing, or otherwise the FMV of Common Stock, and (ii) the number of shares of Company capital stock outstanding following the consummation of all closings of the financing calculated on
a Fully-Diluted Basis; and 
 (b) Company’s achievement of a Market Capitalization of at least $500,000,000; and 

(c) Company undergoing a Company Sale where the applicable Acquisition Value exceeds $500,000,000. 

1.75. “Equity Event Shares” has the meaning set forth in Section 4.4.1. 

1.76. “E.U.” means the European Union, including the United Kingdom, regardless of its membership in the
European Union. 
 1.77. “E.U. Major Market Countries” means the United Kingdom (regardless of its membership in the
European Union), Germany, Italy, France and Spain. 
 1.78. “Exchange Act” means the United States Securities
and Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.79. “Executive Officers”
has the meaning set forth in Section 11.7. 
 1.80. “FDA” means the United States Food and Drug Administration. 

  
 14 

 1.81. “Field” means, solely with respect to products and
processes directed to the Targets, the prevention or treatment of human disease (i) using gene therapy, (ii) using editing (including modifying) of Genetic Material or (iii) using targeting of Genetic Material (including targeting of
Genetic Material to modify associated chromatin), either (a) ex vivo for subsequent administration to a human, in the case of the foregoing clause (ii) or (iii) of a product so edited or targeted, or (b) in vivo, by a product
administered to a human, in the case of the foregoing clause (ii) or (iii) of a product that so edits or targets; provided that, the Field does not include (I) the prevention or treatment of human disease using a small or large molecule
that (A) was identified or discovered using technology Covered by the Patent Rights, (B) is Covered by (x) a Valid Claim of the Patent Rights Covering the identifying or discovering of small or large molecules, and/or (y) a product-by-process or similar Valid Claim of the Patent Rights directed to a small or large molecule so identified or discovered, and (C) is not Covered by any other
Valid Claim of the Patent Rights; (II) (A) modifying animals or animal cells for the creation, making, having made, use, sale, offer for sale, having sold, exportation and importation of organs suitable for xenotransplantation into humans or
(B) research and development, and commercialization and other use or exploitation, of products or services in the field of Livestock Applications; (III) production or processing of small or large molecules, including for the prevention or
treatment of human disease, that are made using technology Covered by the Patent Rights, unless such small or large molecules (xx) are used for (1) gene therapy, (2) editing (including modifying) of Genetic Material or
(3) targeting of Genetic Material (including targeting of Genetic Material to modify associated chromatin), in the case of (2) and (3) to the extent such editing or targeting is achieved through the use of CRISPR Technology or TALE
Technology (other than through the making of such small or large molecules) and in each case (1), (2) and (3) as set forth in clauses (a) and (b) above, and (yy) are not otherwise excluded from this definition of Field; (IV) Ag
Products; and (V) any products, including without limitation any Ag Product or any product in the field of Livestock Applications, that provide nutritional benefits, unless such products (aa) are regulated by a Regulatory Authority as a drug or
biologic pursuant to Section 505 of the United States Federal Food, Drug, and Cosmetic Act of 1938, as amended, Section 351 of the United States Public Health Service Act of 1944, as amended, or any successor laws, or equivalent laws or
regulations in jurisdictions outside the United States and (bb) are otherwise included in this definition of Field. In addition, with respect to the Delivery Patent Rights, the Field only includes targeting of Genetic Material as set forth in
clauses (a) and (b) above if such targeting is related to the use of CRISPR Technology, TALE Technology or zinc finger nuclease technology. 

1.82. “First Commercial Sale” means the date of the first sale by Company, its Affiliate or a Sublicensee of a Licensed
Product or Enabled Product to a Third Party following receipt of Regulatory Approval in the country in which such Licensed Product or Enabled Product is sold, excluding, however, any sale or other distribution for use in a clinical study, charitable
purposes or compassionate use or similar limited purposes. 
 1.83. “FMV of Common Stock” means (a) if
Company’s shares of Common Stock are Public Securities as of the applicable determination date, the Closing Price, or (b) if Company’s shares of Common Stock are not Public Securities as of the applicable determination date, the value
determined by dividing (1) the Enterprise Value as determined in the most recent Valuation Analysis prior to such date by (2) the total number of issued and outstanding shares of Common Stock (assuming conversion of all outstanding stock
other than common stock into common stock). 

  
 15 

 1.84. “Fully-Diluted Basis” means, as of a specified date,
the number of shares of common stock of Company then-outstanding plus the number of shares of common stock of Company issuable upon exercise or conversion of then-outstanding convertible securities or warrants, options, or other rights to subscribe
for, purchase or acquire from Company any capital stock of Company (which shall be determined without regard to whether such securities or rights are then vested, exercisable or convertible) plus, without duplication, the number of shares reserved
and available for future grant under any then-existing equity incentive plan of Company; provided that, for clarity, “other rights to subscribe for, purchase or acquire” shall not include (i) preemptive or other rights to participate
in new offerings of securities by Company, (ii) obligations under a purchase agreement for preferred stock of Company to acquire additional shares of such preferred stock on the same terms as those purchased at an initial closing upon the
passage of time or meeting (or waiver) of specified Company performance conditions or (iii) anti-dilution provisions that have not been triggered. 

1.85. “Genetic Material” means all DNA (including without limitation DNA in and outside chromosomes) and RNA. 

1.86. “Group” means two or more Persons acting as a partnership, limited partnership, syndicate or other group
for the purposes of acquiring, holding, voting or disposing of the securities of a company. 
 1.87. “Harvard” has the
meaning set forth in the Preamble. 
 1.88. “Harvard Confidential Information” has the meaning set forth in
Section 11.1.1. 
 1.89. “Harvard Controlled Patents” has the meaning set forth in the Recitals. 

1.90. “Harvard/MIT/Broad Co-Owned Cas9-I Patent
Rights” has the meaning set forth in the Recitals. 
 1.91. “HHMI” has the meaning set forth in the Recitals. 

1.92. “HHMI Indemnitees” has the meaning set forth in Section 9.1.3. 

1.93. “HHMI License” has the meaning set forth in Section 2.2.1. 

1.94. “HHMI Names” has the meaning set forth in Section 11.2. 

1.95. “IND” means an FDA Investigational New Drug application, or equivalent application or submission for
approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

1.96. “Indemnitees” has the meaning set forth in Section 9.1.1. 

1.97. “Indemnitor” has the meaning set forth in Section 9.1.1. 

  
 16 

 1.98. “Ineligible Sublicensees” has the meaning set forth in
Section 10.3.1.2. 
 1.99. “Informed Party” has the meaning set forth in Section 4.6.2.3. 

1.100. “Infringement” has the meaning set forth in Section 7.2. 

1.101. “Initial Public Offering” means a firm-commitment underwritten public offering of equity
securities of Company, or any successor thereto, pursuant to an effective registration statement under the Securities Act (or any equivalent registration statement with respect to jurisdictions outside the United States) following which such equity
securities shall be publicly held. 
 1.102. “Initial Shares” has the meaning set forth in Section 4.4.1. 

1.103. “Institution Names” has the meaning set forth in Section 11.2. 

1.104. “Internal Research Purposes” means use as a research tool for research purposes in the field of human
therapeutics in Company’s or its Affiliates’ internal laboratories, provided, however, that notwithstanding the foregoing, “Internal Research Purposes” shall expressly exclude (a) any human or clinical use, including,
without limitation, any administration into humans or any diagnostic or prognostic use, (b) any human germline modification, including modifying the DNA of human embryos or human reproductive cells, (c) any in vivo veterinary or
livestock use (for clarity, the use of any animal or animal cell in preclinical research shall be included in “Internal Research Purposes”), (d) the manufacture, distribution, importation, exportation, transportation, sale, offer for sale,
marketing, promotion or other exploitation or use of, or as, a testing service, therapeutic or diagnostic for humans or animals, or (e) any use or application relating to the stimulation of biased inheritance of particular genes or traits
within a population of plants or animals. 
 1.105. “Invoicing Entity” has the meaning set forth in Section 1.123. 

1.106. “Iowa” has the meaning set forth in the Recitals. 

1.107. “License Issue Fee” has the meaning set forth in Section 4.2.1. 

1.108. “License Fees” has the meaning set forth in Section 4.3. 

1.109. “Licensed Product” means any product or process that is a Cas9 Licensed Product or Cas9-II Group B Licensed Product. 
 1.110. “Licenses” means (a) this
Agreement and (b) the Cpf1 Agreement; “License” means any of the licenses set forth in the foregoing (a) or (b). 

1.111. “Licensor Institution” and “Licensor Institutions” have the meanings set
forth in the Preamble. 
 1.112. “Licensor Institution Confidential Information” has the meaning set forth in
Section 11.1.1. 

  
 17 

 1.113. “Litigation Expenses” has the meaning set forth in
Section 7.2.3. 
 1.114. “Livestock Applications” means (a) the modification or alteration of
livestock, or of any products, cells or materials derived from livestock, or the use or provision of any processes, methods or services using livestock, or the use of any products, cells or materials derived from livestock, for the purposes of
(i) affecting the fitness of such livestock, including affecting their ability to survive or reproduce, (ii) creating, expressing, transmitting, conferring, improving, or imparting a Trait of interest in such livestock, or
(iii) bioproduction or bioprocessing, or (b) the use, production, alteration or modification of exotic animals, or of any products, cells, tissues or materials derived from exotic animals (including biomaterials derived from such exotic
animals) in or for consumer goods or products. For the purposes of this definition, (A) “livestock” means (1) cattle, sheep, goats, buffalo, llamas, camels, swine, poultry and fowl (including
egg-producing poultry and fowl), dogs, cats and equine animals, (2) animals used for food or in the production of food, (3) animals ordinarily raised or used on the farm or for home use, consumption,
or profit, and (4) fish used for food, and (B) “exotic animals” means snakes, alligators, elephants, camels and other exotic animals but specifically excludes all rodents. Notwithstanding anything in this definition or elsewhere in
this Agreement to the contrary, Livestock Applications does not include (i) the use of any animal or animal cell in preclinical research or (ii) the treatment of animal disease. 

1.115. “Market Capitalization” means, in the event that the shares of Common Stock are Public Securities, with
respect to a particular Trading Day, the closing price per share of Common Stock on such Trading Day multiplied by the number of shares of Common Stock outstanding as set forth on [**], in each case (a) and (b) [**] on or prior to such Trading
Day. For the purpose of this definition, “Company” shall mean Company or any Affiliate of Company that issues Common Stock. 

1.116. “Merger” means any merger or consolidation of Company with or into another Person where the pre-merger or pre-consolidation, as the case may be, stockholders of Company (or, in the event that there is a related tender offer for Company’s shares prior to the
merger or consolidation by a Person or a Group that is a party to such merger or consolidation, the stockholders of Company immediately prior to the commencement of such related tender offer) do not own, immediately after such merger or
consolidation, as the case may be, a majority of the total voting power represented by the outstanding voting securities of the surviving entity. 

1.117. “Milestone Event” means any milestone event indicated in Section 4.5.1 or 4.5.2. 

1.118. “Milestone Explanation” has the meaning set forth in Section 3.5. 

1.119. “Milestone Payment” means any milestone payment indicated in Section 4.5.1 or 4.5.2 corresponding to
any Milestone Event. 
 1.120. “Milestone Plan” has the meaning set forth in Section 3.5. 

1.121. “MIT” has the meaning set forth in the Recitals. 

  
 18 

 1.122. “MIT/Broad Co-Owned Cas9-I Patent Rights” has the meaning set forth in the Recitals. 
 1.123.
“Net Sales” means the gross amount billed or invoiced by or on behalf of Company, its Affiliates, Sublicensees and any Affiliates of such Sublicensees (in each case, the “Invoicing
Entity”) or if not billed or invoiced the gross amount received by the Invoicing Entity, on sales, leases, uses or other transfers of Licensed Products or Enabled Products, less the following to the extent applicable with respect to
such sales, leases or other transfers and not previously deducted from the gross invoice price: (a) customary trade, quantity or cash discounts to the extent actually allowed and taken; (b) amounts actually repaid or credited by reason of
rejection, return or recall of any previously sold, leased or otherwise transferred Licensed Products or Enabled Products; (c) rebates granted or given; (d) allowances for non-collectible
receivables; (e) customer freight charges that are paid by or on behalf of the Invoicing Entity; and (f) to the extent separately stated on purchase orders, invoices or other documents of sale, any sales, value added or similar taxes,
custom duties or other similar governmental charges levied directly on the production, sale, transportation, delivery or use of a Licensed Product or Enabled Product that are paid by or on behalf of the Invoicing Entity, but not including any tax
levied with respect to income; provided that: 
 (a) in no event shall the aggregate amount of all deductions made pursuant to clauses
(d) and (e) above in any Calendar Quarter exceed [**] percent ([**]%) of Net Sales in such Calendar Quarter; 
 (b) Net Sales shall not
include (a) sales or other transfers of any Licensed Product or Enabled Product used for clinical trials or other research, or (b) donations for charity or compassionate use for which an Invoicing Entity does not receive consideration;

 (c) in any transfers of Licensed Products or Enabled Products between an Invoicing Entity and an Affiliate or Sublicensee of such
Invoicing Entity not for the purpose of resale by such Affiliate or Sublicensee, Net Sales shall be equal to the fair market value of the Licensed Products or Enabled Products so transferred, assuming an arm’s length transaction made in the
ordinary course of business; 
 (d) in the event that (i) an Invoicing Entity receives non-cash
consideration for any Licensed Products or Enabled Products, (ii) an Invoicing Entity sells Licensed Products or Enabled Products in a transaction not at arm’s length with a non-Affiliate of an
Invoicing Entity, or (iii) any Licensed Product or Enabled Product is sold by an Invoicing Entity at a discounted price that is substantially lower than the customary prices charged by such Invoicing Entity, Net Sales shall be calculated based
on the fair market value of such consideration or transaction, assuming an arm’s length transaction made in the ordinary course of business, provided that, if a Licensed Product or Enabled Product is sold under circumstances in which the
discounted price is the result of market forces and not a quid pro quo for value other than the monetary consideration charged in such sale of Licensed Product or Enabled Product, such discounted price shall be deemed to be a customary price; 

(e) with respect to any provision hereof requiring a calculation of fair market value, assuming an arm’s length transaction made in the
ordinary course of business, Invoicing Entity may use the average price of the relevant Licensed Product or Enabled Product sold for cash during the relevant period in the relevant country; and 

  
 19 

 (f) sales of Licensed Products or Enabled Products by an Invoicing Entity to its Affiliate
or a Sublicensee for resale by such Affiliate or Sublicensee shall not be deemed Net Sales. Instead, Net Sales shall be determined based on the gross amount billed or invoiced by such Affiliate or Sublicensee upon resale of such Licensed Products or
Enabled Products to any third party that is not an Affiliate or Sublicensee of the Invoicing Entity. 
 1.124. “Next
Financing” has the meaning set forth in Section 1.74. 
 1.125. “Next Financing Shares” has the meaning set
forth in Section 1.74. 
 1.126. “Other IP” has the meaning set forth in Section 7.2. 

1.127. “Owner Institution” means each of the Cas9-I Institutions and Cas9-II Institutions individually, and “Owner Institutions” means the Cas9-I Institutions and the Cas9-II
Institutions, collectively. 
 1.128. “Party” and “Parties” have the meaning
set forth in the Preamble. 
 1.129. “Patent Challenge” means any direct, or indirect through the actions of
another acting on Company’s, its Affiliate’s, or a Sublicensee’s behalf or upon its or their instruction, dispute or challenge, or any knowing, willful, or reckless assistance in the dispute or challenge, of the validity,
patentability, scope, priority, construction, non-infringement, inventorship, ownership or enforceability of any Patent Right or any claim thereof, or opposition or assistance in the opposition of the grant of
any letters patent within the Patent Rights, in any legal or administrative proceedings, including in a court of law, before the United States Patent and Trademark Office or other agency or tribunal in any jurisdiction, or in arbitration including,
without limitation, by reexamination, inter partes review, opposition, interference, post-grant review, nullity proceeding, preissuance submission, third party submission, derivation proceeding or declaratory judgment action. For clarity, a Patent
Challenge shall not include (1) arguments made by Company that (a) distinguish the inventions claimed in patents or patent applications owned or controlled by Company (“Company Patents”) from those claimed in the
Patent Rights but (b) do not disparage the Patent Rights or challenge the validity, scope, or enforceability of the Patent Rights’ claims under applicable patent laws, regulations or administrative rules, in each case (i) in the
ordinary course of ex parte prosecution of the Company Patents or (ii) in inter partes proceedings before the United States Patent and Trademark Office or other agency or tribunal in any jurisdiction (excluding interferences or derivation
proceedings), or in arbitration, wherein the Company Patents have been challenged; (2) arguments or assertions as to whether the Patent Rights Cover a given product, to the extent arising in a Suit brought by the Licensor Institutions;
(3) Company payments of patent costs to another licensor or assignor of Company Patents as required by the agreement under which Company obtained rights to such patent rights, even if the licensor or assignor is engaging in behavior or
presenting arguments that would themselves be considered a Patent Challenge if done by Company; or (4) Company being named as an essential party, real party in interest or other status similar to either of the foregoing, in an interference
between Patent Rights and Company Patents or other adversarial proceeding similar to an interference. 

  
 20 

 1.130. “Patent Rights” means the Cas9-I Patent Rights and the Cas9-II Patent Rights. 
 1.131.
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated
association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government. 

1.132. “Phase I Clinical Study” means, as to a specific Licensed Product, a study of such product in humans designed to
satisfy the requirements of 21 C.F.R. § 312.21(a), as amended from time to time, or the corresponding regulation in jurisdictions other than the United States. 

1.133. “Phase II Clinical Study” means (a) a preliminary efficacy and safety human clinical study in any country
conducted to evaluate a drug for a particular indication or indications in patients with the disease or condition under study, where at least one of the primary endpoints of such study is an efficacy endpoint, or (b) any human clinical study
that satisfies the requirements of 21 C.F.R. § 312.21(b) in the United States. 
 1.134. “Phase III Clinical Study”
means (a) a human clinical study in any country, whether controlled or uncontrolled, that is performed to obtain Regulatory Approval of a drug after preliminary evidence suggesting effectiveness of the drug under evaluation has been obtained,
and intended to confirm with statistical significance the efficacy and safety of a drug, to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling, or (b) a human clinical study that
satisfies the requirements of 21 C.F.R. § 312.21(c) in the United States. 
 1.135. “Post-Money Valuation” has the
meaning set forth in Section 1.74. 
 1.136. “Principal Trading Market” means the Trading Market on which the Common
Stock is primarily listed on and quoted for trading. 
 1.137. “Prosecution” means the preparation, filing,
prosecution, issuance and maintenance of the Patent Rights, including continuations, continuations-in-part, divisionals, extensions, reexaminations, inter partes review,
reissues, supplemental examination, appeals, interferences, derivation proceedings, oppositions, all other proceedings before the United States Patent and Trademark Office (including the Patent Trial and Appeal Board) and foreign patent offices, and
any judicial or other appeals of the foregoing. Cognates of the word “Prosecution” have their correlative meanings. 
 1.138.
“Public Securities” means securities that are listed on a national securities exchange registered under the Exchange Act or if not listed on a national securities exchange registered under the Exchange Act, quoted on NASDAQ, OTCQB
or other similar quotation system. 

  
 21 

 1.139. “Record Retention Period” has the meaning set forth in
Section 5.3. 
 1.140. “Regulatory Approval” means, with respect to a particular product or service,
receipt of all regulatory clearances or approvals (which in the case of the E.U. may be through the centralized procedure) required in the jurisdiction in question for the sale of the applicable product or service in such jurisdiction, including
receipt of pricing approval, if any, legally required for such sale. 
 1.141. “Regulatory Authority” means
any applicable government regulatory authority involved in granting clearances or approvals for the manufacturing and marketing of a Licensed Product or Enabled Product, including, in the United States, the FDA. 

1.142. “Replacement Product” has the meaning set forth in Section 4.5.6. 

1.143. “Resale Registration Statement” means a registration statement on Form S-1 or Form S-3 filed by Company with the Securities and Exchange Commission under the Securities Act covering the resale by a Licensor Institution of Success Payment Shares.

 1.144. “Reviewed Patent Rights” means, subject to Section 6.2, the
Cas9-I Patent Rights and Cas9-II Group A Patent Rights within and with respect to the specific patent families identified in Exhibit 1.144 (where each patent family is
listed under a distinct “Broad Reference” or “Harvard Reference” number in Exhibit 1.144). 
 1.145.
“Rockefeller” has the meaning set forth in the Recitals. 
 1.146. “Royalties” has the meaning set forth in
Section 4.6.1. 
 1.147. “Royalty Term” means, on a country-by-country and product-by-product basis, the period commencing on the Effective Date and ending on the later of:
(a) the expiration of the last Valid Claim within the Patent Rights Covering the Licensed Product or (b) the tenth (10th) anniversary of the date of the First Commercial Sale of the Licensed Product or Enabled Product; provided that, for
any Enabled Product that was a Licensed Product, the date of the First Commercial Sale in clause (b) shall be deemed to be the earlier of (i) the date of First Commercial Sale of the Enabled Product that was a Licensed Product, and
(ii) the date of the First Commercial Sale of the Licensed Product that became such Enabled Product. 
 1.148. “Schedule 1
Product” means a Licensed Product or an Enabled Product, in each case for the prevention or treatment of human disease for which the prevalence is fewer than [**] patients in the U.S., or which the Licensor Institutions and Company
otherwise agree in writing shall be considered a Schedule 1 Product based on their review and assessment of the available information. 

  
 22 

 1.149. “Schedule 2 Product” means a Licensed Product or an Enabled Product,
in each case for the prevention or treatment of human disease for which the prevalence is [**] patients or greater in the U.S. 
 1.150.
“Section 409A” means Section 409A of the United States Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder. 

1.151. “Securities Act” means the United States Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.152. “Shares” has the meaning set forth in Section 4.4.1. 

1.153. “Single Schedule 1 Product” means all Schedule 1 Products that contain the same active ingredient and no other active
ingredient, or contain the same combination of active ingredients and no other active ingredient, without regard to formulation or dosage. 

1.154. “Single Schedule 2 Product” means all Schedule 2 Products that contain the same active ingredient and no other active
ingredient, or contain the same combination of active ingredients and no other active ingredient, without regard to formulation or dosage. 

1.155. “Skipped Milestone” has the meaning set forth in Section 4.5.1. 

1.156. “Stock Issuance Agreement” means the Stock Issuance Agreement set forth in Exhibit 4.4.1. 

1.157. “Sublicense” means an agreement (other than an assignment of this Agreement in compliance with
Section 11.14) in which Company, an Affiliate of Company or a Sublicensee (a) grants or otherwise transfers any of the rights licensed to Company hereunder or rights relating to Licensed Products or Enabled Products, (b) agrees not to
assert such rights or to sue, prevent or seek a legal remedy for the practice of same, or (c) is under an obligation to grant, assign or transfer any such rights or non-assertion, or to forbear from
granting or transferring such rights, to any other Person, including by means of an option. Agreements expressly considered Sublicenses include (i) licenses, option agreements, “lock up” agreements, right of first refusal agreements, non-assertion agreements, covenants not to sue, distribution agreements that grant or otherwise transfer any rights licensed to Company hereunder, or similar agreements, and (ii) agreements that grant or
otherwise transfer rights licensed to Company under this Agreement along with rights owned by the Company, an Affiliate of Company or a Sublicensee or granted to the Company, an Affiliate of Company or a Sublicensee by a Third Party, but excluded
from this definition of “Sublicense” is any assignment of this Agreement in compliance with Section 11.14. For the avoidance of doubt, if a Sublicense is entered into pursuant to an option or similar agreement that is also a
Sublicense, then the date of execution of the Sublicense shall be the execution date of the option or similar agreement, not the date of the exercise of the option or similar agreement. 

  
 23 

 1.158. “Sublicense Income” means consideration in any form
that Company or an Affiliate receives from a Sublicensee (or is entitled to receive, whether or not offset against amounts payable to a Sublicensee under the Sublicense). Sublicense Income shall include any license fee, license maintenance fee,
minimum royalty payment in excess of earned royalties, option fee, lump sum payment, equity securities received by Company or an Affiliate in connection with a Sublicense, distribution, joint marketing fee, milestone payments and other payments. In
the event Company or an Affiliate receives non-monetary consideration in connection with a Sublicense, Sublicense Income shall be calculated based on the fair market value of such consideration at the time of
the transaction assuming an arm’s length transaction made in the ordinary course of business. 
 Sublicense Income specifically
excludes the following: 
 (a) running royalties on Net Sales; 

(b) payments made by a Sublicensee as consideration for the issuance of equity or debt securities of, or other investment in, Company or an
Affiliate at fair market value, provided that if a Sublicensee pays more than fair market value (such fair market value being determined by reference to the price paid by a non-Sublicensee Third Party for the
equivalent Company security or by a reasonable methodology where such non-Sublicensee Third Party price is not available) for equity or debt securities or other investment in Company or an Affiliate, then the
portion in excess of fair market value shall be considered Sublicense Income; 
 (c) reimbursement for patent expenses (including prosecution
and enforcement expenses) at the Company’s or its Affiliate’s out-of-pocket cost; 

(d) payments to Company or an Affiliate by a Sublicensee under a Sublicense for the purpose of funding the costs of bona fide research and
development of Licensed Products or Enabled Products by the Company or its Affiliates to be conducted on or following the Effective Date of this Agreement and the effective date of such Sublicense, to the extent such amounts are stipulated
in the Sublicense to be allocated specifically to reimburse such costs under the Sublicense, as indicated by inclusion as specific line items in the Sublicense; provided that, to the extent such costs are not actually incurred by Company or its
Affiliates, as evidenced by written documentation of the accounts of Company or its Affiliates, during such definitive periods, such amounts shall be deemed Sublicense Income; and 

(e) payments made by a Sublicensee to Company or an Affiliate solely to the extent such amounts are allocated specifically in the Sublicense as
consideration for a Company Sale or for an option or warrant for a Company Sale at a later date. 
 1.159.
“Sublicensee” means any Third Party of Company to which Company or its Affiliate (or a direct or indirect Sublicensee of Company or its Affiliate) has granted a Sublicense. 

1.160. “Success Payment” has the meaning set forth in Section 4.10.1.2. 

1.161. “Success Payment Shares” has the meaning set forth in Section 4.10.3. 

1.162. “Suit” has the meaning set forth in Section 11.8. 

  
 24 

 1.163. “Suspension” has the meaning set forth in
Section 4.10.3.3. 
 1.164. “TALE Patent Rights” means the Cas9-I Patent Rights
identified on Exhibit 1.25 as TALE Patent Rights. 
 1.165. “TALE Technology” means a Transcription
Activator-Like Effector (TALE) protein DNA binding domain that preferentially binds a specified DNA sequence, and which may also be linked to an effector moiety. 

1.166. “Targets” means the targets set forth in Exhibit 1.166. 

1.167. “Temporary Extension” has the meaning set forth in Section 10.3.1.2. 

1.168. “Term” means the term of this Agreement as set forth in Section 10.1. 

1.169. “Third Party” means any Person that is not (a) an Owner Institution, (b) Company or (c) an
Affiliate of Company. 
 1.170. “Third Party Proposal” has the meaning set forth in Section 3.2.1. 

1.171. “Third Party Proposed Category” has the meaning set forth in Section 3.2.1. 

1.172. “Third Party Proposed Target” has the meaning set forth in Section 3.2.1. 

1.173. “Total Financing Amount” has the meaning set forth in Section 4.4.2. 

1.174. “Trading Day” means (i) a day on which the Common Stock is listed or quoted and traded on its
Principal Trading Market (other than the OTC Bulletin Board), or (ii) if the Common Stock is not listed on a Trading Market (other than the OTC Bulletin Board), a day on which the Common Stock is traded in the over-the-counter market, as reported by the OTC Bulletin Board, or (iii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by Pink Sheets LLC (or any similar organization or agency succeeding to its functions of reporting prices).
In the event that Common Stock are not Public Securities, Trading Day shall mean a business day in Cambridge, Massachusetts. 
 1.175.
“Trading Market” means whichever of the New York Stock Exchange, the NYSE Amex Equities (formerly the American Stock Exchange), the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or
the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 
 1.176. “Trailing
Acquisition Value” means with respect to a Company Sale, the amount equal to [**] after the Company Sale Date, with such amount grossed up [**], including without limitation [**]. 

1.177. “Trailing Value Receipt Date” means the date of receipt by Company or its stockholders of Trailing Acquisition Value.

  
 25 

 1.178. “Trait” means any biochemical, physiological, physical
or other attribute or phenotype of a cell, plant or plant component, or animal or animal component. 
 1.179. “Trigger
Date” means [**]. 
 1.180. “Trigger Date Value Trigger” has the meaning set forth in Section 1.179.

 1.181. “Upfront Acquisition Value” means, with respect to a Company Sale, the amount equal to [**] in a
Company Sale, with such amount grossed up [**]. Any portion of such consideration that is held back or placed into escrow as security for potential indemnification or other claims in connection with such Company Sale shall be [**] the Upfront
Acquisition Value, but shall be [**] the Trailing Acquisition Value if, when and to the extent such consideration is released to Company or its stockholders. 

1.182. “Valid Claim” means: (a) a claim of an issued and unexpired patent within the Patent Rights that has
not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (ii) disclaimed or
rendered unenforceable through disclaimer or otherwise, or (iii) abandoned, or (b) a pending claim of a pending patent application within the Patent Rights, which claim has not been pending for more than [**] from the first substantive
office action with respect to the pending claim and has not been abandoned or finally rejected without the possibility of appeal or refiling or without such appeal having been taken or refiling having been made within the applicable time periods.
Notwithstanding the foregoing, (i) the [**] pendency period set forth in clause (b) above shall only apply if, after [**] of prosecution on the merits of a given application, Company notifies the Licensor Institutions in writing that it
does not believe that Licensor Institutions should continue to prosecute such application and the Licensor Institutions continue to do so at their discretion, and (ii) if the prosecution of a given application is interrupted and/or delayed
(A) by a patent office or (B) due to a Patent Challenge or a patent office proceeding such as an interference, appeal or opposition, then in each case (A) and (B) the pendency of such Patent Challenge or proceeding(s) shall not be
included in the [**] time period set forth above. The invalidity of a particular claim in one or more countries shall not invalidate such claim in any remaining countries. For the avoidance of doubt, a pending claim of a patent application filed
pursuant to the Patent Cooperation Treaty shall be considered pending in all designated jurisdictions. 
 1.183. “Valuation
Analysis” means, with respect to an entity, a valuation analysis of such entity conducted by an independent valuation expert for purposes of compliance with Section 409A and approved by the Board of Directors (or equivalent body) of
such entity in good faith. 
 1.184. “Value Trigger” means each amount shown in the column labeled “Value Trigger”
in Section 4.10.1.2. 

  
 26 

 2. LICENSE. 

2.1 License Grants. 
 2.1.1
License Grant in the Field. Subject to Section 2.2 and the other terms and conditions of this Agreement, including the restrictions set forth in Section 2.8, each Licensor Institution hereby grants to Company, with respect to the
Targets, a worldwide, royalty-bearing license, sublicensable solely in accordance with Section 2.5 below, under the (A) Cas9-I Institutions’ interests in the
Cas9-I Patent Rights solely to make, have made, use, have used, sell, offer for sale, have sold, export and import those Cas9 Licensed Products, the making, using, selling, offering for sale, exporting or
importing of which is Covered by at least one Valid Claim of the Cas9-I Patent Rights, (B) in the case of Broad, the Cas9-II Institutions’ interests in the Cas9-II Group A Patent Rights solely to make, have made, use, have used, sell, offer for sale, have sold, export and import those Cas9 Licensed Products, the making, using, selling, offering for sale, exporting or
importing of which is Covered by at least one Valid Claim of the Cas9-II Group A Patent Rights, and (C) in the case of Broad, the Cas9-II Institutions’
interests in the Cas9-II Group B Patent Rights solely to make, have made, use, have used, sell, offer for sale, have sold, export and import those Cas9 Licensed Products and
Cas9-II Group B Licensed Products, the making, using, selling, offering for sale, exporting or importing of which is Covered by at least one Valid Claim of the Cas9-II
Group B Patent Rights, in each case ((A), (B) and (C)) solely for use in the Field, except that (a) the licenses granted under this Section 2.1.1 exclude (i) the field of modifying animals or animal cells for the creation, making,
having made, use, sale, offer for sale, having sold, exportation and importation of organs suitable for xenotransplantation into humans and (ii) research and development, and commercialization and other use or exploitation, of products or
services in the field of Livestock Applications; and (b) the licenses granted under this Section 2.1.1 exclude (x) human germline modification, including intentionally modifying the DNA of human embryos or human reproductive cells,
and (y) the stimulation of biased inheritance of particular genes or traits within a population of plants or animals. The licenses granted under this Section 2.1.1 will be (aa) co-exclusive (with
Editas, or its successor or assign, or another Person (the identity of which other Person Broad will use good faith efforts to disclose to Company), who in each of the foregoing cases, for the avoidance of doubt, has the right to sublicense), with
respect to the license under the Cas9-I Institutions’ interests in the Cas9-I Patent Rights and the Cas9-II
Institutions’ interests in the Cas9-II Group A Patent Rights, and (bb) non-exclusive with respect to the license under the
Cas9-II Institutions’ interests in the Cas9-II Group B Patent Rights. 

2.1.2 Non-Exclusive License Grant. Subject to Section 2.2 and the other terms and
conditions of this Agreement, including the restrictions set forth in Section 2.8, each Licensor Institution hereby grants to Company a non-exclusive, worldwide, royalty-bearing license, sublicensable
solely in accordance with Section 2.5 below, under the Cas9-I Institutions’ interests in the Cas9-I Patent Rights and, in the case of Broad, the Cas9-II Institutions’ interests in the Cas9-II Patent Rights (a) for Internal Research Purposes, (b) for research, development and commercialization of products
(including Enabled Products) for the prevention or treatment of human disease outside of the Editas Cas9-I Exclusive Field (in the case of the Cas9-I Institutions’
interests in the Cas9-I Patent Rights) and outside of the Editas Cas9-II Exclusive Field (in the case of the Cas9-II
Institutions’ interests in the Cas9-II Patent Rights), respectively, 

  
 27 

 
and (c) with respect to the Targets, to make, have made, use, have used, sell, offer for sale, have sold, export and import Enabled Products for use within the Field; provided, however, that
notwithstanding the foregoing, (x) the license granted under this Section 2.1.2 excludes (i) human germline modification, including intentionally modifying the DNA of human embryos or human reproductive cells, (ii) the
stimulation of biased inheritance of particular genes or traits within a population of plants or animals, (iii) Ag Products, and (iv) any products, including without limitation any Ag Product or any product in the field of Livestock
Applications, that provide nutritional benefits, unless such products (aa) are regulated by a Regulatory Authority as a drug or biologic pursuant to Section 505 of the United States Federal Food, Drug, and Cosmetic Act of 1938, as amended,
Section 351 of the United States Public Health Service Act of 1944, as amended, or any successor laws, or equivalent laws or regulations in jurisdictions outside the United States and (bb) are otherwise included in the definition of Field, and
(y) the license granted by Harvard under the Church IP excludes (A) the field of modifying animals or animal cells for the creation, making, having made, use, sale, offer for sale, having sold, exportation and importation of organs
suitable for xenotransplantation into humans and (B) research and development, and commercialization and other use or exploitation of products or services, in the field of Livestock Applications. 

2.2 Reservation of Rights. Notwithstanding anything herein to the contrary: 

2.2.1 Government and Non-Profit Rights. Notwithstanding anything to the contrary herein, any and
all licenses and other rights granted under this Agreement are limited by and subject to (a) any rights or obligations of the Owner Institutions and United States government under 35 U.S.C. §§
200-212 and 37 CFR Part 401 et seq.; any right granted in this Agreement greater than that permitted under 35 U.S.C. §§ 200-212 and 37 CFR Part 401 et seq.
shall be subject to modification as may be required to conform to the provisions of those statutes and regulations, and (b) the Owner Institutions’ reservation of the right, for each of the Owner Institutions and other academic, government
and non-profit entities, to make, use and practice the Patent Rights for research, teaching, or educational purposes. Further, Company acknowledges that it has been informed that certain of the Cas9-I Patent Rights were developed, at least in part, by employees of HHMI and that HHMI has a fully paid-up, non-exclusive,
irrevocable, worldwide license to exercise any intellectual property rights with respect to such Cas9-I Patent Rights for research purposes, with the right to sublicense to
non-profit and governmental entities (the “HHMI License”). For the avoidance of doubt, the HHMI License includes, but is not limited to, (i) the right to make, use, perform and practice
the subject matter described in such Cas9-I Patent Rights for research, teaching, educational and scholarly purposes (including, but not limited to, the right to enter into projects permitted under 15 U.S.C.
3710a (the CRADA statute) or other sponsored research projects or collaborations whether or not such collaborations are formal or informal), in all fields in all territories at any time without restriction; and (ii) the right to research,
develop, make, have made, use, distribute, import or otherwise practice such Cas9-I Patent Rights and applicable Cas9 Licensed Products as research products or research tools, or for research purposes in the
Field. Any and all licenses and other rights granted under this Agreement are explicitly made subject to the HHMI License. 

  
 28 

 2.2.2 Research Reservation. Notwithstanding anything to the contrary herein, in
addition to the reservation of rights under Section 2.2.1, the co-exclusive license granted to Company in the Field under Section 2.1.1 of this Agreement is subject to: 

2.2.2.1 The Owner Institutions’ reservation of the right, for each of them and for other not-for-profit research organizations and government agencies, to make, use, perform and practice the subject matter described in the Patent Rights for research, teaching, educational and scholarly purposes
(including, but not limited to, the right to enter into projects permitted under 15 U.S.C. 3710a (the CRADA statute) or other sponsored research projects or collaborations whether or not such collaborations are formal or informal), in all fields in
all territories at any time without restriction. For clarity, sponsored research funded by a commercial entity shall be considered research for purposes of this Section 2.2.2 and the HHMI License. 

2.2.2.2 The Owner Institutions’ reservation of the right, for each of them and for any Third Party (including non-profit and for-profit entities), to research, develop, make, have made, use, offer for sale, sell, have sold, import or otherwise exploit the Patent Rights and Licensed
Products as research products or research tools, or for research purposes in the Field. Without otherwise limiting or expanding the foregoing, for the purposes of this Section 2.2.2.2, “research purposes” shall not be interpreted to
include the administration of a Licensed Product into any human. 
 2.3 Affiliates. The licenses granted to Company under
Section 2.1 include the right to have some or all of Company’s rights or obligations under this Agreement exercised or performed by one or more of Company’s Affiliates on Company’s behalf; provided, however, that: 

2.3.1 Company shall notify the Licensor Institutions in writing [**] in advance of any Affiliate exercising or performing any of Company’s
rights or obligations under this Agreement; 
 2.3.2 prior to any Affiliate exercising or performing any of Company’s rights or
obligations under this Agreement, such Affiliate shall agree in writing with Company to be bound by the terms and conditions of this Agreement as if it were Company hereunder, including specific written agreement (a) to indemnify, defend and
hold Indemnitees and HHMI Indemnitees harmless, and carry insurance, under the same terms as Article 9 of this Agreement, and (b) that the Owner Institutions and HHMI are express third party beneficiaries of such writing; 

2.3.3 no such Affiliate shall be entitled to grant, directly or indirectly, to any Person any right of whatever nature under, or with respect
to, or permitting any use or exploitation of, any of the Patent Rights, including any right to develop, manufacture, market or sell Licensed Products (a) if doing so would result in a Sublicense of Company’s rights through more than [**]
tiers (including the grant of rights from Company to the applicable Affiliate) and (b) unless such grant of rights is a Sublicense and includes all applicable restrictions and conditions on the granting of Sublicenses as set forth herein; 

  
 29 

 2.3.4 any act or omission by an Affiliate of Company shall be deemed an act or omission by
Company hereunder, and Company shall be responsible for each of its Affiliates complying with all obligations of Company under this Agreement (including without limitation all restrictions placed on Company herein); and 

2.3.5 any assumption of rights or obligations by Affiliates of Company under this Agreement shall not relieve Company of any of its obligations
under this Agreement. 
 2.4 Right to Subcontract. If Company desires to exercise any of the rights or obligations that Company may
have under this Agreement by subcontracting the exercise or performance of all or any portion of such rights and obligations on Company’s behalf, Company shall be entitled to do so, provided that (a) such contract service providers obtain
no rights in or to the Patent Rights except for the limited purpose of performing the applicable contracted services on behalf of the Company, (b) any subcontract granted or entered into by Company as contemplated by this Section 2.4 of
the exercise or performance of all or any portion of the rights or obligations that Company may have under this Agreement shall not relieve Company from any of its obligations under this Agreement, (c) any act or omission by a subcontractor of
Company shall be deemed an act or omission by Company hereunder, and (d) Company shall be responsible for each of its subcontractors complying with all obligations of Company under this Agreement (including without limitation all restrictions
placed on Company herein); provided that any subcontract or other agreement that, in whole or in part, grants or otherwise transfers any of the rights licensed to Company hereunder, or otherwise falls under the definition of a Sublicense, shall be
deemed a Sublicense and not a subcontract hereunder and shall be subject to all restrictions and requirements applicable to Sublicenses under this Agreement. 

2.5 Sublicenses. 
 2.5.1
Sublicense Rights. Company shall be entitled to sublicense (through up to [**] tiers) the rights granted to it under Section 2.1 hereof to Third Parties solely within the Field and subject to the terms of this Section 2.5, provided
that Company and its Sublicensees may only sublicense their rights under Section 2.1.2 together with a sublicense of their rights under Section 2.1.1. 

2.5.2 Sublicense Agreements. Company shall ensure that any Sublicense shall be on terms and conditions in compliance with, and not
inconsistent with, the terms of this Agreement. Notwithstanding any Sublicense, Company shall remain primarily liable to the Licensor Institutions for all of Company’s duties and obligations contained in this Agreement, and any act or omission
of a Sublicensee which would be a breach of this Agreement if performed by Company shall be deemed to be a breach by Company of this Agreement. Any Sublicenses granted by Company may include the right to grant and authorize further Sublicenses
(including to Affiliates of the Sublicensee), in each case subject to all applicable restrictions and conditions on the granting of Sublicenses herein. Subject to the provisions of Section 10.3.1.2 hereof, all Sublicenses shall automatically
terminate effective upon termination of this Agreement unless otherwise agreed in writing by the Licensor Institutions or as provided in Section 10.3.1.2. Company shall furnish the Licensor Institutions with a fully-executed, unredacted copy of
any Sublicense agreement, promptly upon execution of such Sublicense; provided that Company may redact from such copy (a) the identity of a Target selected for 

  
 30 

 
research, development or commercialization under the Sublicense and (b) other proprietary non-public technical information of Company or the
applicable Sublicensee. Notwithstanding the foregoing, Company shall not redact any information reasonably necessary for the Licensor Institutions to evaluate and confirm compliance of such Sublicense with the terms and conditions of this Agreement.
The Licensor Institutions shall use such copies solely for the purpose of monitoring Company’s and its Sublicensees’ compliance with their obligations, and enforcing the Licensor Institutions’ rights, under this Agreement. Any
Sublicense shall require a written agreement, which shall be subject and subordinate to the terms and conditions of this Agreement, and shall contain, among other things, the following: 

2.5.2.1 all provisions necessary to ensure Company’s ability to perform its obligations under this Agreement; 

2.5.2.2 a section requiring Sublicensee to indemnify, defend and hold Indemnitees and HHMI Indemnitees harmless, and carry insurance, under the
same terms set forth in Article 9 of this Agreement; 
 2.5.2.3 a statement that the Licensor Institutions are intended third party
beneficiaries of such Sublicense for the purpose of enforcing all patent challenge, indemnification, and insurance provisions of such Sublicense and enforcing the right to terminate such Sublicense for breach of the patent challenge, indemnification
and insurance provisions of such Sublicense; and a statement that HHMI and each other Owner Institution are intended third party beneficiaries of such Sublicense for the purpose of enforcing HHMI and such Owner Institution’s respective rights,
including indemnification and insurance provisions, under this Agreement; 
 2.5.2.4 a provision stating that in the event Sublicensee
directly or indirectly brings, assumes, or participates in, or knowingly, willfully or recklessly assists in bringing, a Patent Challenge then Company shall be entitled to terminate the Sublicense; 

2.5.2.5 a provision specifying that, in the event of termination of the licenses set forth in Sections 2.1 in whole or in part (e.g., as to one
license or the other, or termination in a particular country), any existing Sublicense agreement shall terminate to the same extent of such terminated license, subject to Sublicensee’s right to receive a Direct License from the Licensor
Institutions in accordance with Section 10.3.1.2 hereof; 
 2.5.2.6 a provision prohibiting the Sublicensee from sublicensing its rights
under such Sublicense agreement (a) if doing do would result in a Sublicense of Company’s rights through more than [**] tiers and (b) unless such further sublicense includes all applicable restrictions and conditions on the granting
of Sublicenses as set forth herein; 
 2.5.2.7 a provision requiring Sublicensee to comply with Section 8.1 (Compliance with Law) and
Section 11.2 (Use of Name) of this Agreement; and 

  
 31 

 2.5.2.8 a provision prohibiting the Sublicensee from assigning the Sublicense
agreement without the prior written consent of the Licensor Institutions, except that Sublicensee may assign the Sublicense agreement without such prior written consent to the same extent Company may assign this Agreement under Section 11.14.

 2.6 U.S. Manufacturing. Company agrees that any Licensed Products used or sold in the United States that are subject to 35
U.S.C. §§ 201-211 and the regulations promulgated thereunder, as amended, or any successor statutes or regulations shall, to the extent required by law, be manufactured substantially in the United
States. 
 2.7 No Other Grant of Rights. Except as expressly provided herein, nothing in this Agreement shall be construed to confer
any ownership interest, license or other rights upon Company or its Affiliates or Sublicensees by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of the Licensor Institutions or
MIT, or any other entity, regardless of whether such technology, intellectual property rights, products or biological materials are dominant, subordinate or otherwise related to any Patent Rights. 

2.8 Additional Limitations on Exercise of License Rights. 

2.8.1 Germline Modification. Company will not use the Patent Rights for human germline modification, including intentionally modifying
the DNA of human embryos or human reproductive cells. 
 2.8.2 Gene-Drive Applications. Company will not use the Patent Rights for the
stimulation of biased inheritance of particular genes or traits within a population of plants or animals. 
 2.8.3 General
Restriction. Without limiting the foregoing Sections 2.8.1 and 2.8.2, Company will not use the Patent Rights except in accordance with the terms of the licenses granted under Section 2.1. 

3. DEVELOPMENT AND COMMERCIALIZATION. 

3.1 Diligence; Development Milestones. Company shall use commercially reasonable efforts or shall cause at least one of its Affiliates
or Sublicensees to use commercially reasonable efforts: (a) to research and develop Cas9 Licensed Products within the Field; (b) to introduce Cas9 Licensed Products within the Field into the commercial market; and (c) to market Cas9
Licensed Products within the Field following such introduction into the market and make such Cas9 Licensed Products reasonably available to the public. In addition, Company, by itself or through any of its Affiliates or Sublicensees, shall achieve
each of the Development Milestones specified in Exhibit 3.1 within the corresponding time period specified in Exhibit 3.1. 

  
 32 

 3.2 Inclusive Innovation Model. 

3.2.1 If at any time after the second anniversary of the Effective Date a Third Party makes a bona fide proposal (a “Third Party
Proposal”) to the Licensor Institutions for developing (a) a product within the Field, but outside the Cardiovascular Disease Field, with respect to a specific Target (which specific Target, the “Third Party Proposed
Target”) or (b) a product within the Field, but outside the Cardiovascular Disease Field, and within a specific Cas9 Patent Rights Category (the “Third Party Proposed Category”) that, in each case, may require or for
which a license under any of the Patent Rights for which Company’s license hereunder is co-exclusive is desired, then in each case ((a) or (b)), if the Licensor Institutions are interested in having such
product developed and commercialized, the Licensor Institutions may notify Company of the Third Party Proposal, and shall include in such notification information regarding the Third Party Proposal, including the Third Party Proposed Target or Third
Party Proposed Category, as applicable, specified in such Third Party Proposal and, to the extent permitted by such Third Party, the identity of the Third Party that provided the Third Party Proposal (which identity shall be deemed to be Licensor
Institution Confidential Information). Within [**] after the receipt of such notification from the Licensor Institutions, Company shall notify the Licensor Institutions regarding whether it or any of its Affiliate or Sublicensees is (or is
interested in) developing Cas9 Licensed Products in the Field with respect to the Third Party Proposed Target specified in the Third Party Proposal or within the Third Party Proposed Category specified in the Third Party Proposal, as applicable (the
“Company Notification”). 
 3.2.2 If Company notifies the Licensor Institutions within such [**] period that it or any of
its Affiliates or Sublicensees is currently developing or is interested in developing Cas9 Licensed Products in the Field with respect to the Third Party Proposed Target specified in the Third Party Proposal or within the Third Party Proposed
Category specified in the Third Party Proposal, as applicable, the Parties will negotiate in good faith and agree, during the [**] following the Company Notification (or such longer time as will be agreed to by the Parties in writing), upon a
development plan with respect to the development and commercialization of such Third Party Proposed Target or Third Party Proposed Category, as applicable, which development plan will be similar to the Development Plan with respect to other Licensed
Products developed by Company, subject to necessary adjustments, and will include reasonable milestones. If the Parties agree on such development plan and milestones within such [**] period, Company shall maintain its co-exclusive license(s) hereunder with respect to such Third Party Proposed Target or Third Party Proposed Category, as applicable, but shall be obligated (a) to use commercially reasonable efforts to develop
and commercialize at least one Cas9 Licensed Product in the Field with respect to such Third Party Proposed Target or Third Party Proposed Category, as applicable, in accordance with such new development plan and (b) to meet the milestones in
such development plan with at least one such Cas9 Licensed Product. For the avoidance of doubt, Company’s development plan for the Third Party Proposed Target or Third Party Proposed Category may be for development and commercialization within
or outside the Cardiovascular Disease Field. 
 3.2.3 If (a) Company fails to send the Company Notification to the Licensor Institutions
under Section 3.2.2 within [**] following its receipt of a notice from the Licensor Institutions regarding a Third Party Proposal, (b) the Parties do not agree on a development plan and milestones that are acceptable to the Licensor
Institutions, in their reasonable judgment, within the time period set forth in Section 3.2.2, or (c) the Parties agree on such a development plan and milestones within such time period, but Company thereafter fails to comply in any
material respect with such mutually agreed development and commercialization obligations, and fails to cure such noncompliance after notice from the Licensor Institutions within the time 

  
 33 

 
periods specified in Section 3.5 (applied mutatis mutandis), then in each case ((a)-(c)), (y) the Licensor Institutions will be free to terminate Company’s rights under
Section 2.1 with respect to the Third Party Proposed Target or Third Party Proposed Category, as applicable, specified in the applicable Third Party Proposal, and (z) the Licensor Institutions will be free to grant to Third Parties
licenses within the Field (i) under the Patent Rights that are exclusively or co-exclusively licensed to Company with respect to the Third Party Proposed Target or (ii) under the Patent Rights that
are exclusively or co-exclusively licensed to Company within the Third Party Proposed Category, as applicable, provided that such Third Party licenses do not grant rights to commercialize products intended for
use in the Cardiovascular Disease Field. 
 3.2.4 If Company states in the Company Notification that it and its Affiliates and Sublicensees
are not (and are not interested in) developing Cas9 Licensed Products with respect to the Third Party Proposed Target specified in the Third Party Proposal or within the Third Party Proposed Category specified in the Third Party Proposal, as
applicable, but that it wishes to grant a Sublicense to such Third Party with respect to the Third Party Proposed Target or the Third Party Proposed Category, as applicable, then (a) Broad will use good faith efforts to promptly disclose to
Company, to the extent permitted by such Third Party, the identity of the Third Party that provided the Third Party Proposal (which identity shall be deemed to be Licensor Institution Confidential Information) and (b) Company will have [**] (or
such longer time as will be agreed to by the Parties in writing) to negotiate and enter into such a Sublicense agreement with such Third Party in the Field; provided, however, that if Company demonstrates that it and such Third Party have entered
into a term sheet with respect to such a Sublicense agreement during such [**], Company will be entitled to extend the period for the execution of a binding Sublicense agreement by an additional [**] (or such longer time as will be agreed to by the
Parties in writing). 
 3.2.5 If Company fails to enter into such a Sublicense agreement within such [**] period or such [**] period (or such
longer time as will be agreed to by the Parties in writing), as applicable, Company shall promptly (but in any event within [**] of the end of such period) provide the Licensor Institutions in writing an explanation for such failure along with the
proposed terms last offered by Company to the prospective Sublicensee. If the Licensor Institutions determine in their good faith judgment that the terms last offered by Company to such Third Party were commercially reasonable, the Licensor
Institutions shall notify Company of such determination. Alternatively, if the Licensor Institutions determine in their good faith judgment that the terms last offered by Company to such Third Party were not commercially reasonable, the
Licensor Institutions shall notify Company of such determination, including Licensor Institutions’ reasoning therefor. In either case, the Licensor Institutions shall provide Company with an additional [**] to enter into a Sublicense with such
Third Party. If Company reasonably believes that its entry into a Sublicense agreement with such Third Party on commercially reasonable terms would require Company to make payments under this Agreement with respect to such Sublicense agreement in
excess of the payments that Company would receive under such Sublicense agreement, then (a) Company shall promptly notify the Licensor Institutions thereof, and (b) the Parties shall promptly discuss in good faith potential solutions to
address such outcome. In any event, if Company fails to enter into an agreement with such Third Party within such additional [**] period, then (y) the Licensor Institutions will be free to terminate Company’s rights under Section 2.1
with respect to the Third Party Proposed Target or 

  
 34 

 
Third Party Proposed Category, as applicable, specified in the applicable Third Party Proposal, and (z) the Licensor Institutions will be free to grant to Third Parties licenses within the
Field (i) under the Patent Rights that are exclusively or co-exclusively licensed to Company with respect to the Third Party Proposed Target or (ii) under the Patent Rights that are exclusively or co-exclusively licensed to Company within the Third Party Proposed Category, as applicable, provided that such Third Party licenses do not grant rights to commercialize products intended for use in the
Cardiovascular Disease Field. 
 3.3 Development Plan; Adjustments. The Development Plan for the development and commercialization of
Licensed Products and Enabled Products is attached hereto as Exhibit 3.3. Company shall be entitled, from time to time, to make such commercially reasonable adjustments to the Development Plan as Company believes, in its good faith judgment, are
needed in order to improve Company’s ability to meet the Development Milestones in Exhibit 3.1. 
 3.4 Reporting. Within [**]
after the end of each Calendar Year, Company shall furnish the Licensor Institutions with: 
 3.4.1 (i) a written report summarizing its, its
Affiliates’ and its Sublicensees’ efforts during the prior year to develop and commercialize Cas9 Licensed Products within the Field and (ii) a written report summarizing its, its Affiliates’ and its Sublicensees’ efforts
during the prior year to develop and commercialize Cas9-II Group B Licensed Products within the Field, including: (a) research and development activities, including information regarding specific Licensed
Products and Enabled Products in development and their therapeutic applications; (b) status of applications for Regulatory Approvals; (c) commercialization efforts; and (d) marketing efforts; which report must contain a sufficient
level of detail for the Licensor Institutions to assess whether Company is in compliance with its obligations under Article 3 and a discussion of intended efforts for the then-current year. Together with each report prepared and provided under this
Section 3.4.1, Company shall provide the Licensor Institutions with a copy of the then-current Development Plan which shall include sufficient detail to enable the Licensor Institutions to assess what Licensed Products and Enabled Products are
in development and the status of such development; and 
 3.4.2 (i) a brief written report summarizing its, its Affiliates’ and its
Sublicensees’ efforts during the prior year to develop and commercialize Cas9 Licensed Products and Cas9 Enabled Products for the prevention or treatment of human disease outside the Field and (ii) a brief written report summarizing its,
its Affiliates’ and its Sublicensees’ efforts during the prior year to develop and commercialize Cas9-II Group B Licensed Products and Cas9-II Group B Enabled
Products for the prevention or treatment of human disease outside the Field. 
 3.5 Failure to Meet Development Milestone; Opportunity to
Cure. If Company believes that, despite using commercially reasonable efforts, it will not achieve a Development Milestone, it may notify the Licensor Institutions in writing in advance of the relevant deadline. Company shall include with such
notice (a) a reasonable explanation of the reasons for such failure (lack of finances or development preference for a non-Cas9 Licensed Product shall not constitute reasonable basis for such failure)
(“Milestone Explanation”) and (b) a reasonable, detailed, written plan for promptly achieving a reasonable extended and/or amended milestone, which plan shall include information, if applicable, regarding which Licensor
Institution’s Cas9-I Patent Rights or Cas9-II Patent Rights Cover any Cas9 Licensed Product that will achieve such milestone (“Milestone Plan”).

  
 35 

 3.5.1 If Company so notifies the Licensor Institutions, but fails to provide the Licensor
Institutions with both a Milestone Explanation and Milestone Plan, then Company shall have an additional [**] or until the original deadline of the relevant Development Milestone, whichever is later, to meet such milestone. Company’s failure to
do so shall constitute a material breach of this Agreement and the Licensor Institutions shall have the right to terminate this Agreement upon written notice to Company, subject to Section 3.5.6. 

3.5.2 If Company so notifies the Licensor Institutions and provides the Licensor Institutions with a Milestone Explanation and Milestone Plan,
both of which are reasonably acceptable to Broad (and Harvard, if any Harvard Controlled Patent Covers the Licensed Product that is the subject of the Milestone Plan), then Exhibit 3.1 shall be amended automatically to incorporate the extended
and/or amended milestone set forth in the Milestone Plan. 
 3.5.3 If Company so notifies the Licensor Institutions and provides the Licensor
Institutions with a Milestone Explanation and Milestone Plan, but the Milestone Explanation is not reasonably acceptable to Broad (and Harvard, if any Harvard Controlled Patent Covers the Licensed Product that is the subject of the Milestone
Explanation) (e.g., Company asserts lack of finances or development preference for a non-Licensed Product), then the Licensor Institutions shall notify Company that the Milestone Explanation is not acceptable
and explain to Company why the Milestone Explanation is not acceptable and Company shall have an additional [**] or until the original deadline of the relevant Development Milestone, whichever is later, to meet such milestone. Company’s failure
to do so shall constitute a material breach of this Agreement and the Licensor Institutions shall have the right to terminate this Agreement upon written notice to Company, subject to Section 3.5.6. 

3.5.4 If Company so notifies the Licensor Institutions and provides the Licensor Institutions with a Milestone Explanation and Milestone Plan,
but the Milestone Plan is not reasonably acceptable to Broad (and Harvard, if any Harvard Controlled Patent Covers the Licensed Product that is the subject of the Milestone Plan), then the Licensor Institutions shall notify Company that the
Milestone Plan is not reasonably acceptable, explain to Company why the Milestone Plan is not reasonably acceptable and shall provide Company with suggestions for a reasonably acceptable Milestone Plan. Company shall have one opportunity to provide
the Licensor Institutions with a Milestone Plan reasonably acceptable to Broad (and Harvard, if any Harvard Controlled Patent Covers the Licensed Product that is the subject of the Milestone Plan) within [**] of the notice from the Licensor
Institution(s) described in the previous sentence, during which time Broad (and Harvard, if any Harvard Controlled Patent Covers the Licensed Product that is the subject of the Milestone Plan) agree(s) to work with Company in its effort to develop a
reasonably acceptable Milestone Plan. If, within such [**], Company provides the Licensor Institutions with a Milestone Plan reasonably acceptable to Broad (and Harvard, if any Harvard Controlled Patent Covers the Licensed Product that is the
subject of the Milestone Plan), then Exhibit 3.1 shall be amended automatically to incorporate 

  
 36 

 
the extended and/or amended milestone set forth in the Milestone Plan. If, within such [**], Company fails to provide a Milestone Plan reasonably acceptable to Broad (and Harvard, if any Harvard
Controlled Patent Covers the Licensed Product that is the subject of the Milestone Plan), then Company shall have an additional [**] or until the original deadline of the relevant Development Milestone, whichever is later, to meet such milestone.
Company’s failure to do so shall constitute a material breach of this Agreement and the Licensor Institutions shall have the right to terminate this Agreement upon written notice to Company, subject to Section 3.5.6. 

3.5.5 For clarity, if Company fails to achieve a Development Milestone and does not avail itself of the procedure set forth in this
Section 3.5, then the Licensor Institutions shall have the right to terminate this Agreement upon written notice to Company, subject to Section 3.5.6. Disputes arising under Section 3.5 shall not be subject to resolution by the
Executive Officers under Section 11.7. 
 3.5.6 If the Licensor Institutions elect to terminate this Agreement pursuant to this
Section 3.5, then, notwithstanding anything to the contrary in this Section 3.5, Company’s rights under this Agreement shall not terminate under this Section 3.5, and this Agreement shall remain in effect, solely with respect to
a particular Target if, at the time the Licensor Institutions have the right to terminate, Company provides evidence reasonably acceptable to the Licensor Institutions that Company (a) is not in breach of its diligence obligations in accordance
with Exhibit 3.1 with respect to such particular Target, without opportunity to cure such breach in accordance with this Section 3.5, and (b) is (i) researching and developing Cas9 Licensed Products within the Field directed to such
Target, or is causing at least one of its Affiliates or Sublicensees to do so; (ii) if applicable, using commercially reasonable efforts, or is causing at least one of its Affiliates or Sublicensees to use commercially reasonable efforts, to
introduce Cas9 Licensed Products within the Field directed to such Target into the commercial market; and (iii) if applicable, using commercially reasonable efforts, or is causing at least one of its Affiliates or Sublicensees to use
commercially reasonable efforts, to market Cas9 Licensed Products within the Field directed to such Target following such introduction into the market and make such Cas9 Licensed Products reasonably available to the public; and, thereafter, for the
remainder of the Term, Company continues, or causes at least one of its Affiliates or Sublicensees to continue, to develop and commercialize Cas9 Licensed Products directed to the particular Target in accordance with the foregoing clauses (i)-(iii).
For clarity, the Parties agree and acknowledge that this Section 3.5.6 does not create an obligation to achieve Development Milestones under Section 3.1 with respect to Licensed Products in the Field directed to more than [**] Targets,
consistent with the conditions set forth in Exhibit 3.1; provided, however, that if Company fails to meet a Diligence Milestone specified in Exhibit 3.1, the Licensor Institutions may terminate this Agreement in accordance with this
Section 3.5.6. 
 4. CONSIDERATION FOR GRANT OF LICENSE. 

4.1 Division of Consideration. Each element of consideration set forth in this Article 4 shall be provided by Company to each Licensor
Institution in split amounts, with [**] percent ([**]%) of the applicable consideration paid to Harvard and [**] percent ([**]%) of the applicable consideration paid to Broad in accordance with the payment methods set forth in Article 5 hereof. 

  
 37 

 4.2 License Issue Fee. 

4.2.1 Cash Consideration. Company shall pay to the Licensor Institutions a non-refundable
license fee (“License Issue Fee”) of one hundred and twenty-five thousand dollars ($125,000), due and payable within [**] after the Effective Date. 

4.3 License Maintenance Fees. Company shall pay to the Licensor Institutions the annual license maintenance fees (“License
Fees”) in the table below pursuant to this Section 4.3. 
  

					
	 Date
	  	License Fee	 
	 [**] anniversary of the Effective Date
	  	$	[**]	 
	 [**] anniversary of the Effective Date
	  	$	[**]	 
	 [**] anniversary of the Effective Date and each anniversary of the Effective Date
thereafter
	  	$	[**]	 

 Each such License Fee shall be due and payable on January
1st of the Calendar Year to which such fee applies, and [**] percent ([**]%) of the amount of each such License Fee shall be creditable against any Royalties due and payable under Section 4.6
below with respect to Licensed Products or Enabled Products sold in the same Calendar Year in which such License Fee was due. 
 4.4
Issuance of Equity. 
 4.4.1 Initial and Equity Event Issuances. Subject to the execution and delivery by the Parties of
the Stock Issuance Agreement, Company shall, as partial consideration for the licenses granted hereunder, issue to the Licensor Institutions, (i) as of the Effective Date an aggregate of 1,278,161 shares of Common Stock, representing [**]
percent ([**]%) of Company’s outstanding capital stock on a Fully-Diluted Basis as of the date of such issuance and after giving effect to such issuance (the “Initial Shares”) and (ii) contingent upon and effective
as of an Equity Event, such additional number of shares of Common Stock (the “Equity Event Shares”) such that the sum of the Initial Shares, any then-outstanding Anti-Dilution Shares issued pursuant to Section 4.4.2 and the
Equity Event Shares represents [**] percent ([**]%) of Company’s outstanding capital stock on a Fully-Diluted Basis as of the date of such issuance and after giving effect to such issuance (the Initial Shares, the Anti-Dilution Shares and the
Equity Event Shares, collectively, the “Shares”). The Licensor Institutions hereby agree that, as a condition to and effective as of the issuance of the Shares, the Licensor Institutions, will execute that certain Right of First
Refusal and Co-Sale Agreement and Voting Agreement by and among the Company and the stockholders set forth therein, each dated August 7, 2018, as a common stockholder of Company. 

  
 38 

 4.4.2 Anti-Dilution Issuances. Until the cumulative arm’s length investment in
Company reaches $[**] (the “Total Financing Amount”), Company will issue to the Licensor Institutions, on a pro rata basis, from time to time and for no additional consideration, additional shares of Common Stock of Company (the
“Anti-Dilution Shares”) as will cause the Licensor Institutions to own pursuant to this Agreement and the Cpf1 Agreement an aggregate percentage of Company’s outstanding capital stock on a Fully-Diluted Basis that is equal to
the Anti-Dilution Threshold as measured at the time such Total Financing Amount is reached and as calculated after giving effect to the anti-dilutive issuance to the Licensor Institutions. Company shall provide the Licensor Institutions with
evidence of the issuance of such Anti-Dilution Shares promptly after their issuance. 
 4.5 Milestone Payments. 

4.5.1 Development Milestone Payments. Company shall pay to the Licensor Institutions the Milestone Payments set forth in this
Section 4.5.1 with respect to each Single Schedule 1 Product or each Single Schedule 2 Product, as applicable, to achieve each Milestone Event, regardless of whether such Milestone Event is achieved by Company, an Affiliate of Company or a
Sublicensee: 
  

									
	 Milestone Event
	  	Schedule 1 Milestone
Payment (in Dollars)	 	  	Schedule 2 Milestone
Payment (in Dollars)	 
	 [**]
	  	 	[**]	 	  	 	[**]	 
	 [**]
	  	 	[**]	 	  	 	[**]	 
	 [**]
	  	 	[**]	 	  	 	[**]	 
	 [**]
	  	 	[**]	 	  	 	[**]	 
	 [**]
	  	 	[**]	 	  	 	[**]	 
	 [**]
	  	 	[**]	 	  	 	[**]	 

  

	*	 Milestone Events subject to Change of Control Multiplier in accordance with Section 4.5.4.

	†	 For the purposes of this Section 4.5.1, “[**]” means [**]. 

Company shall notify the Licensor Institutions in writing within [**] following the achievement of each Milestone Event described in
Section 4.5.1, and shall make the appropriate Milestone Payment within [**] after the achievement of such Milestone Event. Each Milestone Payment is payable only once for each Single Schedule 1 Product or Single Schedule 2 Product, as
applicable. The Milestone Events set forth in Section 4.5.1 are intended to be successive; for example, if a Single Schedule 1 Product is not required to undergo the event associated with a particular Milestone Event for such Single Schedule 1
Product (a “Skipped Milestone”), then such Skipped Milestone shall be deemed to have been achieved upon the achievement by such Single Schedule 1 Product of the next successive Milestone Event (“Achieved
Milestone”); provided that the Milestone Events based on [**] shall not be deemed to be successive with [**] 

  
 39 

 
(i.e., if the Milestone Event for [**] occurs prior to the Milestone Event for [**], the Milestone Event for [**] shall not be deemed a Skipped Milestone). Payment for any Skipped Milestone that
is owed in accordance with the provisions of this Section 4.5.1 shall be due within [**] after the achievement of the Achieved Milestone. 

4.5.2 Sales Milestone Payments. Company shall pay to the Licensor Institutions, within [**] of the end of the Calendar Year in which the
following sales Milestone Events are first achieved, the following Milestone Payments on a Schedule 1 Product-by-Schedule 1 Product or Schedule 2 Product-by-Schedule 2 Product basis, regardless of whether such Milestone Event is achieved by Company, an Affiliate of Company or a Sublicensee, or a combination thereof:

  

					
	 Milestone Event
	  	Milestone Payment
(in Dollars)	 
	 $[**] dollars in aggregate Net Sales
	  	$	[**]	 
	 $[**] dollars in aggregate Net Sales
	  	$	[**]	 

 4.5.3 Adjustment for Enabled Products. The Milestone Payments set forth in Section 4.5.1 or
Section 4.5.2 above shall be reduced by [**] percent ([**]%) for any Schedule 1 Product or Schedule 2 Product that is an Enabled Product. 

4.5.4 Change of Control Multiplier. In the event that a Change of Control of Company occurs at any time during the Term, the Milestone
Payments for those Milestone Events designated by an asterisk (*) in Section 4.5.1 that have not yet been paid by Company shall be increased by [**] percent ([**]%) (the “Change of Control Multiplier”). 

4.5.5 Milestone Payments for Schedule 1 Products and Schedule 2 Products. In the event that a Licensed Product or Enabled Product is
both a Schedule 1 Product and a Schedule 2 Product, then Company shall pay the applicable Milestone Payment based on whether the achievement of each Milestone Event first occurred with respect to development, regulatory approval or sales of a
Licensed Product or Enabled Product as a Single Schedule 1 Product or Single Schedule 2 Product, with simultaneous achievement being deemed to have first occurred with respect to a Licensed Product or Enabled Product as a Single Schedule 2 Product.
If achievement of a Milestone Event first occurs with respect to development, regulatory approval or sales of a Licensed Product or Enabled Product as a Single Schedule 1 Product, Company shall pay the difference between the applicable Milestone
Payment for a Single Schedule 2 Product and the applicable Milestone Payment for a Single Schedule 1 Product, if such Licensed Product or Enabled Product thereafter achieves such Milestone Event with respect to development, regulatory approval or
sales as a Single Schedule 2 Product. If achievement of a Milestone Event first occurs with respect to development, regulatory approval or sales of a Licensed Product or Enabled Product as a Single Schedule 2 Product, no additional Milestone
Payments shall be due if such Licensed Product or Enabled Product thereafter achieves such Milestone Event with respect to development, regulatory approval or sales as a Single Schedule 1 Product. For clarity, under no circumstances shall Company
pay Milestone Payments for a Licensed Product or Enabled Product that are more than the Milestone Payments set forth for a Single Schedule 2 Product. 

  
 40 

 4.5.6 Replacement Products. If (A) development of a Licensed Product is
terminated after any Milestone Payment set forth in Section 4.5.1 or Section 4.5.2, as applicable, has been made with respect to such Licensed Product and (B) another Licensed Product is selected to replace the terminated Licensed
Product and the selected Licensed Product is for the same, substantially similar or closely related indication and targets the same Target as the terminated Licensed Product (“Replacement Product”), then there shall be no payment
due upon achievement of the same milestone by such Replacement Product for which the Licensor Institutions already received a Milestone Payment for the original Licensed Product. 

4.6 Royalties. 
 4.6.1
Royalty Rates. Company shall pay to the Licensor Institutions running royalties (“Royalties”) on Net Sales of Licensed Products and Enabled Products during the applicable Royalty Term at the applicable royalty rate set forth
below within [**] following the last day of the Calendar Quarter in which such Royalty accrues. The Parties acknowledge that Royalties shall be determined on a Licensed
Product-by-Licensed Product or Enabled Product-by-Enabled Product basis, as applicable,
and on a country-by-country basis. If the manufacture, use, performance or sale of any Licensed Product is Covered by more than one Valid Claim of the Patent Rights,
multiple Royalties shall not be due as a result of being so Covered. 
 4.6.1.1 Royalty Rates for Cas9 Licensed Products
(adjusted for Cas9-II Group B Licensed Products as set forth in Section 4.6.1.3). Company shall pay to the Licensor Institutions a royalty on the aggregate annual Net Sales of
Cas9 Licensed Products, as applicable, as follows: 
  

					
	 Royalty Tiers
	  	Royalty Rate	 
	 The portion of aggregate annual Net Sales up to and including [**] dollars ($[**])
	  	 	[**]	% 
	 The portion of aggregate annual Net Sales greater than [**] dollars ($[**]) and less than [**]
dollars ($[**])
	  	 	[**]	% 
	 The portion of aggregate annual Net Sales greater than [**] dollars ($[**])
	  	 	[**]	% 

 For clarity, upon expiration of the last Valid Claim within the Patent Rights Covering the applicable Licensed
Product above, such Licensed Product shall be deemed an Enabled Product for which the Royalty rates set forth in Section 4.6.1.2 shall apply for the remainder of the Royalty Term. 

  
 41 

 4.6.1.2 Royalty Rates for Cas9 Enabled Products (adjusted for Cas9-II Group B Enabled Products as set forth in Section 4.6.1.3). 
  

					
	 Royalty Tier
	  	Royalty Rate	 
	 The portion of aggregate annual Net Sales up to and including [**] dollars ($[**])
	  	 	[**]	% 
	 The portion of aggregate annual Net Sales greater than [**] dollars ($[**]) and less than [**]
dollars ($[**])
	  	 	[**]	% 
	 The portion of aggregate annual Net Sales greater than [**] dollars ($[**])
	  	 	[**]	% 

 4.6.1.3 Adjustment for Cas9-II Group B Patent Right Products.
The applicable royalty rate set forth in Section 4.6.1.1 shall be reduced by [**] percent ([**]%) for each Cas9-II Group B Licensed Product. The applicable royalty rate set forth in Section 4.6.1.2
shall be reduced by [**] percent ([**]%) for each Cas9-II Group B Enabled Product. If during a Calendar Quarter, a Licensed Product or an Enabled Product is a Cas9-II
Group B Licensed Product or Cas9-II Group B Enabled Product (as applicable) for only a part of the Calendar Quarter, then the royalty rate adjustment set forth in this Section 4.6.1.3 shall be applied on
a pro rata basis based on the part of such Calendar Quarter during which such Licensed Product or Enabled Product (as applicable) is a Cas9-II Group B Licensed Product or
Cas9-II Group B Enabled Product (as applicable). 
 4.6.2 Royalty Offset. 

4.6.2.1 Royalties Under Multiple Agreements. On a
product-by-product basis, with respect to a Licensed Product or an Enabled Product (each as defined in the Cpf1 Agreement) or with respect to a Licensed Product or
Enabled Product (each as defined in this Agreement), if Company is required to pay Royalties (as defined in the Cpf1 Agreement or this Agreement, as applicable) under both (i) this Agreement and (ii) the Cpf1 Agreement, then Company shall
be entitled to credit [**] percent ([**]%) of the Royalties (as defined in the Cpf1 Agreement) payable under the Cpf1 Agreement prior to the application of any royalty offset set forth in the Cpf1 Agreement against the Royalties payable under
Section 4.6.1. As a condition of the offset in this Section 4.6.2.1, in the event that Company takes a credit against Royalties payable under this Agreement pursuant to this Section 4.6.2.1, then in the royalty reports due to the
Licensor Institutions under Section 5.1.1 at the time such credit is taken, Company shall include a calculation of the credit taken and, with the first such royalty report on which such credit is taken, the basis for Company’s
determination of such credit. 
 4.6.2.2 Third Party IP. On a
product-by-product basis, if Company is legally required by a future court order, settlement agreement, contract, or other legally binding written commitment to make
payments to a Third Party of running royalties on net sales of Licensed Products or Enabled Products for a license under or the use of patent rights held by 

  
 42 

 
such Third Party that Cover such Licensed Products or Enabled Products and that are necessary for the commercialization of such Licensed Products or Enabled Products, then Company shall be
entitled to credit up to [**] percent ([**]%) of such running royalties actually paid by Company to such Third Party against the Royalties payable under this Agreement, provided that if such running royalties are also creditable against payments
under the Cpf1 Agreement, then such credit shall be applied to this Agreement and the Cpf1 Agreement on a pro rata basis based on the amount of Royalties (as defined in this Agreement or the Cpf1 Agreement, as applicable) payable under each
applicable agreement. For clarity, the aggregate amount credited under the preceding sentence shall in no event exceed [**] percent ([**]%) of the applicable running royalties actually paid by Company to the applicable Third Party. As a condition of
the offset in this Section 4.6.2.2, Company shall use commercially reasonable efforts to include a provision in any agreement with such Third Party executed after the Effective Date requiring that payment of royalties by Company to such Third
Parties must be offset as a result of Royalties payable under this Agreement by at least the same percentage of net sales as the Licensor Institutions have offset against their Royalties pursuant to this Section 4.6.2. In the event Company
determines that the use of such Third Party patent rights is necessary for the commercialization of Licensed Products or Enabled Products, and takes a credit against Royalties payable under this Agreement, then in the royalty reports due to the
Licensor Institutions under Section 5.1.1 at the time such credit is taken, Company shall include a calculation of the credit taken and, with the first such royalty report on which such credit is taken, the basis for Company’s
determination of commercial necessity. 
 4.6.2.3 Co-Exclusive Adjustment. On a Target-by-Target basis, (a) if Editas (or an Editas sublicensee) publicly discloses that it has initiated a research or development program that uses technology covered
by the Patent Rights and is directed to a Target (a “Competing Program”), then Company, Broad or Harvard may notify the other two parties of such Competing Program or (b) if Company, Broad’s Office of Strategic Alliances
and Partnering or Harvard’s Office of Technology Development (the “Informed Party”) receives credible information that Editas (or an Editas sublicensee) has initiated a Competing Program directed to a Target and
such Competing Program has not been publicly disclosed, then the Informed Party shall notify the other two parties of such Competing Program, in each case subject to the Informed Party’s (and if the Informed Party is Broad’s Office of
Strategic Alliances and Partnering, then Broad’s, and if the Informed Party is Harvard’s Office of Technology Development, then Harvard’s) confidentiality obligations to Third Parties (each such notice under the foregoing clauses
(a) and (b), a “Competing Program Notice”). Upon a party’s receipt of a Competing Program Notice, (i) the Milestone Payments and royalties payable to the Licensor Institutions under Section 4.5 and
Section 4.6 with respect to the Target that is the subject of the Competing Program that is the subject of such Competing Program Notice shall be reduced by [**] percent ([**]%), and (ii) if Company has made Milestone Payments or royalty
payments under Section 4.5 or Section 4.6 of this Agreement with respect to the Target that is the subject of the Competing Program that is the subject of such Competing Program Notice prior to the receipt of the Competing Program Notice,
then Company shall be entitled to offset the foregoing deduction against future Milestone Payments or royalties payable to the Licensor Institutions pursuant to Section 4.5 and Section 4.6, subject to Section 4.6.2.4. Disputes arising
under this Section 4.6.2.3 shall be referred to the Executive Officers for resolution under Section 11.7, and there shall be no reduction in Milestone Payments or royalties under this Section 4.6.2.3 during the pendency of any such
dispute. 

  
 43 

 4.6.2.4 Minimum Royalty. Notwithstanding anything to the contrary herein (a) on
a product-by-product basis, in no event shall payments to the Licensor Institutions under this Agreement be reduced pursuant to this Section 4.6.2 such that the
Licensor Institutions receive less than (i) [**] percent ([**]%) of the applicable rate set forth in Section 4.6.1, if Company is entitled to offset Royalties under this Agreement pursuant to Section 4.6.2.3 and either or both of
Section 4.6.2.1 or Section 4.6.2.2, or (ii) otherwise, [**] percent ([**]%) of the applicable rate set forth in Section 4.6.1, and (b) any amounts that are not offset during a reporting period shall not be creditable against
payments arising in subsequent reporting periods. 
 4.6.3 Patent Challenge. In the event that Company or any of its agents,
Affiliates or Sublicensees is or becomes a Challenging Party, then (a) Company shall provide the Licensor Institutions with at least [**] notice prior to taking any such action, (b) Company shall pay all reasonable costs, fees and expenses
associated with such Patent Challenge that are incurred by the Owner Institutions and their trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel, and staff, including reasonable attorneys’ fees and all
reasonable costs associated with administrative, judicial or other proceedings, within [**] after receiving an invoice from the Licensor Institutions for same; (c) the co-exclusive licenses granted in
this Agreement may, as of the date of initiation of said challenge or opposition, (i) upon notice by Broad to Company with respect to Broad Controlled Patents or Cas9-II Patent Rights, be converted by
Broad at its option into a non-exclusive license for the remainder of the Term or (ii) upon notice by Harvard to Company with respect to Harvard Controlled Patents, be converted by Harvard at its option
into a non-exclusive license for the remainder of the Term, and in such events described in the foregoing subsections (i) and (ii), the relevant Owner Institutions shall have the right to grant licenses
under their respective Patent Rights to any Person, subject to the then-existing non-exclusive license provided herein; (d) any fees, royalties, milestones or revenues payable to the Licensor Institutions
under Section 4.2 through Section 4.7 shall double in amount if and when any Patent Right survives the Patent Challenge such that it remains valid in whole or in part; and (e) at any time after the Patent Challenge is brought, Broad
may, at its option, terminate this Agreement according to Section 10.2 with respect to Broad Controlled Patents or Cas9-II Patent Rights and Harvard may, at its option, terminate this Agreement according
to Section 10.2 with respect to Harvard Controlled Patents; provided that if any of subsections (a) through (e) are held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any of the other said
subsections. Notwithstanding any provision of this Agreement to the contrary, Company shall not have the right to assume or participate in the defense, settlement or other disposition of such Patent Challenge through its status as licensee under
this Agreement, but shall pay associated costs, fees and expenses as provided in this Section 4.6.3. The Parties agree that any challenge or opposition to a Patent Right by Company may be detrimental to the Owner Institutions, and that the
above provisions shall constitute reasonable liquidated damages to reasonably compensate the Owner Institutions for any loss they may incur as a result of Company taking such action. 

  
 44 

 4.7 Sublicense Income. Subject to Section 4.8, Company shall pay to the Licensor
Institutions, within [**] following the last day of the Calendar Quarter in which such Sublicense Income is received by Company, a percentage of Sublicense Income within [**] following the last day of the Calendar Quarter in which such Sublicense
Income is received by Company, in accordance with the rates set forth in this Section 4.7; provided, however, that, for the purpose of calculating payments under this Section 4.7, Company may deduct from the aggregate Sublicense Income
received by Company in a given Calendar Quarter an amount equal to the total payments made by Company to the Licensor Institutions under Article 6 in such Calendar Quarter. For the avoidance of doubt, in the event any Sublicensee transfers rights
granted or transferred by the Licensor Institutions under this Agreement along with rights owned by the Company or granted to the Company by a Third Party, Company shall pay to the Licensor Institutions the following percentages of all Sublicense
Income received by Company or its Affiliates under such Sublicense without deduction from or apportionment of any part of such consideration. Company agrees that all rights relevant to making, using, selling, offering to sell or importing particular
Licensed Products or Enabled Products shall be included in or deemed to be included in the same Sublicense under which the rights granted or otherwise transferred to Company hereunder are granted with respect to such Licensed Products or Enabled
Products for the purpose of calculating Sublicense Income. 
 4.7.1 [**] percent ([**]%) of Sublicense Income received with respect to a
Sublicense executed prior to the date on which the Company has [**]; 
 4.7.2 [**] percent ([**]%) of Sublicense Income received with respect
to a Sublicense executed on or after the date on which the Company has [**]; 
 4.7.3 [**] percent ([**]%) of Sublicense Income received with
respect to a Sublicense executed on or after the date on which the [**]. 
 4.8 Sublicense Income Offset. On a Sublicense-by-Sublicense and Calendar Quarter-by-Calendar Quarter basis, if Company is required
to pay Sublicense Income (as defined in the Cpf1 Agreement or this Agreement, as applicable) under both (a) this Agreement and (b) the Cpf1 Agreement under the same Sublicense in a given Calendar Quarter, then Company shall be entitled to
credit [**] percent ([**]%) of the Sublicense Income (as defined in the Cpf1 Agreement) payable under the Cpf1 Agreement with respect to such Sublicense in such Calendar Quarter prior to the application of any applicable offset set forth in the Cpf1
Agreement against the Sublicense Income payable under Section 4.7 with respect to such Sublicense in such Calendar Quarter; provided that in no event will Sublicense Income payments under this Agreement be reduced pursuant to this
Section 4.8 by more than [**] percent ([**]%) of the payments that would otherwise be payable pursuant to Section 4.7. 
 4.9
Complex Consideration. Company acknowledges and agrees that the Parties have chosen to apply set royalty rates and milestone payments to the rights granted under this Agreement for Company’s convenience in calculating and paying
royalties and milestones. In doing so, Company acknowledges and agrees that certain royalty rates and milestones payments chosen incorporate discounts reflecting that certain products and processes may not be Covered by the Valid Claims of the
Patent Rights but may be based upon, derived from or use the Patent Rights or other licensed intellectual property rights, so that Company, unless explicitly provided otherwise in this Agreement, shall not be entitled to a reduction in the royalty
rate or milestone payment, even if it does not at all times need or use a license to specific Patent Rights, until the end of the Royalty Term for such product or process. 

  
 45 

 4.10 Additional Consideration. 

4.10.1 Success Payments. 

4.10.1.1 Notice. Company shall notify the Licensor Institutions of any payment payable to the Licensor Institutions under this
Section 4.10.1 no later than [**] after the applicable Trigger Date. Such notice shall include the date of such Trigger Date and (a) in the case of a Trigger Date that is not a Company Sale Date or a Trailing Value Receipt Date, a
determination of the Average Market Capitalization as of such Trigger Date or (b) in the case of a Trigger Date that is a Company Sale Date or a Trailing Value Receipt Date, the Upfront Acquisition Value and Trailing Acquisition Value received,
as applicable. 
 4.10.1.2 Achievement of Value Triggers. Following a Trigger Date that is not a Company Sale Date or a Trailing
Value Receipt Date, Company shall pay to the Licensor Institutions the payment indicated in the column labeled “Success Payment” (each such payment, a “Success Payment”) opposite the Trigger Date Value Trigger associated
with such Trigger Date: 
  

					
	 Value Trigger
	  	Success Payment (in Dollars)	 
	 [**]
	  	 	[**]	 
	 [**]
	  	 	[**]	 
	 [**]
	  	 	[**]	 
	 [**]
	  	 	[**]	 
	 [**]
	  	 	[**]	 
	 $10 billion
	  	 	[**]	 

  

	*	 These Success Payments only apply if a Licensed Product Covered by a Valid Claim of the Patent Rights under
this Agreement, or a Licensed Product Covered by a Valid Claim of the Patent Rights under the Cpf1 Agreement (as those terms are defined in the Cpf1 Agreement), in each case, developed by or on behalf of Company or its Affiliate or Sublicensee (as
defined under this Agreement or the Cpf1 Agreement, as applicable) is or has been the subject of a Clinical Study in connection with such development as of the applicable Trigger Date. 

For the avoidance of doubt, more than one Success Payment may become due and payable based on the Average Market Capitalization determined on
any single Trigger Date. By way of example under the immediately preceding sentence, if the Average Market Capitalization on the first Trigger Date is [**] dollars ($[**]), then Company shall pay to the Licensor Institutions aggregate Success
Payments equal to [**] dollars ($[**]). For the avoidance of doubt, the maximum amount payable by Company to the Licensor Institutions pursuant to this Section 4.10.1.2 shall be thirty-one million two
hundred and fifty thousand dollars ($31,250,000). 

  
 46 

 4.10.2 Company Sale Payments. Notwithstanding anything to the contrary herein, if
Company undergoes a Company Sale, then (a) the Licensor Institutions shall receive the applicable Company Sale Success Payment no later than the earlier of (i) [**] after the Company Sale Date and (ii) the first business day following the
date upon which Company, its stockholders or its payment agent, as the case may be, first receives payment of the consideration with respect to such Company Sale, (b) no later than [**] after any Trailing Value Receipt Date on which the
applicable Acquisition Value is greater than or equal to a Value Trigger that corresponds to a Success Payment that previously has not become due and payable, the Licensor Institutions shall receive such unpaid Success Payment and (c) no
Success Payments shall become due hereunder on the basis of Average Market Capitalization equaling or exceeding a Value Trigger. Any payments payable under this Section 4.10.2 must be paid solely in cash or in Public Securities of the
Company’s successor or acquirer, or a combination thereof. With respect to any (i) Company Sale or (ii) Asset Sale to an Affiliate of Company, Company shall cause the acquirer, successor, assignee or licensee of Company or of
Company’s assets, as applicable, to assume Company’s obligations hereunder. 
 4.10.3 Manner and Timing of Payment of Success
Payments. Any Success Payment provided herein that is payable with respect to a Trigger Date and that is not paid in connection with a Company Sale pursuant to Section 4.10.2, may be paid by Company, in its sole discretion, in cash or in a
grant to the Licensor Institutions of a number of shares of Common Stock (any such shares, “Success Payment Shares”), or a combination thereof. Company shall notify the Licensor Institutions of its election with regard to the form
of payment of a Success Payment no later than [**] after the applicable Trigger Date (the “Election Date”). If Company elects to pay any Success Payment (or portion thereof) in cash, Company shall pay to the Licensor Institutions
such Success Payment within [**] following the applicable Election Date. 
 4.10.3.1 Issuance of Success Payment Shares. If
Company elects to pay any Success Payment (or portion thereof) in Success Payment Shares, Company shall issue a number of Success Payment Shares equal to the quotient determined by dividing the applicable Success Payment amount (or portion thereof)
by the FMV of Common Stock on the day immediately prior to the date of issuance of such Success Payment Shares to the Licensor Institutions, in the names of the Licensor Institutions or each of their respective designees, upon instruction by the
Licensor Institutions and in accordance with such instructions, within [**] following such Election Date and in accordance with such instructions. Notwithstanding the foregoing, Company may defer any such issuance of Success Payment Shares until the
date that is [**] after the date of the Initial Public Offering of Company, provided that in the event of any such deferral, (i) the applicable Success Payment amount shall accrue interest from the applicable Election Date to the later of
(A) the date on which such Success Payment and all accrued interest thereon is paid in full, if such Success Payment is paid in cash, or (B) otherwise, the date on which all such Success Payment Shares are issued and covered by an
effective Resale Registration Statement, at the rate of [**] percent ([**]%) per annum (compounded quarterly), 

  
 47 

 
and (ii) Company shall, prior to the date that is [**] after the date of the Initial Public Offering of Company, (x) issue a number of Success Payment Shares equal to the quotient
determined by dividing the applicable Success Payment (or portion thereof) plus the accrued interest by the FMV of Common Stock on the day immediately prior to the date of issuance of such Success Payment Shares to the Licensor Institutions, in the
names of the Licensor Institutions or each of their respective designees, upon instruction by the Licensor Institutions and in accordance with such instructions, or (y) pay to the Licensor Institutions in cash an amount equal to the applicable
Success Payment plus the accrued interest. 
 4.10.3.2 Securities Act Registration. All Success Payment Shares issued under
this Section 4.10.3 shall be registered under the Securities Act and covered by an effective Resale Registration Statement at the time of issuance, if the Common Stock is then publicly traded. All expenses related to the registration,
qualification or compliance with registration of the Success Payment Shares shall be borne by Company. 
 4.10.3.3 Resale Registration
Statement. Any Resale Registration Statement shall include a “final” prospectus, including the information required by Item 507 of Regulation S-K of the Securities Act, as provided by the
Licensor Institutions covered by such Resale Registration Statement. Notwithstanding the foregoing, [**], Company shall [**] to Company [**] to Company [**] to the Company [**]. Notwithstanding anything to the contrary in this Agreement, if the
filing, initial effectiveness or continued use of a Resale Registration Statement at any time would require Company to make an Adverse Disclosure (as defined below), Company may, upon giving prompt written notice of such action to the Licensor
Institutions, delay the filing or initial effectiveness of, or suspend use of, the Resale Registration Statement (a “Suspension”); provided, however, that (a) Company shall not be permitted to exercise a Suspension more than
[**] period for a period not to exceed [**] and (b) the applicable Success Payment shall accrue interest from the applicable Election Date until the later of (i) the date on which such Success Payment and all accrued interest is paid in
full, if such Success Payment is paid in cash, or (ii) otherwise, the date on which all such Success Payment Shares are issued and covered by an effective Resale Registration Statement, at the rate of [**] percent ([**]%) per annum (compounded
quarterly). In the case of a Suspension, the Licensor Institutions agree to suspend use of the applicable prospectus in connection with any sale or purchase of, or offer to sell or purchase, Success Payment Shares, upon receipt of the notice
referred to above. Company shall immediately notify the Licensor Institutions in writing upon the termination of any Suspension, amend or supplement the prospectus, if necessary, so it does not contain any untrue statement or omission and furnish to
the Licensor Institutions such numbers of copies of the prospectus as so amended or supplemented as the Licensor Institutions may reasonably request. If Company does not terminate a Suspension within [**] following the date on which it notifies the
Licensor Institutions thereof, then the Licensor Institutions may request in writing that Company file a Resale Registration Statement with respect to the Success Payment Shares, in which case, subject to the terms of this Section 4.10.3.3,
Company shall, within [**] following such request, (A) file a Resale Registration Statement with respect to the Success Payment Shares (the number of which Success Payment Shares will be calculated to account for any accrued interest with
respect to the Success Payment) or (B) pay to the Licensor Institutions in cash an amount equal to the applicable Success Payment plus the accrued interest thereon. “Adverse Disclosure” means public disclosure of material non-public information that, 

  
 48 

 
in the good faith judgment of the board of directors of Company: (x) would be required to be made in any registration statement filed with the Securities and Exchange Commission by Company
so that such registration statement, from and after its effective date, does not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading; (y) would not be required to be made at such time but for the filing, effectiveness or continued use of such registration statement; and (iii) Company has a bona fide business purpose for not disclosing publicly. 

4.11 Share Issuance Limitation. In no event shall Company issue to the Licensor Institutions shares of Common Stock (i) if and to
the extent that such issuance would result in a change of control (within the meaning of NASDAQ Listing Rule 5635(b), as amended from time to time), or (ii) if and to the extent such issuance would result in the issuance of more than nineteen
and nine-tenths percent (19.9%) of the Common Stock, for the purposes of the NASDAQ Listing Rule 5635(d)(1), as amended from time to time. 

4.12 Non-Circumvention. Company shall not undertake any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action for the purpose of avoiding the observance or performance of its payment obligations under Sections 4.10.1 and 4.4.2 and any related definitions. 

 

	5.	 REPORTS; PAYMENTS; RECORDS. 

5.1 Reports and Payments. 

5.1.1 Reports. Within [**] after the conclusion of each Calendar Quarter commencing with the first Calendar Quarter in which Net Sales
are generated or Sublicense Income is received, Company shall deliver to the Licensor Institutions a report containing the following information (in each instance, with a
product-by-product and country-by-country breakdown and, in the case of the requirement
under Section 5.1.1(c), to the extent such itemized listing of allowable deductions is available from Sublicensees under the terms of the relevant Sublicenses): 
  

	 	(a)	 the number of units of Licensed Products and Enabled Products sold, leased, performed or otherwise transferred,
by Invoicing Entities for the applicable Calendar Quarter; 

  

	 	(b)	 the gross amount billed or invoiced for Licensed Products and Enabled Products sold, leased, performed or
otherwise transferred by Invoicing Entities during the applicable Calendar Quarter; 

  

	 	(c)	 a calculation of Net Sales for the applicable Calendar Quarter, including an itemized listing of allowable
deductions; 

  

	 	(d)	 a reasonably detailed accounting of all Sublicense Income received during the applicable Calendar Quarter;

  
 49 

	 	(e)	 the total amount payable to the Licensor Institutions in dollars on Net Sales and Sublicense Income for the
applicable Calendar Quarter, together with the exchange rates used for conversion; and 

  

	 	(f)	 a list of [**] the Licensed Products. 

Company shall use reasonable efforts to include in each Sublicense a provision requiring the Sublicensee to provide the information required
under this Section 5.1.1. 
 Each such report shall be certified on behalf of Company as true, correct and complete in all material
respects with respect to the information required under Sections 5.1.1(a) through (f), and with respect to the information provided under Section 5.1.1(f), Company shall certify that based solely on its commercially reasonable efforts to
determine such information, Company believes such information is true, correct and complete in all material respects. If no amounts are due to Licensor Institutions for a particular Calendar Quarter, the report shall so state. 

5.2 Payment Currency. All payments due under this Agreement shall be paid in United States dollars. Conversion of foreign currency to
United States dollars shall be made as of the last working day of the applicable Calendar Quarter at the applicable conversion rate existing in the United States (as reported in the Wall Street Journal) or, solely with respect to
Sublicensees, at another commercially reasonable, publicly available, applicable conversion rate as may be provided in a Sublicense. Such payments shall be without deduction of exchange, collection or other charges. 

5.3 Records. Company shall maintain, and shall cause its Affiliates and Sublicensees to maintain, complete and accurate records of
Licensed Products and Enabled Products that are made, used, sold, performed, leased or transferred under this Agreement, any amounts payable to the Licensor Institutions in relation to such Licensed Products or Enabled Products, and all Sublicense
Income received by Company and its Affiliates, which records shall contain sufficient information to permit the Licensor Institutions to confirm the accuracy of any reports or notifications delivered under Section 5.1. Company, its Affiliates
and/or its Sublicensees, as applicable, shall retain such records relating to a given Calendar Year for at least [**] after the conclusion of that Calendar Year (the “Record Retention Period”). 

5.3.1 Audit of Company and Affiliates. During the Record Retention Period, the Licensor Institutions shall have the right, at their
expense, to cause an independent, certified public accountant (or, in the event of a non-financial audit, other appropriate auditor) chosen by the Licensor Institutions and reasonably acceptable to Company to
inspect such records of Company and its Affiliates during normal business hours for the purposes of verifying the accuracy of any reports and payments delivered under this Agreement and Company’s compliance with the terms hereof. Such
accountant or other auditor, as applicable, shall not disclose to the Licensor Institutions any information other than information relating to the accuracy of reports and payments delivered under this Agreement. The Parties shall reconcile any
underpayment or overpayment within [**] after the accountant delivers the results of the audit. If any audit performed under this Section 5.3.1 reveals an underpayment in excess of [**] percent ([**]%) in any Calendar Year, Company shall
reimburse the Licensor Institutions for all amounts incurred in connection with such audit. The Licensor Institutions may exercise their rights under this Section 5.3.1 [**] per audited entity, [**] and only with reasonable prior notice to the
audited entity. 

  
 50 

 5.3.2 Audit of Sublicensees. During the Record Retention Period, the Licensor
Institutions shall have the right, at their expense, to require Company to make available to an independent, certified public accountant (or, in the event of a non-financial audit, other appropriate auditor)
chosen by the Licensor Institutions and reasonably acceptable to Company, during normal business hours, such information as Company has in its possession with respect to reports and payments from Sublicensees for the purposes of verifying the
accuracy of any reports and payments delivered under this Agreement and Company’s compliance with the terms hereof. If such information as Company has in its possession is not sufficient for such purposes, the Licensor Institutions shall have
the right, at their expense, to cause Company to exercise its right under a Sublicense to cause an independent, certified public accountant (or, in the event of a non-financial audit, other appropriate
auditor) chosen by the Licensor Institutions and reasonably acceptable to Company to inspect such records of Sublicensee during normal business hours for the purposes of verifying the accuracy of any reports and payments delivered under this
Agreement and Company’s compliance with the terms hereof. Such accountant or other auditor, as applicable, shall not disclose to the Licensor Institutions any information other than information relating to the accuracy of reports and payments
delivered under this Agreement and then only to the extent such accountant or other auditor may disclose such information to Company under the terms of the relevant Sublicense. If Company does not have the right to conduct an audit of such
Sublicensee for the relevant Calendar Year, Company and the Licensor Institutions shall meet and use reasonable efforts to agree on an appropriate course of action. The Parties shall reconcile any underpayment or overpayment within [**] after the
accountant delivers the results of the audit. If any audit performed under this Section 5.3.2 reveals an underpayment to the Licensor Institutions in excess of [**] percent ([**]%) in any Calendar Year, Company shall reimburse the Licensor
Institutions for all amounts incurred in connection with such audit. The Licensor Institutions may exercise their rights under this Section 5.3.2 [**] per Sublicensee, [**] and only with reasonable prior notice to Company and any audited
Sublicensee. 
 5.4 Late Payments. Any payments by Company that are not paid on or before the date such payments are due under this
Agreement shall bear interest at the lower of (a) [**] percent ([**]%) per month and (b) the maximum rate allowed by law. Interest shall accrue beginning on the first day following the due date for payment and shall be compounded quarterly.
Payment of such interest by Company shall not limit, in any way, the Licensor Institutions’ right to exercise any other remedies the Licensor Institutions may have as a consequence of the lateness of any payment. 

5.5 Payment Method. Each payment due to any Licensor Institution under this Agreement shall be paid by check or wire transfer of funds
to an account(s) in accordance with written instructions provided by such Licensor Institution. If made by wire transfer, such payments shall be marked so as to refer to this Agreement. 

  
 51 

 5.6 Withholding and Similar Taxes. All amounts to be paid to the Licensor
Institutions pursuant to this Agreement shall be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar taxes imposed on Company or other government imposed fees or taxes imposed
on Company, except as permitted in the definition of Net Sales. 
  

	6.	 PATENT PROSECUTION. 

6.1 Prosecution of Patent Rights. As between the Parties, Broad and Harvard shall each have and exercise in their sole discretion
exclusive control over the Prosecution of the respective Patent Rights that each controls. The Licensor Institutions shall keep Company reasonably informed regarding the Prosecution of the respective Reviewed Patent Rights that each controls.
Without limiting the foregoing, each of Broad and Harvard shall: (a) provide Company a reasonable opportunity to review and comment on all material submissions and correspondence with respect to the respective Reviewed Patent Rights that each
controls prior to filing of such material submissions and correspondence; provided, however, that copies of patent applications within the respective Reviewed Patent Rights will not be provided prior to filing, and (b) consider in good faith
Company’s comments and recommendations with respect thereto; provided, however, that final decision-making authority with respect to the Prosecution of all Patent Rights shall vest in the Licensor Institutions. 

6.2 Fees and Expenses.  

6.2.1 Reviewed Patent Rights Fee. Subject to Section 6.3.1, Company shall pay to the Licensor Institutions within [**] following
the end of each Calendar Year a fee equal to (a) [**] dollars ($[**]) for the first [**] patent families within the Reviewed Patent Rights (where each patent family is listed under a distinct “Broad Reference” or “Harvard
Reference” number in Exhibit 1.144) and (b) [**] dollars ($[**]) per patent family for each additional patent family in excess of [**] within the Reviewed Patent Rights (where each patent family is listed under a distinct “Broad
Reference” or “Harvard Reference” number in Exhibit 1.144). Company may elect to revise the scope of the Reviewed Patent Rights, either by (i) including one or more additional patent families within the Patent Rights to Exhibit
1.144 or by (ii) substituting one or more patent families in Exhibit 1.144 with one or more other patent families within the Patent Rights, in each of which case ((i) and (ii)) Company will notify the Licensor Institutions in writing of such
election and the Parties will amend this Agreement to update Exhibit 1.144 in accordance with such election within [**] following the Licensor Institutions’ receipt of the applicable notice; provided, however, that Company may not elect to
substitute patent families in Exhibit 1.144 pursuant to the foregoing clause (ii) more than [**]. Notwithstanding the foregoing, Company may elect, at any time upon the issuance of [**] prior written notice to the Licensor Institutions, to
relinquish its rights under Section 6.1 with respect to the Prosecution of certain Reviewed Patent Rights. Upon receipt of such notice by the Licensor Institutions, such Patent Rights shall no longer be deemed Reviewed Patent Rights under this
Agreement; provided, however, that, subject to Section 6.3.1, Company shall continue to reimburse the Licensor Institutions for all expenses incurred after the Effective Date (A) in the Prosecution of any claims or actions specifically
requested by Company or any of its representatives with respect to any of such Patent Rights or (B) with respect to the Prosecution of any such Patent Rights that are no longer licensed under the Editas
Cas9-I License Agreement or the Editas Cas9-II License Agreement (to the extent such expenses have not been reimbursed by a Third Party). 

  
 52 

 6.2.2 Expenses for Company-Requested Actions. Subject to Section 6.3.1, in
addition to the payment obligations set forth in Section 6.2.1, Company shall reimburse each Licensor Institution for all documented, out-of-pocket expenses,
including [**] after the Effective Date [**] (to the extent such expenses have not been reimbursed by a Third Party) within [**] after the date of each invoice from the applicable Licensor Institution for such expenses. 

6.2.3 Expenses for Patent Rights Abandoned by Editas. In the event that any Patent Right is no longer licensed under the Editas Cas9-I License Agreement or the Editas Cas9-II License Agreement, the Licensor Institutions shall notify Company thereof within [**] of the effective date of such change to
the relevant Editas license agreement. Unless Company informs the Licensor Institutions in writing within [**] following its receipt of the applicable notice that it does not wish to pay for the Prosecution of such Patent Right in one or more
jurisdictions (in which case such Patent Right shall be deemed to be an Abandoned Patent Right in such jurisdiction(s)) Company shall, subject to Section 6.3.1, reimburse each Licensor Institution (to the extent not reimbursed by a Third Party)
for all documented, out-of-pocket expenses, including [**] under this Section 6.2.3 within [**] after the date of each invoice from the applicable Licensor
Institution for such expenses, up to the maximum of the greater of, on a patent family-by-patent family (where each patent family is listed under a distinct “Broad
Reference” or “Harvard Reference” number) and annual basis, (a) [**] dollars ($[**]) and (b) an amount equal to the aggregate out-of-pocket expenses
(including [**]. 
 6.3 Abandonment. 

6.3.1 Abandonment by Company. If Company decides that it does not wish to pay for the Prosecution of any Patent Rights in a particular
country under Section 6.2.2 or Section 6.2.3 (such Patent Rights in such country, the “Abandoned Patent Rights”), Company shall provide the Licensor Institutions with prompt written notice of such election. [**] after
receipt of such notice by the Licensor Institutions, Company shall be released from its obligations to reimburse the Licensor Institutions under Section 6.2 for the expenses incurred thereafter as to such Abandoned Patent Rights; provided,
however, that expenses authorized prior to the receipt by the Licensor Institutions of such notice shall be deemed incurred prior to the notice. In the event of Company’s election not to pay for the Prosecution of any Abandoned Patent Rights in
a particular country, any license granted to Company hereunder with respect to such Abandoned Patent Rights shall terminate (solely with respect to such Abandoned Patent Right and such country), and Company shall have no rights hereunder to exploit
such Abandoned Patent Rights in such country. The Licensor Institutions shall be free, without further notice or obligation to Company, to grant rights in and to such Abandoned Patent Rights to Third Parties in the Field without limitation. 

  
 53 

 6.3.2 Abandonment by Licensor Institutions. Except with respect to the Cas9-II Group B Patent Rights, each Licensor Institution agrees to maintain any application or patent within the Patent Rights that it controls for as long as (a) Company continues to meet its obligation to
reimburse expenses associated with such application or patent in accordance with Section 6.2, (b) there is a good faith basis for doing so, and (c) doing so is consistent with the applicable Licensor Institution’s prosecution
strategy. For the avoidance of doubt, this Section 6.3.2 shall not apply and shall not limit the Licensor Institutions’ right to cease Prosecution of a given application within the Patent Rights in lieu of a divisional, continuation or continuation-in-part application that is also within the Patent Rights. 

6.4 Large Entity Designation. The Parties hereby agree that the Licensor Institutions shall pay the fees prescribed for
large entities to the USPTO with respect to the Patent Rights. 
 6.5 Marking. Company shall, and shall cause its Affiliates and
Sublicensees to, mark all Licensed Products sold, performed or otherwise disposed of in such a manner as to conform with the patent laws and practice of the country to which such products are shipped or in which such products are sold for purposes
of ensuring maximum enforceability of the Patent Rights in such country. 
  

	7.	 ENFORCEMENT OF PATENT RIGHTS. 

7.1 Notification. As between the Parties, and subject to any confidentiality obligations of Company owed to any Third Party, Company
shall inform (i) Broad promptly in writing of any alleged infringement of the Broad Controlled Patents and Cas9-II Patent Rights by a Third Party that Company becomes aware of, along with any available
evidence thereof, and (ii) Harvard promptly in writing of any alleged infringement of the Harvard Controlled Patents by a Third Party that Company becomes aware of, along with any available evidence thereof. A Licensor Institution shall inform
Company promptly in writing of any alleged infringement of any Patent Rights within the Field by a Third Party that such Licensor Institution becomes aware of, along with any available evidence thereof. 

7.2 Licensor Institutions’ Enforcement Right.  

7.2.1 As between the Parties, except as otherwise set forth in this Article 7, Broad and Harvard shall each have the sole right, but shall not
be obligated, at their sole discretion, to prosecute at their own expense all infringements of the respective Patent Rights that each controls. So long as Company remains the co-exclusive licensee of any
Patent Rights with respect to a Licensed Product in the Field, as between the Parties, Company shall, subject to the terms of this Article 7, have the first right, but not the obligation, to institute infringement suits under such Patent Rights with
respect to such Licensed Product in the Field where Company reasonably determines that a Third Party is marketing or has specific plans and is preparing to market an infringing product in any country that competes with such Licensed Product in the
Field (“Infringement”); provided, however, that pursuant to the Editas Cas9-I License Agreement or the Editas Cas9-II License Agreement, Editas may have
certain existing, independent first rights to institute infringement suits under certain of the Patent Rights, and thus, notwithstanding anything to the contrary in this Agreement, Company’s rights under this Section 7.2 are subject to an
obligation to coordinate with Editas, as set forth in Section 7.2.2, and are subject and subordinate to the rights of Editas existing as of the Effective Date, as may be amended from time to time, subject to Sections 8.2.1 and 8.2.2.
Notwithstanding anything to the contrary contained herein with respect to any Infringement, if Company owns one or more 

  
 54 

 
issued patents that cover the allegedly infringing product (“Other IP”), Company shall not initiate action under the Patent Rights unless it (x) also asserts [**] of such
Other IP or (y) obtains written consent from the Licensor Institutions, which consent shall not be unreasonably withheld. Company shall use the same degree of diligence in prosecuting such Infringement as it uses or would use in prosecuting
infringement of its own patent rights. 
 7.2.2 Before Company commences an action with respect to any Infringement: 

7.2.2.1 Company shall deliver a written notice to Editas informing it of such Infringement and Company shall use reasonable efforts to
coordinate its enforcement efforts with respect to such Infringement with Editas for a period not to exceed [**] following the delivery of such notice (or such other period that the Parties may agree upon); 

7.2.2.2 Company shall provide evidence to the Licensor Institutions that (a) it has delivered such written notice to Editas and has used
reasonable efforts to coordinate its enforcement efforts with respect to such Infringement with Editas during such [**] period (or such other period that the Parties may agree upon), and (b) it has good faith basis for initiating action with
respect to such Infringement, and further, Company shall briefly summarize to Licensor Institutions whether and, if so, how Company and Editas will coordinate enforcement efforts, or whether Company will (subject to any obligation to obtain the
consent of the Licensor Institutions, as set forth in Section 7.2.1) independently enforce the Patent Rights with respect to such Infringement, as applicable; and 

7.2.2.3 Company shall consult with the applicable Owner Institutions with respect to its proposed course of action to address the Infringement
and shall consider in good faith the views of the applicable Owner Institutions, and potential effects on the public interest in making its decision whether to take such action, especially with regard to the locally-affordable availability of
Licensed Products or equivalents thereof, e.g., generic products, in Developing Countries. Notwithstanding the foregoing or anything to the contrary contained in this Agreement, Company agrees that the relevant Licensor Institution(s) shall hold
final decision-making authority, to be exercised in good faith, on a case-by-case basis, as to whether Company shall be permitted to enforce the Patent Rights in any
Developing Country. 
 7.2.3 Subject to Editas’ rights described in Section 7.2.1, should Company elect (and, where consent of a
Licensor Institution is required, be permitted) to take action against an actual or potential infringer of Patent Rights, Company shall select counsel reasonably acceptable to the applicable Owner Institutions, shall keep the applicable Owner
Institutions reasonably informed of the progress of the action and shall give the Owner Institutions a reasonable opportunity in advance to consult with Company and offer their views about major decisions affecting the action. Company shall give
careful consideration to those views, but shall have the right to control the action; provided, however, that if Company fails to defend in good faith the validity and/or enforceability of the Patent Rights in the action, or if Company’s
co-exclusive license to a Valid Claim in the suit terminates pursuant to Section 10.2, or if infringement in the Field terminates, the Owner Institutions may elect to take control of the action pursuant to Section 7.3. The expenses of
Company with respect to any suit or suits that Company elects to bring in accordance with this Section 7.2 shall be paid for entirely by Company. If required under Applicable Law to establish standing for the initiation or

  
 55 

 
maintenance of such infringement action by Company, (a) the relevant Owner Institutions shall, upon request of Company or as required by a court or procedural rules, or may voluntarily, join
or be joined as a party to such action, provided that no Owner Institution shall be the first named party in such action, (b) Company shall hold the Owner Institutions free, clear and harmless from and against any and all costs and expenses,
including attorneys’ fees, incurred in conjunction with the prosecution, adjudication, defense, management or settlement of, or joinder to, such suits and any related appeals, remands or other related proceedings (“Litigation
Expenses”), and (c) Company shall reimburse any and all Litigation Expenses incurred by the Owner Institutions within [**] after receiving an invoice (including a copy of detailed time and expense entries from attorneys) from the
applicable Owner Institutions for the same. Company shall not compromise or settle such litigation without the prior written consent of the applicable Owner Institutions, which shall not be unreasonably withheld. In the event that Company exercises
its right to institute an action against any Infringement pursuant to this Section 7.2, out of any sums recovered in such suit or in settlement thereof, it shall first reimburse the Owner Institutions for any unreimbursed Litigation Expenses
and then reimburse itself for all of its litigation expenses necessarily incurred in the prosecution of any such action. The remainder of any sums recovered shall be divided as follows: (i) Company shall receive an amount equal to its lost
profits or a reasonable royalty on the infringing sales, or whichever measure of damages the court shall have applied; (ii) the Licensor Institutions shall receive an amount equal to the royalties and other amounts that Company would have paid
to the Licensor Institutions if Company had sold the infringing products or services rather than the infringer, provided that (A) amounts payable under clause (ii) shall in no event exceed the amounts payable under clause (i) above
and (B) in the event that the remainder of any sums recovered is insufficient to fully satisfy both of the foregoing clauses (i) and (ii) then Company and the Licensor Institutions shall receive a pro rata share of such remainder in
relative proportion to the amounts that would have been payable to Company and the Licensor Institutions under clauses (i) and (ii); and (iii) the balance, if any, remaining after Company and the Licensor Institutions have been compensated
under the foregoing clauses (i) and (ii) shall be shared by the Parties as follows: [**] percent ([**]%) to Company and [**] percent ([**]%) to the Licensor Institutions. 

7.3 Suit by Owner Institutions. If Company has the right but does not take action in the prosecution, prevention or termination
of any Infringement pursuant to Section 7.2 above, and has the right but has not commenced negotiations with the suspected infringer for the discontinuance of said Infringement, within [**] after receipt of notice from Licensor Institutions of
the existence of such Infringement, the Owner Institution that owns the Patent Right subject to the Infringement may elect to do so. The Owner Institutions shall give due consideration to Company’s reasons for not initiating a lawsuit or
otherwise making or prosecuting a claim. Subject to Section 7.4, any and all expenses, including reasonable attorneys’ fees, incurred by Owner Institutions with respect to the prosecution, adjudication or settlement of a suit in accordance
with this Section 7.3, including any related appeals, shall be paid for entirely by the applicable Owner Institutions. In the event that an Owner Institution exercises its right to initiate or maintain an action against any Infringement
pursuant to this Section 7.3, it shall retain all sums recovered in such suit or in settlement thereof. 

  
 56 

 7.4 Own Counsel. The Party initiating the suit shall have the sole and exclusive
right to elect counsel for any suit initiated by it pursuant to Section 7.2 or Section 7.3; provided that such counsel is reasonably acceptable to the other Party. The other Party shall have the right to participate in and be represented
by counsel of its own selection and at its own expense in any suit instituted under this Article 7 by the first Party for Infringement. 

7.5 Cooperation. Each Party agrees to cooperate fully in any action under this Article 7 that is controlled by the other Party,
including executing legal papers and cooperating in the prosecution as may be reasonably requested by the controlling Party; provided that the controlling Party reimburses the cooperating Party promptly for any costs and expenses incurred by the
cooperating Party in connection with providing such requested cooperation within [**] after receiving an invoice from the cooperating Party for the same. 

7.6 Patent Validity Challenge. Each Party shall promptly notify the other Party in the event it receives notice of any legal or
administrative action by any Third Party against a Patent Right, including any opposition, nullity action, revocation, inter partes review, post-grant review, compulsory license proceeding, or declaratory judgment action. All such proceedings
shall be Prosecution of the Patent Rights and controlled by the Owner Institutions in a manner consistent with Section 6.1; provided however, that if any such proceeding is part of or occurs due to any action or activities of Company or its
Affiliates or Sublicensees, then Company will be responsible for reimbursing the Owner Institutions for one hundred percent (100%) of the out-of-pocket expenses incurred
by the applicable Owner Institution in defending such action (to the extent such expenses have not been reimbursed by a Third Party). 
  

	8.	 WARRANTIES; LIMITATION OF LIABILITY. 

8.1 Compliance with Law. Company represents and warrants that it shall comply, and shall ensure that its Affiliates and Sublicensees
comply, with all Applicable Law, including all local, state, federal and international laws and regulations applicable to the development, manufacture, use, sale, performance and importation of Licensed Products and Enabled Products. Without
limiting the foregoing, Company represents and warrants, on behalf of itself and its Affiliates and Sublicensees, that it shall comply with all applicable United States laws and regulations controlling the export of certain commodities and technical
data, including without limitation all Export Administration Regulations of the United States Department of Commerce. Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and
technical data to specified countries. Company hereby gives written assurance that it shall comply with, and shall cause its Affiliates to comply with (and shall contractually obligate its Affiliates and Sublicensees to comply with), all applicable
United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates or Sublicensees, and that it shall indemnify, defend, and hold Indemnitees and HHMI
Indemnitees harmless (in accordance with Section 9.1) for the consequences of any such violation. 
 8.2 Representations, Warranties
and Covenants. 
 8.2.1 By Broad. Broad represents and warrants that (A) Broad has the authority and right to enter into and
perform its obligations under this Agreement and grant the licenses granted by Broad to Company herein, (B) as of the Effective Date, to the best of the knowledge of Broad’s Office of Strategic Alliances and Partnering, the execution,
delivery and performance 

  
 57 

 
of this Agreement by Broad does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which it is a party or is otherwise bound, and (C) as of the
Effective Date, to the best of the knowledge of Broad’s Office of Strategic Alliances and Partnering, no consent of any Third Party, including without limitation any governmental authority, is required for Broad to execute, deliver and perform
under this Agreement, including without limitation to grant the licenses granted by Broad to Company herein, except for such consents as may have been obtained prior to the Effective Date. Further, Broad will not, during the Term and to the
knowledge of Broad’s Office of Strategic Alliances and Partnering, enter into any agreement (or amend or modify any existing agreement in any manner) that is inconsistent with the co-exclusive rights and
licenses granted to Company in the Field hereunder and subject to the terms and conditions of this Agreement. 
 8.2.2 By Harvard.
Harvard represents and warrants that (A) Harvard has the authority and right to enter into and perform its obligations under this Agreement and grant the licenses granted by Harvard to Company herein, (B) as of the Effective Date, to the
best of the knowledge of Harvard’s Office of Technology Development, the execution, delivery and performance of this Agreement by Harvard does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which
it is a party or is otherwise bound, and (C) as of the Effective Date, to the best of the knowledge of Harvard’s Office of Technology Development, no consent of any Third Party, including without limitation any governmental authority, is
required for Harvard to execute, deliver and perform under this Agreement, including without limitation to grant the licenses granted by Harvard to Company herein, except for such consents as may have been obtained prior to the Effective Date.
Further, Harvard will not, during the Term and to the knowledge of Harvard’s Office of Technology Development, enter into any agreement (or amend or modify any existing agreement in any manner) that is inconsistent with the co-exclusive rights and licenses granted to Company in the Field hereunder and subject to the terms and conditions of this Agreement. 

8.2.3 By Company. Company represents and warrants that Company has the authority and right to enter into and perform its obligations
under this Agreement. The Company further represents and warrants that as of the Effective Date (A) to the best of Company’s knowledge, the execution, delivery and performance of this Agreement by Company does not conflict with, or
constitute a breach of, any order, judgment, agreement or instrument to which it is a party or, to its knowledge, is otherwise bound, and (B) to the best of Company’s knowledge, no consent of any Third Party, including without limitation
any governmental authority, is required for Company to execute, deliver and perform under this Agreement, except for such consents as may have been obtained prior to the Effective Date. 

  
 58 

 8.3 Disclaimer. 

8.3.1 NOTHING CONTAINED HEREIN SHALL BE DEEMED TO BE A WARRANTY BY ANY OWNER INSTITUTION THAT IT CAN OR WILL BE ABLE TO OBTAIN PATENTS ON
PATENT APPLICATIONS INCLUDED IN THE PATENT RIGHTS, OR THAT ANY OF THE PATENT RIGHTS WILL AFFORD ADEQUATE OR COMMERCIALLY WORTHWHILE PROTECTION. 

8.3.2 NO OWNER INSTITUTION MAKES ANY WARRANTIES WHATSOEVER AS TO THE COMMERCIAL OR SCIENTIFIC VALUE OF THE PATENT RIGHTS. NO OWNER INSTITUTION
MAKES ANY REPRESENTATION THAT THE PRACTICE OF THE PATENT RIGHTS OR THE DEVELOPMENT, MANUFACTURE, USE, SALE OR IMPORTATION OF ANY LICENSED PRODUCT, OR ANY ELEMENT THEREOF, WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS. 

8.3.3 EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER COMPANY NOR ANY OWNER INSTITUTION MAKES ANY WARRANTY WITH RESPECT TO
ANY TECHNOLOGY, PATENTS, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND COMPANY AND THE OWNER INSTITUTIONS EACH HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT
TO ANY AND ALL OF THE FOREGOING. 
 8.4 Limitation of Liability. 

8.4.1 Except with respect to matters for which Company is obligated to indemnify Indemnitees under Article 9, no Party shall be
liable to any other Party with respect to any subject matter of this Agreement under any contract, negligence, strict liability or other legal or equitable theory for (a) any indirect, incidental, consequential or punitive damages or lost
profits or (b) cost of procurement of substitute goods, technology or services. 
 8.4.2 The Owner Institutions’ aggregate
liability for all damages of any kind arising out of or relating to this Agreement or its subject matter under any contract, negligence, strict liability or other legal or equitable theory shall not exceed the amounts paid to the Licensor
Institutions under this Agreement (including the value of the Shares and, if applicable, Success Payment Shares issued pursuant to this Agreement, in each case calculated at the time of sale, or other disposition in connection with a Company Sale,
of the applicable Share or Success Payment Share by the applicable Owner Institution). 
  

	9.	 INDEMNIFICATION AND INSURANCE. 

9.1 Indemnification. 

9.1.1 Indemnity. Company shall, and shall cause its Affiliates and Sublicensees to, indemnify, defend and hold harmless each Owner
Institution and each of their current and former directors, governing board members, trustees, officers, faculty, affiliated investigators, medical and professional staff, employees, students, and agents and their respective successors,

  
 59 

 
heirs and assigns (collectively, the “Indemnitees”) from and against any liability, cost, expense, damage, deficiency, loss or obligation of any kind or nature (including
reasonable attorneys’ fees and other costs and expenses of litigation or defense) to which any Indemnitee may become subject as a result of any Third Party claim, suit, investigation, action, demand or judgment based upon, arising out of, or
otherwise relating to this Agreement or any Sublicense or subcontract, including (a) any such cause of action relating to product liability concerning any product, process, or service made, used, sold or performed pursuant to any right or
license granted under this Agreement and (b) any such cause of action relating to any Environmental Impact involving or arising from a Licensed Product or Enabled Product (collectively, “Claims”), except to the extent any such
Claim results from or arises out of the gross negligence or willful misconduct of an Indemnitee or material breach of this Agreement by the Licensor Institutions. Company and each of its Affiliates and Sublicensees are referred to as
“Indemnitor” below. 
 9.1.2 Procedures. The Indemnitees agree to provide Company with prompt written notice of any
Claim for which indemnification is sought under this Agreement. Indemnitor agrees, at its own expense, to provide attorneys reasonably acceptable to the Licensor Institutions and the applicable indemnified Owner Institution to defend against any
such Claim. The Indemnitees shall cooperate with Indemnitor, at Indemnitor’s expense, in such defense and shall permit Indemnitor to conduct and control such defense and the disposition of such Claim (including without limitation all decisions
relative to litigation, appeal, and settlement); provided, however, that any Indemnitee shall have the right to retain its own counsel, at the expense of Indemnitor, if representation of such Indemnitee by the counsel retained by Indemnitor would be
inappropriate because of actual or potential differences in the interests of such Indemnitee and any other party represented by such counsel. The Licensor Institutions and the applicable indemnified Owner Institution agree to use diligent efforts to
select counsel, and to cause any other Indemnitees affiliated with their respective institutions to select counsel, that minimizes the number of counsel retained by all Indemnitees if representation of an Indemnitee by the counsel retained by
Indemnitor would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other party represented by such counsel. Indemnitor agrees to keep counsel(s) for Indemnitees informed of the progress in the
defense and disposition of such claim and to consult with the Licensor Institutions and the applicable indemnified Owner Institution with regard to any proposed settlement. Company shall not settle any Claim that has an adverse effect on the rights
of any Indemnitee hereunder that is not immaterial or that admits any liability by or imposes any obligation on any Indemnitee without the prior written consent of such Indemnitee, which consent shall not be unreasonably withheld, conditioned or
delayed. An Indemnitee may not settle any Claim without the prior written consent of Company, which consent shall not be unreasonably withheld, conditioned or delayed. 

9.1.3 HHMI Indemnity. HHMI, and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”), shall
be indemnified, defended by counsel acceptable to HHMI, and held harmless by Company, from and against any liability, cost, expense, damage, deficiency, loss or obligation, of any kind or nature (including without limitation, reasonable
attorneys’ fees and other costs and expenses of defense) based upon, arising out of, or otherwise relating to any Third Party claim (collectively, “HHMI Claims”), based upon, arising out of, or otherwise relating to this
Agreement or any Sublicense, including without limitation any cause of 

  
 60 

 
action relating to product liability. The previous sentence shall not apply to any HHMI Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross
negligence or willful misconduct of an HHMI Indemnitee. Notwithstanding Section 8.4 or any other provision of this Agreement, Company’s obligation to defend, indemnify and hold harmless the HHMI Indemnitees under this paragraph shall not
be subject to any limitation or exclusion of liability or damages or otherwise limited in any way. 
 9.2 Insurance. 

9.2.1 Beginning at the time any Licensed Product or Enabled Product is being commercially distributed or sold (other than for the purpose of
obtaining Regulatory Approval) by Company, or by an Affiliate, Sublicensee or agent of Company, Company shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than [**] dollars ($[**])
per incident and [**] dollars ($[**]) annual aggregate and naming the Indemnitees and HHMI Indemnitees as additional insureds. During clinical trials of any such Licensed Product or Enabled Product, Company shall, at its sole cost and expense,
procure and maintain commercial general liability insurance in such equal or lesser amount as the Licensor Institutions or any other Owner Institution shall require, naming the Indemnitees and HHMI Indemnitees as additional insureds. Such commercial
general liability insurance shall provide (a) product liability coverage and (b) broad form contractual liability coverage for Company’s indemnification obligations under this Agreement. 

9.2.2 If Company elects to self-insure all or part of the limits described above in Section 9.2.1 (including deductibles or retentions
that are in excess of [**] dollars ($[**]) annual aggregate) such self-insurance program must be acceptable to the Owner Institutions and their respective insurers in their sole discretion. The minimum amounts of insurance coverage required shall
not be construed to create a limit of Company’s liability with respect to its indemnification obligations under this Agreement. 
 9.2.3
Company shall provide each Owner Institution with written evidence of such insurance upon request of such Owner Institution. Company shall provide each Owner Institution with written notice at least [**] prior to the cancellation, non-renewal or material change in such insurance. If Company does not obtain replacement insurance providing comparable coverage within such [**] period, the Licensor Institutions shall have the right to terminate
this Agreement effective at the end of such [**] period without notice or any additional waiting periods. 
 9.2.4 Company shall maintain
such commercial general liability insurance beyond the expiration or termination of this Agreement during: (a) the period that any Licensed Product or Enabled Product is being commercially distributed, sold or performed by Company, or an
Affiliate, Sublicensee or agent of Company; and (b) a reasonable period after the period referred to in (a) above, which in no event shall be less than [**]. 

  
 61 

	10.	 TERM AND TERMINATION. 

10.1 Term. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article
10, shall continue in full force and effect until the expiration of the last to expire Valid Claim (the “Term”). Upon such expiration, the Company shall have a worldwide, perpetual, irrevocable, fully paid up, sublicensable license
under the rights and licenses granted to Company under Section 2.1, subject to Section 10.4. 
 10.2 Termination. 

10.2.1 Joint Action of Licensor Institutions. The Licensor Institutions’ rights to terminate this Agreement set forth in this
Section 10.2 shall be joint, not several. Neither Licensor Institution acting alone shall have the right to terminate this Agreement; provided, however, that each Licensor Institution shall severally be entitled to terminate the licenses
granted to Company herein under such Licensor Institution’s respective rights in the Patent Rights to the same extent Licensor Institutions are entitled to terminate this Agreement pursuant to Sections 10.2.3.2, 10.2.4 and 10.2.5 hereof. 

10.2.2 Termination Without Cause. Company may terminate this Agreement without cause upon four (4) months’ prior written
notice to the Licensor Institutions. 
 10.2.3 Termination for Default. 

10.2.3.1 In the event that either Party commits a material breach of its material obligations under this Agreement and fails to cure such
breach within [**] (or [**] in the case of failure to make any payment) after receiving written notice thereof from the other Party, the other Party may terminate this Agreement immediately upon written notice to the Party in breach. 

10.2.3.2 If Company defaults in its material obligations under Section 9.2 to procure and maintain insurance, or if Company has in any
event failed to comply with the notice requirements contained therein, and fails to cure such default (i) within [**] after receiving written notice thereof from Broad, then Broad may terminate this Agreement immediately, with respect to Broad
Controlled Patents and Cas9-II Patent Rights, upon written notice to Company and (ii) within [**] after receiving written notice thereof from Harvard, then Harvard may terminate this Agreement
immediately, with respect to Harvard Controlled Patents, upon written notice to Company. If such default of Company’s material obligations under Section 9.2 arises as a result of a breach by a Sublicensee of the terms of a Sublicense,
Company may cure such breach by purchasing additional insurance that covers the gaps in coverage created by virtue of such Sublicensee’s breach. For clarity, under this Section 10.2.3.2, each Licensor Institution shall severally be
entitled to terminate the licenses granted to Company herein under such Licensor Institution’s respective rights in the Patent Rights, pursuant to Section 10.2.1. 

10.2.3.3 The Licensor Institutions shall be entitled to terminate this Agreement in accordance with the provisions of Sections 3.2 and 3.5.

 10.2.3.4 Notwithstanding the foregoing provisions of this Section 10.2.3, if Company disputes a material breach or other default
alleged by the Licensor Institutions pursuant to Section 10.2.3.1 or 10.2.3.2 by written notice to the Licensor Institutions within the relevant cure period, then the Licensor Institutions shall not have the right to terminate this Agreement
unless it has been determined, in accordance with Section 11.7, that this Agreement was materially breached and Company fails to cure such material breach or default within the relevant cure period after such determination. 

  
 62 

 10.2.4 Termination for Patent Challenge. If Company or any of its Affiliates or
Sublicensees directly or indirectly brings, assumes or participates in, or knowingly, willfully or recklessly assists in bringing a Patent Challenge (except as required under a court order or subpoena), then the following shall apply: (a) if
Company or any of its Affiliates is the party so bringing, assuming, participating in or assisting in such Patent Challenge, then (i) Broad shall be entitled to immediately terminate this Agreement with respect to Broad Controlled Patents and Cas9-II Patent Rights upon written notice to Company and (ii) Harvard shall be entitled to immediately terminate this Agreement with respect to Harvard Controlled Patents upon written notice to Company, and
(b) if a Sublicensee is the party so bringing, assuming, participating in or assisting in such Patent Challenge, then (i) (x) Broad shall be entitled to immediately terminate the rights hereunder with respect to Broad Controlled Patents
and Cas9-II Patent Rights as and to the extent sublicensed to a Sublicensee upon written notice to Company and (y) Harvard shall be entitled to immediately terminate the rights hereunder with respect to
Harvard Controlled Patents as and to the extent sublicensed to a Sublicensee upon written notice to Company and (ii) (x) Broad shall grant Company a period not to exceed [**] from the date of notice by Broad to Company of its intention to
terminate the Agreement with respect to Broad Controlled Patents and Cas9-II Patent Rights due to such Sublicensee bringing, assuming, participating in or assisting in a Patent Challenge, during which period
Company may terminate any and all agreements with such Sublicensee that contain a Sublicense with respect to Broad Controlled Patents and Cas9-II Patent Rights and (y) Harvard shall grant Company a period
not to exceed [**] from the date of notice by Harvard to Company of its intention to terminate the Agreement with respect to Harvard Controlled Patents due to such Sublicensee bringing, assuming, participating in or assisting in a Patent Challenge,
during which period Company may terminate any and all agreements with such Sublicensee that contain a Sublicense with respect to Harvard Controlled Patents. If, pursuant to the foregoing clause (ii), Company terminates such agreement(s) during such
[**] period, then (A) Broad shall not be entitled to terminate this Agreement with respect to Broad Controlled Patents and Cas9-II Patent Rights by virtue of such Sublicensee bringing, assuming,
participating in or assisting in such Patent Challenge and (B) Harvard shall not be entitled to terminate this Agreement with respect to Harvard Controlled Patents by virtue of such Sublicensee bringing, assuming, participating in or assisting
in such Patent Challenge. However, if Company does not terminate such agreement(s) during such [**] period, then (I) Broad shall be entitled to immediately terminate this Agreement with respect to Broad Controlled Patents and Cas9-II Patent Rights upon written notice to Company thereof and (II) Harvard shall be entitled to immediately terminate this Agreement with respect to Harvard Controlled Patents upon written notice to Company
thereof. For clarity, under this Section 10.2.4, each Licensor Institution shall severally be entitled to terminate the licenses granted to Company herein under such Licensor Institution’s respective rights in the Patent Rights, pursuant
to Section 10.2.1. 

  
 63 

 10.2.5 Bankruptcy. Broad may terminate this Agreement with respect to Broad
Controlled Patents and Cas9-II Patent Rights, and Harvard may terminate this Agreement with respect to Harvard Controlled Patents, upon notice to Company if Company becomes subject to a Bankruptcy Event or in
the event of dissolution or cessation of operations of the Company. For clarity, under this Section 10.2.5, each Licensor Institution shall severally be entitled to terminate the licenses granted to Company herein under such Licensor
Institution’s respective rights in the Patent Rights, pursuant to Section 10.2.1. 
 10.2.6 Termination without Prejudice.
The Licensor Institutions’ right of termination in this Section 10.2 shall be in addition and without prejudice to, and shall not constitute a waiver of, any right of the Licensor Institutions for recovery of any monies then due to it
hereunder or any other right or remedy the Licensor Institutions may have at law, in equity or under this Agreement. 
 10.3 Effect of
Termination. 
 10.3.1 Termination of Rights. Upon expiration or termination of this Agreement by either Party pursuant to any of
the provisions of Section 10.2: 
 10.3.1.1 the rights and licenses granted to Company under Article 2 shall terminate, all rights in
and to and under the Patent Rights shall revert to the Licensor Institutions and neither Company nor its Affiliates may make any further use or exploitation of the Patent Rights; and 

10.3.1.2 all existing Sublicenses shall automatically terminate [**] following the effective date of termination of this Agreement; provided
that, if any Sublicensee is (i) an Affiliate of Company or (ii) in material default of any material provision of the applicable Sublicense such that Company would have the right to terminate the Sublicense ((i) and (ii) together,
“Ineligible Sublicensees”) then the applicable Sublicense to which such Sublicensee is a party shall terminate effective immediately upon termination of this Agreement. Upon termination of this Agreement pursuant to any of the
provisions of Section 10.2, (A) Company shall promptly provide notice of such termination to any Sublicensee, (B) each Sublicensee that is not an Ineligible Sublicensee shall have the right to enter into a separate license agreement
directly with the Licensor Institutions (a “Direct License”) on substantially the same non-economic terms and conditions set forth in the Sublicense and on economic terms providing for the
payment by such Sublicensee to the Licensor Institutions of the consideration that otherwise would have been payable to the Licensor Institutions if the applicable Sublicense and this Agreement were still simultaneously in effect, adjusted as if a
Change of Control of Company had occurred (i.e., the Change of Control Multiplier shall automatically apply in accordance with Section 4.5.4 as of the effective date of termination of this Agreement, resulting in any Milestone Payments that
have not accrued at such time being increased by [**]%), and (C) the Licensor Institutions shall automatically grant each such Sublicensee a temporary continuation (to expire upon the earlier of (x) execution of the Direct License or
(y) the date that is [**] following termination of this Agreement) of the rights and obligations such Sublicensee had as a Sublicensee under this Agreement (a “Temporary Extension”); provided that, under both the Direct License
and the Temporary Extension, (a) the Licensor Institutions shall not have (i) any obligations that are greater than or inconsistent with the obligations of the Licensor Institutions under this Agreement or the nature of the Licensor
Institutions as an academic and non-profit entity or (ii) any fewer rights than it has under this Agreement; (b) there shall be no representations, warranties, expenses or liabilities of or on any
Owner Institution that are not 

  
 64 

 
included in this Agreement; (c) all obligations arising prior to execution of the Direct License and grant of the Temporary Extension shall remain the responsibility of Company and the
Licensor Institutions shall be released from any and all liability relating to such obligations; (d) the terms of such Direct License and Temporary Extension shall provide for payment to the Licensor Institutions of the same consideration that
would have been payable to the Licensor Institutions if the applicable Sublicense and this Agreement were still simultaneously in effect, adjusted as if a Change of Control of Company had occurred (i.e., the Change of Control Multiplier shall
automatically apply in accordance with Section 4.5.4 as of the effective date of termination of this Agreement); and (e) such modifications shall be included as are reasonably necessary to accommodate the functional and structural
differences between Company and the Licensor Institutions. By way of example and not limiting the foregoing clause (d), if the Sublicense required payment to Company of a license fee and the Licensor Institutions would have been entitled to receive
a percentage of such payment under Section 4.7 of the Agreement, then the Licensor Institutions shall continue to be entitled, under the Temporary Extension or Direct License, to the same share of that same license fee payment under the
Sublicense that the Licensor Institutions would have received had this Agreement and the Sublicense been simultaneously in effect. If any Sublicensee desires to enter into a Direct License, it shall wholly be the responsibility of that Sublicensee
to notify the Licensor Institutions of such desire no later than [**] after the effective date of termination of this Agreement. If the Licensor Institutions and the applicable Sublicensee, for any reason, do not enter into a Direct License within
[**] after the effective date of termination of the Agreement, the applicable Sublicense and Temporary Extension, and all rights granted thereunder, shall automatically terminate. 

10.3.2 Accruing Obligations. Termination or expiration of this Agreement shall not relieve the Parties of obligations accruing prior to
such termination or expiration, including obligations to pay amounts accruing hereunder up to the date of termination or expiration. After the date of termination or expiration (except in the case of termination by the Licensor Institutions pursuant
to Section 10.2), Company, its Affiliates and Sublicensees may sell Licensed Products then in stock; provided that Company shall pay the applicable Royalties and other payments to the Licensor Institutions in accordance with Article 4, provide
reports and audit rights to the Licensor Institutions pursuant to Article 5 and maintain insurance in accordance with the requirements of Section 9.2. The Parties agree that the obligations in Section 4.10.1 shall accrue immediately upon
execution of this Agreement by both Parties, regardless of the events, invoice and payment timing details set forth therein. 
 10.3.3
Enabled Products. After the date of termination or expiration of this Agreement, Company and its Affiliates may continue to sell and provide Enabled Products, provided that (a) for the remaining duration of any Royalty Term applicable to
any such Enabled Product, Company shall pay the applicable Royalties and other payments to the Licensor Institutions in accordance with Article 4, provide reports and audit rights to the Licensor Institutions pursuant to Article 5, and
(b) Company shall maintain insurance in accordance with the requirements of Section 9.2. 

  
 65 

 10.3.4 Disposition of Company Developments. In the event this Agreement is terminated
prior to expiration of the Term, Company shall consider in good faith with the Licensor Institutions during the [**] period after such termination, whether and on what terms Company will: 

10.3.4.1 provide to the Owner Institutions a copy of, and, if requested by the Owner Institutions, grant the Owner Institutions a
sublicensable license to, all patents and patent applications of the Company or its Affiliates that improve or are otherwise related to the Patent Rights or that cover a Licensed Product that any of the Owner Institutions are interested in pursuing
either themselves or through a licensee; provided that the terms of any such license shall be consistent with Company’s obligations under contract and Applicable Law and its officers’ and directors’ fiduciary obligations. In the case
where Harvard is granted a license to any such patents and patent applications of Company or its Affiliates pursuant to this Section 10.3.4.1, such license shall extend to any HHMI employees conducting research at Harvard and/or Broad. 

10.3.4.2 provide the Owner Institutions with access to and, at the Owner Institutions’ request and expense, deliver to the Owner
Institutions a copy of all documents, filings, data and other information in Company’s or its Affiliates’ possession and control as of the date of such termination (other than documents, filings, data and other information owned by
Sublicensees or Third Parties) to the extent pertaining solely to any of the Patent Rights or Licensed Products, including all records required by Regulatory Authorities to be maintained with respect to Licensed Products, all regulatory filings,
approvals, reports, records, correspondence and other regulatory materials (including any related to reimbursement or pricing approvals), and all documents, data and other information related to clinical trials and other studies of Licensed Products
(collectively, “Documentation and Approvals”), if and to the extent that the provision of, access to and delivery of such Documentation and Approvals shall be consistent with Company’s obligations under contract and Applicable
Law; and 
 10.3.4.3 permit the Owner Institutions and their licensees to utilize, reference, cross reference, have access to, and
incorporate in applications and filings (including with any Regulatory Authority in furtherance of applications for regulatory approval) the Documentation and Approvals if and to the extent that the foregoing right to utilize, reference, cross
reference, have access to, incorporate such Documentation and Approvals shall be consistent with Company’s obligations under contract and Applicable Law; provided, however, that notwithstanding anything in the foregoing to the contrary, the
right to utilize, reference, cross reference, have access to, incorporate such Documentation and Approvals shall not be deemed or construed as a grant of any license or other right under any patent or patent application owned or controlled by
Company, its Affiliates or any Third Party. 
 10.3.4.4 It is understood that all of the foregoing provisions of Sections 10.3.4.1-10.3.4.3 shall be subject to agreement by Company and the applicable Owner Institution on the terms and conditions thereof, as first described above in this Section 10.3.4. It is further understood
that, following a Company Sale, any patent, patent application, other intellectual property right or Documentation and Approvals owned or controlled prior to such Company Sale by the acquirer or any of its Affiliates shall not be subject to the
terms of this Section 10.3.4. 

  
 66 

 10.4 Survival. The Parties’ respective rights, obligations and duties under
Articles 5, 9, 10 and 11, Sections 8.3 and 8.4, as well as any rights, obligations and duties which by their nature extend beyond the expiration or termination of this Agreement, shall survive any expiration or termination of this Agreement. In
addition, (i) Section 11.18 and (ii) Company’s obligations under (a) Section 4.4.2, (b) Section 4.7, with respect to Sublicenses granted prior to expiration or termination of the Agreement, and
(c) Sections 4.5, 4.6 and 4.10, shall in each case survive such expiration or termination. 
  

	11.	 MISCELLANEOUS. 

11.1 Confidentiality. 

11.1.1 “Licensor Institution Confidential Information” means (a) any information related to Prosecution of Cas9-I Patent Rights provided to Company by or on behalf of Harvard (“Harvard Confidential Information”); (b) any information related to Prosecution of Patent Rights provided to Company by or on
behalf of Broad (“Broad Confidential Information”); (c) any information or material in tangible form that is marked as “confidential” or proprietary by a Licensor Institution at the time it is sent to Company; and
(c) information that is furnished orally by a Licensor Institution if such Licensor Institution identifies such information as “confidential” or proprietary in writing by a memorandum delivered to Company within [**] after the date of
disclosure. “Company Confidential Information” means (i) the Development Plan; (ii) any reports or notices prepared by Company and provided to the Licensor Institutions pursuant to Sections 3.4, 4.5.1, 4.5.2, 4.10 and
5.1.1; and (iii) any copies of Sublicenses, or information extracted therefrom, provided by Company to the Licensor Institutions under Section 2.5.2. The terms of this Agreement constitute the Confidential Information of both Parties. The
Parties agree the terms of this Agreement may be shared with the Owner Institutions and HHMI. “Confidential Information” means the Licensor Institution Confidential Information and the Company Confidential Information, as
applicable. 
 11.1.2 For the Term of this Agreement and a period of [**] thereafter, (a) Company shall maintain in confidence and shall
not disclose (i) to any third party any Licensor Institution Confidential Information, (ii) to Broad any Harvard Confidential Information, without the prior written consent of Harvard, and (iii) to Harvard any Broad Confidential
Information without the prior written consent of Broad and (b) the Licensor Institutions shall maintain in confidence and shall not disclose to any third party any Company Confidential Information, provided that the Licensor Institutions may
disclose to the Owner Institutions and HHMI (A) this Agreement including any Exhibits and Sublicenses, or information extracted therefrom, and (B) such Confidential Information of Company as an Owner Institution or HHMI, as the case may
be, reasonably requests, provided that any disclosure under the foregoing clauses (A) and (B) shall be made in confidence to the Owner Institutions or HHMI, as the case may be. Each Party shall take all reasonable steps to protect the
Confidential Information of the other Party with the same degree of care used to protect its own confidential or proprietary information. Neither Party shall use the Confidential Information of the other Party for any purpose other than those
contemplated by this Agreement. The foregoing obligations under this Section 11.1.2 shall not apply to: 
  

	 	(i)	 information that is known to the receiving Party or independently developed by the receiving Party prior to the
time of disclosure without use of or reference to the other Party’s Confidential Information, in each case, to the extent evidenced by contemporaneous written records; 

  
 67 

	 	(ii)	 information that is independently developed by the receiving Party at or after the time of disclosure without
use of or reference to the other Party’s Confidential Information, to the extent evidenced by contemporaneous written records; 

  

	 	(iii)	 information disclosed to the receiving Party by a Third Party that has a right to make such disclosure; or

  

	 	(iv)	 information that is publicly disclosed at or prior to the time of disclosure hereunder or becomes patented,
published or otherwise part of the public domain as a result of acts by the furnishing Party or a Third Party obtaining such information as a matter of right. 

11.1.3 Permitted Disclosures. Notwithstanding anything in this Section 11.1 to the contrary, either Party may disclose Confidential
Information of the other Party to the extent such disclosure is reasonably necessary in the following instances: 
 11.1.3.1 prosecuting or
defending litigation in accordance with Article 7 of this Agreement; 
 11.1.3.2 making filings with the Securities and Exchange Commission
or foreign equivalent, any stock exchange or market, or any Regulatory Authorities, which shall include publicly disclosing or filing this Agreement as a “material agreement” in accordance with Applicable Law or applicable stock exchange
regulations; 
 11.1.3.3 complying with Applicable Law or submitting information to governmental authorities, including without limitation
any Regulatory Authority, and including without limitation any order of a court or agency of competent jurisdiction, including without limitation any Regulatory Authority; provided that if either Party is required by Applicable Law to make any
public disclosure of Confidential Information of the other Party, to the extent the Party so required may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to secure
confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise); and 

11.1.3.4 to its Affiliates and its and their prospective and actual acquirers, licensees, sublicensees, distributors, investors, lenders and
underwriters, and (a) its and their employees, consultants, agents, and advisors, on a need to know basis, each of whom prior to disclosure must be bound by written obligations of confidentiality and
non-use of substantially equivalent or greater scope and duration than those set forth in this Article 11, (b) its and their accountants and lawyers, on a need to know basis, each of whom prior to disclosure
must be bound by written or legally enforceable professional ethical obligations of confidentiality and 

  
 68 

 
non-use of substantially equivalent or greater scope and duration than those set forth in this Article 11, (c)
co-owners of any of the Patent Rights, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use, and (d) HHMI (provided
that HHMI receives such information in confidence); provided that the scope of Confidential Information that may be disclosed by Company to any Person under this Section 11.1.3.4 is limited to the terms of this Agreement and any notices given
hereunder and not any other Licensor Institution Confidential Information unless otherwise agreed to in writing by the Licensor Institutions. In addition, notwithstanding anything in this Section 11.1 to the contrary, Broad and Harvard may
disclose to (i) any other co-owner of any of the Patent Rights and (ii) HHMI or any other financial sponsor of the Licensor Institutions with respect to the Patent Rights the existence and terms of
this Agreement (including all Exhibits and Schedules), provided that any such disclosure shall be made in confidence. 
 11.1.4 Additional
Permitted Disclosure. In addition to the rights set forth elsewhere in this Article 11, each Licensor Institution and Company shall have the right to disclose to Third Parties without an obligation of confidentiality all or part of a redacted
copy of this Agreement, or the substance thereof, in the form filed by Company to comply with its obligations under the Securities Act or the Exchange Act or the rules or regulations of a Trading Market. The Party intending to make such disclosure
shall use good faith efforts to notify the other Party in advance of any such disclosure. In the event that such advance notice is not provided by a Party that makes such disclosure, such Party shall notify the other Party of such disclosure
promptly after such disclosure is made. 
 11.2 Use of Name. Except as provided below, Company shall not, and shall ensure that its
Affiliates and Sublicensees shall not, use or register the name “The Broad Institute, Inc.,” “Wyss Institute for Biologically Inspired Engineering at Harvard University,” “President and Fellows of Harvard College,”
“Massachusetts Institute of Technology,” “Lincoln Laboratory,” the “University of Iowa Research Foundation,” the “University of Iowa” or “The Rockefeller University” or any variation, adaptation, or
abbreviation thereof (alone or as part of another name) or any logos, seals, insignia or other words, names, symbols or devices that identify the Owner Institutions or any Owner Institution’s school, unit, division or affiliate
(“Institution Names”) for any purpose except with the prior written approval of, and in accordance with restrictions required by, the applicable Owner Institution, as applicable. Without limiting the foregoing, Company shall, and
shall ensure that its Affiliates and Sublicensees shall, cease all use of Institution Names as permitted under or in connection with this Agreement on the termination or expiration of this Agreement except as otherwise approved in writing by the
applicable Owner Institution. This restriction shall not apply to any information required by law to be disclosed to any governmental entity. Company shall not use or register the name “Howard Hughes Medical Institute” or any variation,
adaptation, or abbreviation thereof (alone or as part of another name) or any logos, seals, insignia or other words, names, symbols or devices that identify HHMI or any unit of HHMI (“HHMI Names”) or of any HHMI employee (including
[**]) in a manner that reasonably could constitute an endorsement of a commercial product or service; but that use for other purposes, even if commercially motivated, is permitted provided that (1) the use is limited to accurately reporting
factual events or occurrences, and (2) any reference to an HHMI Name or any HHMI employees (including [**]) in press releases or similar materials intended for public release is approved by HHMI in advance. 

  
 69 

 11.3 Press Release. Notwithstanding the provisions of Section 11.2, in addition
to (and not in limitation of) the disclosure permitted under Section 11.1.4, the Parties shall agree on a public communications plan that shall define the nature and scope of the information relating to this Agreement and the relationship
between the Parties that shall be disclosed publicly and may issue a press release in such form as is consistent with such communications plan and mutually acceptable to the Parties (and any other Owner Institution to the extent of any reference to
such Owner Institution in such press release). Each Party agrees that it will not issue a press release or other public statement without obtaining the prior written approval of the other Party. Any use of HHMI Names or the name of any HHMI employee
(including [**]) in any such press release must be approved by HHMI in advance. 
 11.4 No Security Interest. Company shall not enter
into any agreement under which Company grants to or otherwise creates in any third party a security interest in this Agreement or any of the rights granted to Company herein. Any grant or creation of a security interest purported or attempted to be
made in violation of the terms of this Section 11.4 shall be null and void and of no legal effect. 
 11.5 Entire Agreement. This
Agreement is the sole agreement with respect to the subject matter hereof and, except as expressly set forth herein, supersedes all other agreements and understandings between the Parties with respect to the same. For the avoidance of doubt, this
Agreement shall not supersede the Cpf1 Agreement. 
 11.6 Notices. Unless otherwise specifically provided, all notices required or
permitted by this Agreement shall be in writing and may be delivered personally, or may be sent by facsimile, expedited delivery or certified mail, return receipt requested, to the following addresses of a Party, unless the other Party is
subsequently notified of any change of address in accordance with this Section 11.6: 
  

			
	If to Company (other than invoices):	  	 Verve Therapeutics, Inc.
 26 Landsdowne
Street
 Cambridge, MA 02139

		
	If to Company (invoices only):	  	 Verve Therapeutics, Inc.
 26 Landsdowne
Street
 Cambridge, MA 02139

		
	If to Licensor Institutions:	  	 The Broad Institute, Inc.
 Chief Operating
Officer
 415 Main Street
 Cambridge, MA 02142

Facsimile: [**]
 Attn: [**]

 
 AND
  

Office of Technology Development
 Harvard University

Richard A. and Susan F. Smith Campus Center, Suite 727
 1350
Massachusetts Avenue
 Cambridge, Massachusetts 02138

Facsimile: [**]
 Attn: [**]

  
 70 

 Any notice shall be deemed to have been received as follows: (a) by personal delivery
or expedited delivery, upon receipt; (b) by facsimile, one business day after transmission or dispatch; (c) by certified mail, as evidenced by the return receipt. If notice is sent by facsimile, a confirming copy of the same shall be sent
by mail to the same address. 
 11.7 Dispute Resolution. The Parties agree that, in the event of any dispute arising out of or
relating to this Agreement (other than disputes arising under Section 3.5 or relating to nonpayment of amounts due to the Licensor Institutions hereunder or disputes affecting the rights or property of HHMI) (a “Dispute”),
either Party by written notice to the other Party may have such issue referred for resolution to the Chief Executive Officer of Company, the Chief Technology Development Officer of Harvard and the Chief Operating Officer of Broad (collectively, the
“Executive Officers”). The Executive Officers shall meet promptly to discuss the matter submitted and to determine a resolution. If the Executive Officers are unable to resolve the Dispute within [**] after it is referred to them,
then the Parties may pursue all other rights and remedies available to them under this Agreement, including the right to terminate the Agreement, and the matter may be brought by a Party as a Suit in a court of competent jurisdiction in accordance
with Section 11.8 hereof. 
 11.8 Governing Law and Jurisdiction. This Agreement will be governed by, and construed in accordance
with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent shall be determined by the law of the
country in which the patent shall have been granted in any competent forum in such country. Any action, suit or other proceeding arising under or relating to this Agreement (a “Suit”) shall be brought in a court of competent
jurisdiction in the Commonwealth of Massachusetts, and the Parties hereby consent to the sole jurisdiction of the state and federal courts sitting in the Commonwealth of Massachusetts. Each Party agrees not to raise any objection at any time to the
laying or maintaining of the venue of any Suit in any of the specified courts, irrevocably waives any claim that Suit has been brought in any inconvenient forum and further irrevocably waives the right to object, with respect to any Suit, that such
court does not have any jurisdiction over such Party. 
 11.9 Binding Effect. This Agreement shall be binding upon and inure to the
benefit of the Parties and their respective legal representatives, successors and permitted assigns. 
 11.10 Headings. Section and
subsection headings are inserted for convenience of reference only and do not form a part of this Agreement. 
 11.11 Counterparts.
The Parties may execute this Agreement in three (3) or more counterparts, each of which shall be deemed an original. 

  
 71 

 11.12 Amendment; Waiver. This Agreement may be amended, modified, superseded or
canceled, and any of the terms may be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party waiving compliance. The delay or failure of either Party at any time or times to require performance of any
provisions hereof shall in no manner affect the rights at a later time to enforce the same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more
instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

11.13 No Agency or Partnership. Nothing contained in this Agreement shall give either Party the right to bind the other, or be deemed to
constitute either Party as agent for or partner of the other or any third party. 
 11.14 Assignment and Successors. This Agreement
may not be assigned by Company, whether by operation of law or otherwise, without the consent of the Licensor Institutions, except that Company may assign or transfer the Agreement without the consent of the Licensor Institutions, to a successor in
interest of all or substantially all of Company’s assets or business related to the Licensed Products or the Agreement, whether by merger, consolidation, sale of assets, or Change of Control or other transaction, provided that (a) the
Company shall provide the Licensor Institutions with a written notice of such assignment or Change of Control including the identity of the assignee, transferee or controlling party, and a copy of the assignment and assumption agreement or other
documentary evidence sufficient to demonstrate Company’s compliance with this Section 11.14 within [**] after such assignment or Change of Control, and (b) such assignee or transferee agrees in writing to assume the obligations to the
Licensor Institutions and HHMI that are being assigned or transferred. An uncured failure of an assignee to agree to be bound by the terms hereof or an uncured failure of Company to notify the Licensor Institutions and provide copies of assignment
documentation as specified above shall be grounds for termination of this Agreement for default. Any attempted assignment in contravention of this Section 11.14 shall be null and void. 

11.15 Force Majeure. Neither Party shall be responsible for delays resulting from causes beyond the reasonable control of such Party,
including fire, explosion, flood, war, strike, or riot, provided that the nonperforming Party uses commercially reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable
dispatch whenever such causes are removed. 
 11.16 Interpretation. Each Party hereto acknowledges and agrees that: (a) it and/or
its counsel reviewed and negotiated the terms and provisions of this Agreement and has contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in
the interpretation of this Agreement; (c) the terms and provisions of this Agreement shall be construed fairly as to both Parties hereto and not in favor of or against either Party, regardless of which Party was generally responsible for the
preparation of this Agreement; (d) all references herein to “dollars” or “$” shall mean United States Dollars; and (e) the use of “include,” “includes,” or “including” herein shall not be
limiting and “or” shall not be exclusive. Each Party hereto further acknowledges and agrees that nothing in this Agreement shall be construed to abridge the rights of Editas under the Editas Cas9-I
License Agreement and Editas Cas9-II License Agreement. 

  
 72 

 11.17 Severability. If any provision of this Agreement is or becomes invalid or is
ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of the Parties that the remainder of this Agreement shall not be affected. 

11.18 HHMI Third Party Beneficiary. HHMI is not a party to this Agreement and has no liability to Company or any licensee,
sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name. 

[The remainder of this page intentionally left blank; signature page follows] 

  
 73 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
duly authorized representatives as of the Effective Date. 
 PRESIDENT AND FELLOWS OF HARVARD COLLEGE: 

 

			
	By:	 	 /s/ Isaac T. Kohlberg

	Name:	 	Isaac T. Kohlberg
	Title:	 	Sr. Associate Provost, Chief Technology Development Officer
	
	Office of Technology Development
	
	Harvard University

  

  
 [Signature Page to Cas9
License Agreement] 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
duly authorized representatives as of the Effective Date. 
  

			
	THE BROAD INSTITUTE, INC.:
		
	By:	 	 /s/ Jesse Souweine

	Name: Jesse Souweine
	Title:   Chief Operating Officer

  

  
 [Signature Page to Cas9
License Agreement] 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
duly authorized representatives as of the Effective Date. 
 VERVE THERAPEUTICS, INC.: 

 

			
	By:	 	 /s/ Andrew D. Ashe

	Name:	 	Andrew D. Ashe
	Title:	 	President & COO

  
 [Signature Page to Cas9
License Agreement] 

 Exhibit 1.166 

Targets 
 The Targets are: 

 

	 	•	 	 Proprotein convertase subtilisin/kexin type 9 (PCSK9) 

 

	 	•	 	 [**] 

  

	 	•	 	 [**] 

  
 77 

 Exhibit 3.1 

Development Milestones 

[**] 

  
 78 

 CONFIDENTIAL 

FIRST AMENDMENT TO 
 CAS9
LICENSE AGREEMENT 
 This FIRST AMENDMENT (the “Amendment”) is entered into as of this 18th day of December, 2019 (the
“Amendment Effective Date”), by and between, on the one hand, the President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts,
having a place of business at Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 (“Harvard”) and The Broad Institute, Inc., a non-profit Massachusetts corporation,
with a principal office at 415 Main Street, Cambridge, MA 02142 (“Broad,” together with Harvard, the “Licensor Institutions” and each individually, a “Licensor Institution”) and, on
the other hand, Verve Therapeutics, Inc., a Delaware corporation, with a principal office at 26 Landsdowne Street, Cambridge, MA 02139 (“Company”). Company and the Licensor Institutions are each referred to herein as a
“Party” and together, the “Parties.” 
 WHEREAS, the Parties entered into that certain Cas9 License Agreement dated
March 15, 2019 (the “Cas9 License”) pursuant to which, among other things, the Licensor Institutions granted to Company certain rights with respect to certain identified Targets; and 

WHEREAS, the Parties now wish to amend the Cas9 License to identify ANGPTL3 as an additional Target, as set forth in this Amendment. 

NOW, THEREFORE, the Parties hereto, intending to be legally bound, hereby agree as follows: 

 

	1.	 Defined Terms. Capitalized terms used in this Amendment and not defined herein shall have the meaning
given to such terms in the Cas9 License, unless otherwise specified herein. 

  

	2.	 Exhibit 1.166. Exhibit 1.166 of the Cas9 License is hereby deleted in its entirety and replaced with
Exhibit 1.166 attached hereto. 

  

	3.	 No Other Modification. Except as specifically set forth in this Amendment, the terms and conditions of
the Cas9 License shall continue in full force and effect and shall apply to this Amendment. This Amendment is the sole agreement with respect to the subject matter of this Amendment and, except as expressly set forth herein, supersedes all other
agreements and understandings between the Parties with respect to the same. For the avoidance of doubt, this Amendment shall not supersede the Cpf1 Agreement. This Amendment may be amended, modified, superseded or canceled, and any of the terms may
be waived, only by a written instrument executed by each Party or, in the case of waiver, by the Party waiving compliance. 

  

	4.	 Miscellaneous. The Parties may execute this Amendment in three (3) or more counterparts, each of
which shall be deemed an original. This Amendment will be governed by, and construed in accordance with, the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision.

 [The remainder of this page intentionally left blank; signature page follows] 

  
 1 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their
duly authorized representatives as of the Amendment Effective Date. 
  

			
	PRESIDENT AND FELLOWS OF HARVARD COLLEGE:
		
	By:	 	 /s/ Isaac T. Kohlberg

	Name: Isaac T. Kohlberg
	Title:   Senior Associate Provost
	
	Chief Technology Development Officer
	
	Office of Technology Development

  

  
 [Signature Page to Cas9
License Amendment] 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their
duly authorized representatives as of the Amendment Effective Date. 
  

			
	THE BROAD INSTITUTE, INC.:
		
	By:	 	 /s/ Jesse Souweine

	Name: Jesse Souweine
	Title:   Chief Operating Officer

  

  
 [Signature Page to Cas9
License Amendment] 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized
representatives as of the Amendment Effective Date. 
 VERVE THERAPEUTICS, INC.: 

 

			
	By:	 	 /s/ Andrew D. Ashe

	Name:	 	Andrew D. Ashe
	Title:	 	President & COO

  
 [Signature Page to Cas9
License Amendment] 

 Exhibit 1.166 

Targets 
 The Targets are: 

 

	 	•	 	 Proprotein convertase subtilisin/kexin type 9 (PCSK9) 

 

	 	•	 	 [**] 

  

	 	•	 	 [**] 

  

	 	•	 	 Angiopoietin-like 3 (ANGPTL3)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]